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While blood proteins are heavily investigated as biomarkers for different diseases, the 
modification state of such proteins is rarely analyzed. Here, we established a novel mass 
spectrometry-based workflow to identify in vivo ADP-ribosylated blood proteins of LPS-
treated pigs as a model for human systemic inflammatory response syndrome. We found that 
ADP-ribosylated proteins are rapidly demodified after sample collection by phosphodiesterases 
and ADP-ribosylhydrolases in the plasma, and thus to prevent demodification, we immediately 
denatured blood samples after collection with guanidine hydrochloride. Moreover, we 
improved the enrichment protocol of modified peptides via ADP-ribosylome specific 
LC/MSMS by depleting free ADP-ribose from samples prior to enrichment. This led to the 
identification of 44 ADP-ribosylated proteins in LPS-treated and 38 in control pigs. These 
proteins were cross-referenced with the plasma proteome, to determine which of the modified 
proteins belong to the plasma fraction of the blood, leading to the identification 12 ADP-
ribosylated plasma proteins in LPS-treated pigs and 13 in control group pigs. Overall, we 
developed a novel method for identifying ADP-ribosylated blood proteins and characterized 
the whole blood and plasma protein ADP-ribosylomes of LPS-treated and control pigs. Further 


















Blutproteine werden oft als Biomarker für verschiedene Krankheiten analysiert, aber deren 
post-translationelle Modifikationen werden selten untersucht. Wir entwickelten ein neues, 
Massenspektrometrie-basiertes Protokoll um in vivo ADP-ribosylierte Blutproteine in LPS-
behandelten Schweinen zu identifizieren, welche als Modell für humanes systemisches 
inflammatorisches response Syndrom dienen. Da ADP-ribosylierte Proteine nach der 
Blutprobenentnahme rasch durch Phosphodiesterasen und ADP-ribosylhydrolasen 
demodifiziert werden, denaturierten wir die Blutproben direkt nach der Entnahme mit 
Guanidinhydrochlorid. Ein optimiertes Anreicherungsprotokoll bei welchem freie ADP-ribose 
depletiert wird, wurde entwickelt um die Peptidanreicherung für die Detektion via ADP-
ribosylom-spezifischer LC-MS/MS zu verbessern. Mit diesem Protokoll wurden 38 
modifizierte Blutproteine in gesunden und 44 in LPS-behandelten Schweinen identifiziert. 
Durch Vergleichen dieser Blutproteine mit dem Plasmaproteom, definierten wir das 
plasmaspezifische ADP-ribosylom: 13 modifizierte Proteine wurden in gesunden und 12 in 
LPS-behandelten Schweinen identifiziert. Zusammengefasst entwickelten wir eine neue 
Methode um ADP-ribosylierte Blutproteine zu identifizieren und charakterisierten erstmals das 
Vollblut- und Plasma-ADP-ribosylom von gesunden und LPS-behandelten Schweinen. 
Weiterführende Untersuchungen dieser Proteine könnten helfen, die molekularen 
Mechanismen von Sepsis besser zu verstehen. 
 
Stichwörter: ADP-ribosylierung, Sepsis, Vollblut, NAD 
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While the analysis of blood proteins as biomarkers for different diseases is common nowadays, 
the modification state of such proteins is only rarely addressed. We observed that ADP-
ribosylated proteins are rapidly demodified after blood sample collection due to active 
phosphodiesterases and ADP-ribosylhydrolases in the plasma, thus, requiring an optimized 
collection procedure for this PTM to prevent demodification. Here, we established a novel mass 
spectrometry based workflow to identify blood proteins that are ADP-ribosylated in healthy 
and lipopolysaccharide treated pigs in vivo, that serves as a model for human systemic 
inflammatory response syndrome. To this extent, blood samples including all cells and soluble 
proteins were immediately denatured with guanidine hydrochloride after collection to prevent 
post-sampling demodification. Moreover, an improved enrichment protocol that depletes free 
ADP-ribose from samples was established to enhance ADP-ribosylated peptide enrichment and 
identification rates in the whole blood lysates via ADP-ribosylome specific LC/MS-MS. 
Application of this modified protocol led to the identification of a total of 38 ADP-ribosylated 
proteins in healthy pigs and 44 in LPS-treated pigs. By cross-referencing these proteins with 
the corresponding plasma proteome, we determined which of the ADP-ribosylated proteins 
belong to the plasma fraction of the blood. This led to the identification of 13 ADP-ribosylated 
plasma proteins in healthy pigs and 12 in LPS-treated pigs.  In summary, we developed a novel 
method for identifying ADP-ribosylated blood proteins and characterized the whole blood and 
plasma protein ADP-ribosylomes of healthy and LPS-treated pigs. This study thus contributes 
to the rapidly developing field of ADP-ribosylation and further characterization of the newly 
identified blood ADP-ribosylome will potentially help unravel the molecular mechanisms that 
drive SIRS and sepsis, two of the major health threats today. 
Keywords: ADP-ribosylation, systemic inflammatory response syndrome, sepsis, whole blood 
lysate, plasma, histidine  
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2. INTRODUCTION 
The clinical condition of systemic inflammatory response syndrome (SIRS) or sepsis is caused 
by pathogen-associated molecular pattern (PAMP) molecules, including lipopolysaccharide 
(LPS) [1]. These molecules interact with toll-like receptors (TLRs) on host immune cells, which 
triggers increased production of pro-inflammatory cytokines by immune cells circulating in the 
blood [2, 3]. Studies suggest that during sepsis, control of the primarily physiological host 
response to the infection is lost, which causes a multitude of systemic dysfunctions that 
ultimately lead to multi-organ failure and the resulting high mortality rates [4]. Although sepsis 
has been extensively studied, the specific molecular mechanisms that drive multi-organ failure 
and eventual death are not fully understood [4, 5]. As sepsis is one of the leading causes of 
death in humans, developing a reproducible study system and accurate diagnostic tools that 
allow sepsis detection at early stages is critical to facilitate appropriate therapeutic interventions 
and further therapeutic developments [5]. Porcine pleuropneumonia, a highly infectious disease 
in pigs that is caused by Actinobacillus pleuropneumoniae, could serve as a model for human 
SIRS and sepsis [6]. LPS derived from A. pleuropneumoniae has been shown to induce 
inflammatory responses by triggering alveolar macrophages to overproduce proinflammatory 
cytokines like IL-1B, IL-6 and TNFα [7]. This proinflammatory cytokine influx, combined 
with the occurrence of typical clinical symptoms such as fever, and elevated heart rate and 
respiratory rates match the defined criteria of human SIRS [3, 6]. Studies highlighting the 
similarity between the proteome of the domestic pig (Sus scrofa domesticus) and humans 
further emphasize the potential of pigs as model systems for human patients, especially for 
infectious disease and inflammation research [8]. 
Plasma is a readily accessible matrix for protein and biomarker research, and the plasma 
proteome has been extensively studied in humans, and various animals including pigs, under 
both healthy conditions and during the acute phase reaction; which is a complex early defense 
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mechanism that the body mounts in response to a triggering event like infection or inflammation 
[9, 10]. Plasma proteins whose abundances increase in response to inflammation or tissue 
damage have been termed positive acute phase proteins (pAPPs). Modern medicine relies on 
the detection of these few pAPPs to distinguish between healthy and diseased human patients 
on an individual basis, as well as large scale monitoring of herd health in farm animals [10]. 
However, the abundance of plasma proteins is not the only relevant feature; their modification 
states have also been previously studied as protein function can be regulated by PTMs [11]. 
These studies have led to the discovery of glycosylated proteins as prognostic markers for 
certain cancer types and phosphorylated proteins as prognostic markers for different diseases 
[12, 13]. The role of other PTMs in plasma have not yet been examined.  
ADP-ribosylation is a dynamic and reversible PTM that transfers one (MARylation) or 
multiple (PARylation) ADP-ribose moieties from NAD+ to an amino acid acceptor site of a 
target protein [14]. The possible acceptor amino acids include lysine, arginine, aspartic acid, 
glutamic acid, cysteine, and serine, as well as the recently discovered tyrosine and histidine 
[15-20]. Different ADP-ribosyltransferases (ARTs) have been described to MARylate or 
PARylate proteins. These enzymes are grouped into three subgroups based on their structural 
similarities to either diphtheria-toxin (ARTDs), cholera-toxin (ARTCs) or sirtuins [21]. Other 
enzymes are able to either hydrolyze the PAR chains (i.e. PARG), leaving a single ADP-ribose 
moiety bound to the protein, or are able to erase MARylation from proteins [22]. ADP-
ribosylation plays a crucial role in many cellular processes including regulation of the 
inflammatory response within cells [23]. In contrast to the well-described role of ADP-
ribosylation in such cellular mechanisms, its role in blood remains mostly uncharacterized. So 
far there has only been a single study reporting a correlation between non-enzymatic ADP-
ribosylated serum proteins and cancer, but studies have not yet linked blood and/or plasma 
protein ADP-ribosylation to inflammatory diseases such as sepsis [24].  
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 Here, we observed that serum prepared via standard methods identified very few ADP-
ribosylated proteins by LC-MS/MS. This led us to first establish various ex vivo biochemical 
assays to determine whether ADP-ribosyltransferases and -hydrolases were present and active 
in the serum/plasma. We found that ADP-ribosylation could be induced by adding NAD+ to 
heat-denatured plasma samples, however it remained unclear whether the observed increase 
was non-enzymatic or ADP-ribosyltransferase mediated. Furthermore, we found that erasers 
were active in the blood. Together, these assays demonstrated that proteins are rapidly 
demodified after blood sample collection prior to MS sample preparation and that standard 
blood sample collection techniques should be modified in order to maintain the modification 
state of proteins at the exact timepoint of blood sample collection. To this extent we collected 
blood samples from healthy and SIRS and sepsis model LPS treated pig both before and after 
NaCl or LPS injections and immediately denatured half of the blood sample with guanidine 
hydrochloride (GndHCl) to avoid demodification. The other half of the blood sample was used 
to prepare plasma. Before analyzing these samples via mass spectrometry (LC-MS/MS), we 
additionally improved the peptide enrichment workflow by reducing PAR chains to MAR 
before trypsin digestion and depleted free ADP-ribose to enhance ADPr-modified peptide 
enrichment efficiencies. We then applied the optimized workflow to the denatured porcine 
blood samples to determine which proteins were ADP-ribosylated in vivo and how modification 
states differed between healthy and LPS-treated pigs. Finally, we compared the whole blood 
ADP-ribosylome to the corresponding plasma proteome to tease out which of the modified 
proteins belong to the cellular fraction of the blood and which to the plasma fraction. 
Interestingly, in addition to serine and lysine, histidine was identified as a common ADPr-
acceptor amino acid in both control and LPS-treated pigs samples, suggesting that the main 




3. MATERIALS AND METHODS 
LPS-induced SIRS study system  
This study was conducted in accordance with the Swiss animal protection ordinance, under 
animal experimentation license number ZH046/17. 4-6 week old pigs (n=10) were housed at 
the University of Zurich animal hospital and randomly allocated to either the control (n=5) or 
LPS group (n=5). The LPS trial lasted for a total of 10 days. From day 1 to 8 pigs were allowed 
to adapt to the new housing facilities and their clinical conditions assessed daily based on 
dyspnea, coughing, lung auscultation, nasal discharge and behavior parameters, which allowed 
us to define their health status and determine if individual animals should be removed from the 
trial. None of the pigs entered into the study showed signs of porcine pleuropneumonia, thus 
no animals were removed from the trial. On day 9 all pigs were again examined clinically, 
weighed, and a first blood sample collected. Pigs were then injected intramuscularly with 0.9% 
NaCl-solution (control group, 250 µl) or with LPS derived from A. pleuropneumoniae 
(treatment group, 250 µl 25% Montanide containing 31.3 µg LPS). Following the injections, 
core body temperatures were assessed after 4, 6, 8, and 10hrs and a second blood sample was 
collected from each pig at the 8hr timepoint. 
 
Blood sample collection and sample preparation 
6 mL of venous blood were collected from each pig at both timepoints as previously described 
[25]. After collection, samples were immediately split into 3 fractions: 2 mL were transferred 
to heparin and EDTA tubes respectively (both BD, USA). Heparin samples were then 
centrifuged (1000x g, 10 min), the plasma separated from the cell pellet and stored at -80 °C 
for downstream plasma proteome analyses. The EDTA samples were kept at RT and 
immediately processed for hematological analyses. The remaining 2 mL were added to falcon 
tubes containing 4 mL of 6M GndHCl and mixed thoroughly to denature the samples. These 
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whole blood lysates (WBL) were then heated to 95 °C for 10 min and stored at -80 °C until LC-
MS/MS ADP-ribosylome analysis.  
 
Western blot analysis 
For Western blot (WB) analyses, samples were prepared using standard SDS-PAGE and 
blotting techniques. Membranes were incubated with blocking solution (3% BSA in TBS-T 
(0.15 M NaCl, 10 mM Tris pH 7.5, 0.05% Tween-20)) for 1-2hrs at room temperature (RT), 
and subsequently incubated overnight at 4 °C with the primary anti-ADPr-antibody (diluted 
1:10’000 in TBS-T; Cell Signaling Technology, USA). Membranes were washed 3x for 5 min 
with TBS-T and incubated IRDye goat-anti-rabbit IgG secondary antibody (diluted 1:15’000 in 
TBS-T, LI-COR Biosciences, USA) for 1hr at RT and washed again as described before 
scanning (Odyssey Scanner, LI-COR Biosciences, USA). 
 
Auto-modification of ARTD1 
ARTD1 (formerly PARP1, Trevigen, USA) was auto-modified by incubating 10 U ARTD1 
with or without 4.5 µg HPF1, 2 µg activated DNA and 5 µM NAD+ in 1x Trevigen PARP1 
reaction buffer at 25 °C for 20 min. The reaction was stopped by adding SDS-LB (final 
concentration 1x) and heating to 95 °C for 10 min. Alternatively, for the experiment 
characterizing eraser activity in plasma, ARTD1 (in-house) was auto-modified by incubating 
0.875 µg ARTD1 with or without 100 µM NAD+, activated DNA (1 µg/reaction) in 1x RB (50 
mM Tris-HCl pH 7.4, 4 mM MgCl2, 250 µM DTT) at 37 °C for 1 hour (total volume of 25 µL 





Induction of ADP-ribosylation ex vivo via heat denaturing 
25 µl of porcine plasma were heat denatured (95 °C, 10 min) in presence or without 100 µM 
NAD+ and subsequently incubated at 37 °C overnight to induce ADP-ribosylation. Samples 
were then diluted with 50 mM Tris pH 7.4 and 6x SDS-LB was added (final concentration 1x), 
sonicated and heated (95 °C, 10 min) before storing at -20 °C. Samples where GndHCl was 
added were subjected to a buffer exchange regime using Microcon-10 kDa centrifugal filter 
units. Centrifugation (14’000x g, 20 min, RT) and washing 2 times with 100 µL 50 mM Tris 
pH 7.4 led to buffer exchange and SDS-PAGE compatibility. The resulting samples were 
resuspended in 25 µL Tris pH 7.4 and prepared as described above.  
 
Induction of ADP-ribosylation ex vivo via hARTC1 
DC27.10 cells expressing human ARTC1 (hARTC1) on the cell membrane (kindly provided 
by F. Koch-Nolte) were grown in RPMI medium (1x) with GlutaMax supplement (Thermo 
Fisher Scientific Inc., USA) and with 5% fetal calf serum at 37 °C. 2 x 106 cells were collected 
via centrifugation (300x g, 5 min, 4 °C) and gently resuspended in 100 µl of plasma. 100 µM 
NAD+ was then added to the cell suspension and samples were incubated at 37 °C for 1hr. The 
resulting plasma was then collected by centrifugation (300x g, 5 min, 4 °C) and analyzed via 
WB. 
 
Cell culture and ADPr-peptide enrichment 
HeLa cells were cultured and treated with H2O2 as previously described and the lysates were 
used to test the new workflow and served as positive and negative controls for LC-MS/MS of 
the WBLs [16]. Wildtype and an evolved Af152 macrodomain, with 1000-fold enhanced 
binding affinity to ADP-ribose  (Nowak et al., manuscript under revision), were expressed and 
purified as previously described [26]. Binding and crosslinking of the GST-Af1521 fusion 
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proteins to Glutathione Sepharose 4B beads, peptide enrichment (“standard workflow”) and 
pre-MS clean-up using stage tips were performed as described in [26-28]. After elution, samples 
were resuspended to 12 µL in MS-buffer (3% ACN, 0.1% formic acid), vortexed briefly, 
sonicated (10 min, 100%, 25 °C), and centrifuged (16’000x g, 2 min, RT) before MS analysis.  
For the new workflow established in this study, samples were diluted to 0.2M GndHCl 
using 1x PARG buffer (50 mM Tris-HCl pH 8.0, 50 mM NaCl, 10 mM MgCl2, 0.25 mM DTT), 
and 4.2 µg PARG (in-house) per 10 mg protein and 10 µL of Benzonase (Merck Millipore, 
GER) per 30 mL were then added to each sample. The samples were incubated at 37 °C for 1hr. 
Samples were then trypsin digested as per the standard protocol and all subsequent steps 
performed as previously described. WBL samples collected during the LPS trial were prepared 
using the new workflow with additional high pH (HpH) and low pH (LpH) fractionation on 
MicroSpin C18 columns (Nest Group Inc., USA) as described in [20]. Samples were eluted 
from the HpH column using three different percentages of ACN (7%, 15%, and 50% in 20 mM 
NH4OH) and from the LpH column using one condition containing 60% ACN / 0.1% TFA. 
 
Preparation of plasma input samples for MS analyses 
Plasma input samples were prepared via filter aided sample preparation (FASP) [29]. Briefly, 
samples were denatured using GndHCl lysis buffer (6 M GndHCl, 5 mM TCEP, 10 mM CAA, 
100 mM Tris-HCl pH 8.0, final concentration 4M), heated (10 min at 99 °C) and sonicated. 100 
µg of protein were transferred onto the Microcon-10 kDa centrifugal filter unit, centrifuged 
(14’000x g, 20 min, RT) and washed 3 times with 100 µL 0.5 M NaCl (centrifugation as 
described). 120 µL of 50 mM ammonium bicarbonate were added to the filter unit and 
centrifuged as described above. Trypsin (Promega, USA) was added at a 1:25 ratio (µg trypsin: 
µg protein), the filter units sealed and incubated overnight (37 °C, 16-20 hrs, 300 rpm). The 
filter units were then centrifuged as described and the columns re-eluted using 80 µL 50 mM 
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ammonium bicarbonate solution. The eluate was acidified with 10% TFA to a pH of 3-4 and 
the samples were then further prepared for MS analysis via Zip Tip clean-up according to the 
Millipore zip tip user guide (Merck Millipore, GER). Samples were resuspended in MS-buffer 
and processed as described for ADPr samples. 
  
Mass spectrometry and data analysis 
LC-MS/MS analyses of ADP-ribosylated peptides were performed using the ProductPreview 
method as described in Bilan et al. at the Functional Genomics Center Zurich using the Orbitrap 
Fusion Lumos mass spectrometer (Thermo Fisher Scientific Inc., USA) [30]. Briefly, 2-5 µL 
of the prepared peptides solutions were eluted over 112 min at 300 nL/min, with ACN 
concentrations ranging from 5% to 95%. Initial high energy HCD scans were then applied to 
detect unique fragmentation ions of ADP-ribose, which in turn triggered product-dependent 
MS-events. Parallel high resolution HCD and EThcD scans were acquired to maximize peptide 
sequence coverage and PTM localization confidences [30].  
Downstream data analysis was performed as previously described [30]. The HCD and 
EThcD deconvoluted separated .msg files were searched against the UniProt database for 
human and porcine proteins respectively using Mascot, and the following search parameters 
were applied: trypsin digests with up to 5 missed cleavages, carbamidomethyl as a fixed 
modification on cysteine (C), acetyl (protein N-term), oxidation (M), and 
ADPr_HCD_249_347_583 DEHKRSY (HCD scans, neutral losses defined in [31] and Gehrig 
et al., manuscript under revision) or ADP-Ribosyl EThcD (for EThcD scans) as variable 
modifications, peptide tolerance = 10 ppm, number of 13C = 1, peptide charge = 2+/3+/4+, 
MS/MS tolerance = 0.05 Da [32]. Briefly, the resulting files were filtered to include only 
peptides with one or more ADP-ribose modifications, peptide scores > 15 (WBL samples) or  
> 20 (HeLa cell lysates) and peptide expect values < 0.05. For ADP-ribose acceptor site 
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localizations, the list of modified peptides was further filtered based on peptide variable 
modification confidence values > 95%. MS analyses of input proteome samples were 
performed using standard data dependent acquisition (DDA) methods. The following search 
parameters were used to search input proteome deconvoluted data: trypsin digests with up to 5 
missed cleavages, carbamidomethyl as a fixed modification on cysteine (C), acetyl (protein N-
term), oxidation (M), peptide tolerance = 10 ppm, number of 13C = 1, peptide charge = 2+/3+/4+, 
MS/MS tolerance = 0.5 Da [32]. Plasma proteome search results were filtered as described 
above for peptide score and peptides expect values, without regard to ADP-ribosylation.   
 
Statistical analysis  
Statistical analyses were performed using R version 3.5.2 [33]. Differing core body 
temperatures and total leukocyte amounts of control/LPS-treated pigs were tested for their 
statistical significance at each time point (0hr, 4hrs, 6hrs, 8hrs and 10hrs post injection or before 
and after injection, respectively). Normal distribution was first tested using a ShapiroWilk 
normality test and subsequently a two-tailed, unpaired t-test (normal distribution) or a 
MannWhitney U test (non-normal distribution) was applied. Differences in peptide presence 
were analyzed by creating 2 x 2 contingency tables for each ADP-ribosylated peptide found in 
plasma samples and then categorizing the data as either (1) control conditions or LPS treatment 
and (2) number of pigs where the peptide was detected or not detected. Due to a non-normal 
distribution as well as unequal and small sample sizes a Fisher’s exact test was used for further 




LPS treatment significantly increases core body temperature and total leukocyte numbers 
in pigs 
The LPS-induced SIRS study system consisted of an LPS trial during which 10 pigs were 
injected with either NaCl (n=5) or LPS (n=5) solutions and blood samples were collected at 
different timepoints (Table 1). To determine how pigs reacted to a single LPS injection (31.3 
µg) the core body temperature and total number of leukocyte were analyzed before and after 
injection, as these are two key symptoms of SIRS. LPS-treated pigs displayed significant (p < 
0.05) increases in core body temperature 4, 6, 8, and 10hrs after injection compared to the 
control group (Suppl. Figure 1A). The total amount of white blood cells also increased 
significantly in the LPS treatment group after injection, while in the control group no significant 
changes were observed before or after NaCl injection (Suppl. Figure 1B). Additionally, protein 
concentrations were assessed for each pig before and after the LPS or NaCl injections. No 
significant differences were observed between the two groups at either timepoint (Suppl. Figure 
1C). Together, these data indicate that the established porcine LPS-induced SIRS model elicits 
clinical and hematological reactions similar to human SIRS.  
 
Optimization of the MS-based workflow to allow detection of low abundant ADP-
ribosylated proteins 
Preliminary experiments with serum samples from NaCl- and LPS-treated pigs revealed that 
the levels of ADP-ribosylation were very low, even below the level of untreated HeLa cell 
culture samples (data not shown). We, therefore, first optimized the standard ADP-ribosylome 
workflow to increase enrichment efficiency prior to MS-based analysis of ADP-ribosylation; 
this was done using H2O2 treated HeLa cells [26]. Here, we included one major change to the 
established standard workflow. We brought the PARG/Benzonase treatments of the lysates 
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forward to the first step of the sample preparation protocol in the hope that this would improve 
trypsin digest efficiency and modified peptide enrichment (Suppl. Figure 2). This was 
rationalized based on studies that have recently demonstrated that S-ADPr modifications are 
typically found within KS and RS motifs, thus reducing PAR chains to MAR modifications 
prior to trypsin digestion could improve protein-to-peptide digestion [18]. In addition, we also 
reasoned that C18 column clean-up after PARG digest would eliminate most of the free ADP-
ribose prior to ADPr-peptide enrichment. This could provide an additional advantage, as 
competitive binding between the free ADP-ribose and ADPr-peptides to the Af1521 
macrodomains would be reduced and, thus, MARylated peptide enrichment efficiencies should 
increase. 
To determine if the protocol modification improved ADP-ribosylome coverage, we 
compared the unique peptides, unique modification sites (> 95% localization confidence) and 
unique modified proteins identified for the standard workflow and new workflow (Figure 1A). 
The new workflow outperformed the standard workflow considerably by identifying ~3x more 
modified peptides, ~2x more unique modification sites and ~2.5x more proteins, suggesting 
that this modification provided an experimental advantage (Figure 1A). Indeed, application of 
the new workflow led to the identification 88 modified proteins, while the standard workflow 
only identified 34 ADP-ribosylated proteins (Figure 1B). Comparison of the standard workflow 
and new workflow coverages revealed that only 5 proteins (5.4%) were uniquely identified in 
samples using the standard workflow, indicating that the sample preparation changes made for 
the new workflow do not bias peptide enrichment or modified protein identifications. 
Importantly, the new workflow identified 59 proteins (63.4%) that were not detected with the 
standard workflow and greatly reduced the number of mis-cleaved peptides (Figure 1C), 
demonstrating that our workflow modifications increased ADP-ribosylome coverage 
considerably (Table 2).  
 19 
In an attempt to further increase our ADP-ribosylome coverage, we applied additional 
sample preparation improvements that were recently established [20]. This included lowering 
acetonitrile concentrations during the SepPak clean-up step to ensure that only the highest 
quality peptides were eluted from the columns prior to ADPr-peptide enrichment. Second, we 
applied the HpH/LpH fractionation protocol to reduce sample complexity and improve peptide 
sequencing during MS analysis. These modifications were again assessed using HeLa H2O2 
treated cell lysates and applied to the new workflow protocol that we developed above. Indeed, 
including these additional sample preparation modifications increased ADP-ribosylated 
peptide, modification site and protein detection rates by 68.7%, 52.9%, and 69% respectively 
(Suppl. Figure 3A & B), indicating that including these additional sample preparation 
modifications further increases ADP-ribosylome coverage. In light of these promising findings, 
the new workflow with fractionation was selected for MS sample preparation for the LPS trial 
blood samples.  
 
ADP-ribosyltransferases are present and active in porcine plasma samples 
Unfortunately, very few ADP-ribosylated proteins were identified when this optimized ADP-
ribosylome MS-workflow was applied to serum samples collected from a preliminary LPS trial 
(data not shown). Therefore, we established various biochemical assays to determine if the 
ADP-ribosylation states of plasma/serum proteins could be altered during sample collection 
and preparation. First, to demonstrate that the anti-pan-ADPr-antibody detects both PARylation 
and MARylation modifications, Western blot (WB) analyses were carried out on ARTD1 (also 
known as PARP1) samples that were modified in vitro via incubation with NAD+, activated 
DNA and/or HPF1 [34]. Auto-modification and strong PARylation of ARTD1 was detected 
when the enzyme was incubated with NAD+ and activated DNA, and, as previously 
demonstrated, the presence of HPF1 strongly shifted the modification state of ARTD1 from 
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PARylation towards MARylation and shorter PAR chains (Figure 2A, Suppl. Figure 5A) [19]. 
Little or no ADP-ribosylation was detectable via WB when ARTD1 was incubated without 
NAD+. Together, these data confirm that this antibody can be used in WBs to detect all forms 
of ADP-ribosylation.  
Next, we determined whether ADP-ribosyltransferases are present in plasma samples 
and if they were active under ADP-ribosylome MS sample preparation conditions. Plasma 
samples from healthy pigs were heat-denatured or denatured with 6M and 0.2M GndHCl, and 
then incubated overnight at 37 ºC in the presence or absence of NAD+. WB analysis of the 
resulting samples revealed that heat-denaturing at 95 ºC for 10 min, combined with subsequent 
overnight incubation at 37 ºC with NAD+, resulted in extensive ADP-ribosylation that was not 
induced in the absence of exogenous NAD+ (Figure 2B, Suppl. Figure 5B). These findings 
suggest that either ADP-ribosylhydrolases present in plasma are more susceptible to heat-
denaturing or that heat-denaturing inactivates both plasma ADPr-writers and -erasers, but 
creates an environment ideal for non-enzymatic ADP-ribosylation modification. Addition of 
GndHCl to the sample at a final concentration of 0.2M reduced the observed increase in ADP-
ribosylation by about half, while full denaturing condition (6M GndHCl) inhibited ADP-
ribosylation completely. These results suggest that adding GndHCl to blood or plasma samples 
at a final concentration of 6M could preserve the ADP-ribosylation state of the sample. 
 
Endogenous erasers of ADP-ribosylation are active in blood samples and rapidly reduce 
ADP-ribosylation after sample collection 
In light of the findings presented above, we wanted to determine whether plasma protein ADP-
ribosylation could be rapidly erased after sample collection and/or during plasma preparation. 
ADP-ribosylation was induced ex vivo in healthy pig plasma samples via incubation with NAD+ 
and DC27.10 cells that ectopically express the R-ADPr-specific ADP-ribosyltransferase 
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hARTC1 [35]. After modification, the cells were removed by centrifugation and the plasma 
incubated at 37 ºC for 15 min, 1hr, 4hrs and overnight (16hrs) to assess if the induced ADP-
ribosylation could subsequently be erased. Indeed, a strong decrease of plasma protein ADP-
ribosylation was observed already after 1hr and 4hrs. Most strikingly, ADP-ribosylation levels 
were reduced to those of untreated samples when the DC27.10 cell modified plasma samples 
were incubated overnight at 37 ºC (Figure 2C (left panel), Suppl. Figure 5C (left panel)), 
suggesting that R-ADPr modifications are rapidly erased in plasma and blood samples.  
Nevertheless, it remains unclear if the observed demodification was mediated by classic 
ADP-ribosylhydrolases present in the plasma. Indeed, studies have demonstrated that 
phosphodiesterases (PDEs), enzymes are known to reduce ADP-ribose to phosphoribose, are 
abundant in the blood and, thus, could also be responsible for the observed loss of plasma 
protein ADP-ribosylation [36, 37]. Based on this hypothesis, we repeated the experiment 
described above (Figure 2C (right panel), Suppl. Figure 5C (right panel)), but included cAMP 
in the reactions as this metabolite can compete with ADP-ribose as a PDE substrate. 
Interestingly, addition of 100 µM cAMP partially blocked the observed demodification for the 
first hour of incubation (Figure 2C, right panel). Together, these findings indicate that PDEs 
present in the plasma actively erase mono-ADPr plasma protein modifications within 1hr at 37 
ºC. These finding are critical, as blood collection and plasma preparation times fall within this 
time frame; thus, endogenous ADP-ribosylation modifications could be substantially reduced, 
or entirely lost, using standard sample preparation methodologies. 
Having established that R-ADPr modifications could be demodified in the plasma, we 
determined if this also holds true for other ADPr-amino acid acceptor modifications. To address 
this, we used ARTD1, which is mainly modified on serine (S) residues [38]. ARTD1 was auto-
modified in the presence of NAD+, activated DNA and HPF1. Following auto-modification, 
PJ34 (to inhibit further modification) and plasma were added, and the samples incubated for 
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1hr, 4hrs, and overnight (16hrs) at 37 °C. These samples were then analyzed via WB to 
determine if the amount of ADP-ribosylation decreased in the presence of plasma (Figure 2D, 
Suppl. Figure 5D). Indeed, ARTD1 ADP-ribosylation states gradually decreased when plasma 
was present; this was most evident following overnight incubation at 37 ºC. Together, these 
findings suggest that plasma ADP-ribosylation demodification is not specific to one ADPr-
amino acid acceptor linkage and it is likely that all ADPr-acceptor site modifications can be 
erased in the plasma. Moreover, these results demonstrate that ADP-ribosylhydrolases and 
PDEs are likely present in plasma samples and that in vivo ADP-ribosylated plasma proteins 
are demodified shortly after blood sampling prior to MS sample preparation. Therefore, 
optimization of the sample collection is crucial to preserve in vivo ADP-ribosylation.  
 
MS analysis of the in vivo whole blood ADP-ribosylome identifies 38 modified proteins in 
healthy pigs and 44 in LPS-treated pigs 
To identify the whole blood ADP-ribosylome of healthy and LPS-treated pigs via LC-MS/MS, 
we collected two different types of samples from the animals. First, whole blood lysates 
(WBLs) were generated by immediately denaturing the samples with 6M GndHCl after 
collection. These samples were processed for LC-MS/MS analysis using the new ADP-
ribosylome enrichment workflow with fractionation presented above (Figure 1, Suppl. Figure 
1). Second, to define the plasma-specific ADP-ribosylome, part of each blood sample was anti-
coagulated and processed to plasma. The plasma proteomes of each of these samples were 
defined via standard shot gun LC-MS/MS methods.  
We compared the amount of unique peptides, unique modification sites (> 95% 
localization confidence) and unique modified proteins identified in the WBLs of NaCl- and 
LPS-treated pigs and found that there were no significant differences in the amounts of either 
ADP-ribosylated peptides, unique modification sites or modified proteins between the two 
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groups (Figure 3A). A total of 64 ADP-ribosylated proteins were identified in the WBLs, 20 of 
which were uniquely found in the control group and 26 in the LPS-treated group respectively 
(Figure 3B). The modified proteins that were unique to the control group include proteins such 
as SENP5, HBE1, and RAD51D (Figure 3C, Table 3). While most of the proteins were only 
identified in 1 of the 5 control group pigs, the proteins MNS1 and YTHDC2 were found in 2 
and 3 of these pigs respectively (Figure 3C). 26 of the 64 ADP-ribosylated proteins detected in 
WBLs were unique to the LPS-treated group, including proteins such as SATB2, CA1, and 
HES2 (Figure 3D, Table 4). Similar to the trend observed for proteins unique to the control 
group, most of these modified proteins were again identified only for 1 of the 5 LPS-treated 
pigs, whereas 2 proteins (ARRDC5 and MYO3B) were identified for 2 pigs each (Figure 3D). 
Interestingly, 18 modified proteins were identified in both NaCl- and LPS-treated pigs 
including the porcine acute phase protein AHSG as well as hemoglobin subunits alpha and beta 
(Figure 3E, Tables 3 and 4). However, due to small sample numbers (n=5), no statistical 
differences in regard of the ADP-ribosylated proteins were found when analyzing the whole 
blood lysates.  
 
Comparison of the WBL ADP-ribosylome and input plasma proteome identifies 15 
modified plasma proteins 
To determine which of the modified proteins identified in the WBLs belong to the plasma 
fraction of the blood, we performed single-shot plasma proteome analyses and identified 828 
plasma proteins in healthy and 636 in LPS-treated pigs respectively (Figure 4A, Table 5). These 
two plasma proteomes were combined to generate a pig plasma reference proteome that 
contained 1055 unique proteins. This reference plasma proteome was then compared to the 
whole blood ADP-ribosylomes, which allowed us to identify the in vivo plasma ADP-
ribosylome (Figure 4B). Overall, the control and LPS-treated groups showed very similar 
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amounts of unique peptides, unique modification sites (> 95% localization confidence), and 
ADP-ribosylated protein identifications, similar to the findings for the WBL ADP-ribosylome 
(Figure 4C). However, of the 13 ADP-ribosylated plasma proteins that were identified in 
healthy pigs and 12 in LPS-treated pigs, 3 were unique to the control group and 2 to the LPS-
treated group (Figure 4D). The 3 proteins belonging to the control group only including 
biliverdin reductase B (BLVRB), Cache domain containing 1 protein (CACHD1) and 
hemoglobin subunit epsilon (HBE1) (Figure 3C) and the 2 modified plasma proteins unique to 
the LPS treatment group were carbonic anhydrase 1 (CA1) and an uncharacterized protein 
(Figure 3D). Due to small sample numbers (n=5), and the fact that some of these proteins were 
only identified in a single animal, differences in the presence of the 15 ADP-ribosylated plasma 
proteins were not significant.  
In addition, functional protein association network analyses (STRING) were performed 
for the ADP-ribosylated proteins identified in the WBL samples as well as the plasma and 
cellular fractions individually. Functional enrichments found in the WBL network included 
oxygen transport (HBA, HBB, and HBE1) as well as nicotinamide nucleotide metabolic process 
(MDH1 and GAPDH) (Figure 5) [39]. When analyzing only the cellular fraction of the blood 
ADP-ribosylome, we identified functional enrichment for microtubule associated proteins 
(BICD1 and BICD2) [39]. Within the plasma ADP-ribosylome, multiple molecular processes 
such as oxygen transport (HBB and HBE1), organonitrogen compound metabolic process 
(ALDH9A1, MDH1, GAPDH, and CACHD1), oxidation reduction process (ALDH9A1, 
MDH1, and GAPDH) as well as nicotinamide nucleotide metabolic processes (MDH1 and 
GAPDH) were functionally enriched [39]. In conclusion, applying the new workflow with 
fractionation to the WBL samples helped us identify the first ever blood ADP-ribosylome and 
the results indicate that there are most likely biologically relevant differences in the WBL and 
plasma ADP-ribosylomes of mock treated and LPS-treated pigs.  
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Serine and histidine are the most abundant ADP-ribose acceptor sites in WBL and plasma  
When analyzing protein ADP-ribosylation, the acceptor amino acids are of great interest since 
their distributions can help define the ADP-ribosyltransferases that could write the observed 
modifications. Thus, we determined the number of unique modification sites with > 95% PTM 
localization confidence in the WBL samples (including cellular and plasma proteins) as well as 
the plasma ADP-ribosylome (plasma proteins only). Interestingly, H- and S-ADPr 
modifications were both equally abundant in control and LPS-treated pigs (Suppl. Figure 4A). 
While the search algorithm also identified Y-ADPr, R-ADPr, D-ADPr and E-ADPr, these sites 
were ~3-time more abundant in both control and LPS-treated WBL samples. Very similar 
distributions and amounts of unique acceptor sites with high PTM localization confidences 
were identified when analyzing the ADPr-acceptor sites of the plasma protein ADP-ribosylome 
(Figure Suppl. 4B). Together, these data demonstrate that the most prominent unique ADPr-
acceptor sites with highest PTM localization confidence are indeed found within the plasma 
ADP-ribosylome and not the cellular fraction of the whole blood ADP-ribosylome. This could 
be due to the fact that plasma proteins, like HBB and AHSG are highly abundant and modified 
at multiple sites. Most interestingly, given that these results indicate that H-ADPr modifications 
are as abundant as S-ADPr modification, these data also suggest that the most active ADP-





In this study, we aimed to identify the whole blood and plasma protein ADP-ribosylomes in a 
porcine model for human SIRS and sepsis. To this extent, we first established the SIRS model 
by injecting pigs with either NaCl (control group) or A. pleuropneumoniae-derived LPS 
(treatment group) and monitored their clinical and hematological responses for 10hrs post-
injection. Preliminary experiments identified very few ADP-ribosylated proteins in serum 
samples from LPS treated pigs, we thus optimized the current ADP-ribosylated peptide 
enrichment workflow for downstream LC-MS/MS analysis. This was achieved by reducing 
long PAR chains to MAR before tryptic digestion, which was subsequently followed by 
depletion of PARG-generated free ADP-ribose from the samples prior to ADPr-peptide 
enrichments. We assessed efficacy of these optimizations using HeLa H2O2 treated cell lysates, 
which is the gold-standard sample for ADP-ribosylome analyses within the field, and found 
that ADP-ribosylated protein identifications increased ~2.5x when compared to the current 
state-of-the-art ADP-ribosylome MS-workflow (standard workflow) [18, 20]. Unfortunately, 
applying this optimized workflow to serum samples from LPS-treated and healthy pigs failed 
to improve ADP-ribosylated protein identifications. This led us to establish various ex vivo 
biochemical assays to determine whether ADP-ribosyltransferases and -hydrolases were 
present and active in the plasma/serum. Interestingly, we found that ADP-ribosylation could be 
induced by adding NAD+ to heat-denatured plasma samples and that ex vivo  and in vitro 
induced ADP-ribosylation was efficiently erased after incubation periods between 1hr and 
16hrs at 37 °C. These assays suggested that proteins are rapidly demodified after blood sample 
collection prior to MS sample preparation and that the sample collection protocol required 
optimization to maintain modification states at the time of sample collection. To this extent, we 
denatured blood samples from control and LPS-treated pigs immediately following collection 
and then defined the ADP-ribosylome of these whole blood lysates using the new ADPr-MS-
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based workflow described above. This led to the identification of 38 ADP-ribosylated blood 
proteins in healthy pigs and 44 in LPS-treated pigs. To determine which of these ADP-
ribosylated proteins were modified plasma proteins, we cross-referenced the whole blood ADP-
ribosylomes with the total plasma proteome and identified 15 ADP-ribosylated plasma proteins, 
10 of which were found in both groups, 3 that were unique to the control group and 2 to the 
LPS-treated group. 
To improve the enrichment efficiency of the existing MS sample preparation workflow, 
we performed a PARG treatment prior to trypsin digestion and sample clean-up prior to ADPr 
peptide enrichment. We reasoned that i) reducing the long and/or branched PAR chains to MAR 
modifications before trypsin digestion would improve the accessibility of digestion sites within 
the proteins and that ii) eliminating the free ADP-ribose could provide an additional advantage, 
as competitive binding between the free ADP-ribose and the modified peptides to the Af1521 
macrodomains would be reduced. Indeed, recent studies demonstrate that S-ADPr 
modifications are typically found within KS and RS motifs and, thus, reducing the large PAR 
chains could facilitate tryptic digestion, since trypsin is known to cleave peptide bonds after K 
and R [18, 40]. Introducing fractionation off of the C18 columns using different concentrations 
of ACN in either NH4OH (HpH) or TFA (LpH) to the sample preparation workflow further 
improved ADP-ribosylome coverage most likely by reducing sample complexity as described 
for HeLa cells [41]. 
After identifying very few ADP-ribosylated proteins in preliminary experiments using 
the optimized new workflow enrichment protocol, we performed various ex vivo modification 
and demodification assays that, taken together, suggest that ADP-ribosyltransferases and 
erasers of ADP-ribosylation (including PDEs) are present and active in the blood, even after 
sample collection. To further assess the presence of these enzymes in the blood samples, we 
analyzed the reference plasma proteome with respect to known writers and eraser of ADP-
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ribosylation and found that ARTC3 was present in all control and LPS pigs. ARTC3 has been 
previously identified in porcine muscle samples as well human plasma samples and is known 
to ADP-ribosylate arginine residues [42, 43]. However, only few arginine modifications were 
detected in the blood samples via MS analyses of, suggesting that either this enzyme is most 
likely not the main writer of ADP-ribosylation in the blood or that it is not entirely arginine 
specific, but can also modify other acceptor sites. Interestingly, one of the most abundantly 
modified amino acids in the ADP-ribosylomes of control and LPS-treated pigs was histidine, 
which is the most recently identified ADPr-acceptor amino acid [20]. This novel finding 
suggests that an uncharacterized ADP-ribosyltransferase could be present in the blood and 
responsible for the modification of histidine residues on these target proteins. Despite the fact 
that sirtuins and phosphodiesterases have been previously identified in human plasma, we did 
not identify any of the known ADP-ribosylhydrolases, or phosphodiesterases in the pig plasma 
samples analyzed here [42]. Since many known writers and erasers of ADP-ribosylation are 
localized within cells, they could be released into the blood after cell necrosis/lysis, and the 
resulting concentrations of writers and erasers in the plasma would most likely be very low, 
emphasizing the need for a highly sensitive method to detect these enzymes. Therefore, in depth 
analysis either via depletion and fractionation of the plasma proteome or parallel reaction 
monitoring (PRM)-MS could be applied to identify other writers or erasers that are present [44].  
In order to fully characterize and understand the functionality and potential downstream 
effects of blood protein ADP-ribosylation, the identification of ADP-ribosylated proteins is key 
and needs to be established. The novel method described and tested in this study provides a first 
step towards analyzing in vivo ADP-ribosylated blood and plasma proteins at the timepoint of 
sample collection and avoids post-sampling demodification. The modified proteins identified 
provide a first description of the in vivo whole blood and plasma ADP-ribosylomes and could 
influence protein functions in various ways. For example, two of the most heavily modified 
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proteins found in WBLs of both control and LPS samples were hemoglobin subunits alpha and 
beta, which are known to interact with drugs along with their important role in oxygen transport 
[45]. Thus, ADP-ribosylation of the hemoglobin subunits could alter its binding affinity to 
drugs or oxygen, carbon dioxide and/or carbon monoxide similarly as described for different 
hemoglobin mutations resulting in low affinity O2 binding due to its large size and structural 
interference [46]. Indeed, the peptides containing the histidine residues important for O2 binding  
(His87 in HBA and His93 in HBB) were found to be modified in both control and LPS-treated 
pigs [47]. Furthermore, ADP-ribosylation could negatively affect the drug binding capabilities 
of hemoglobin, ultimately resulting in increased renal excretion of drugs, similar to what has 
been described for glycosylation of drug binding plasma proteins [48]. Other plasma proteins 
that were found to be ADP-ribosylated included AHSG, which was modified in all 5 control 
pigs, but only 2 LPS pigs. This protein is a secreted acute phase protein in pigs, and total 
concentration of AHSG is routinely measured in a clinical setting to roughly quantify ongoing 
inflammatory reactions [32, 49]. Examining the modification state of AHSG at different 
timepoints during infection as opposed to only measuring abundance in blood samples could 
potentially help determine duration and severity of bacterial infections in pigs and possibly even 
predict clinical deterioration early-on. To further investigate this hypothesis, a time-course 
study with a targeted approach for AHSG ADP-ribosylation could be applied to the LPS model 
system.  
A possible mechanism leading to changes in ADP-ribosylation during severe SIRS or 
sepsis includes damage and intravascular decay of white blood cells, as well as the release of 
NAD+ and intracellular ADP-ribosylation writers and erasers to the blood as a result of tissue 
damage and cellular necrosis. Since intracellular proteins such as histones have been shown to 
be released into the blood stream under SIRS-like conditions, it is entirely possible that the 
ADP-ribosyltransferases and -hydrolases are also released into the blood stream and are could 
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be responsible for the modification of blood proteins found only in LPS-treated pigs [50]. 
Accordingly, some of the proteins found in the plasma ADP-ribosylome are known intracellular 
proteins such as GAPDH, BLVRB, and MDH1, that were likely released into the blood stream 
after cell damage and could, thus, serve as a marker for cell lysis and severity of SIRS. 
Even though no significant differences were detected between the control and LPS 
group due to small sample sizes, directly analyzing and validating the proteins that were found 
to be uniquely modified in healthy or LPS-treated pigs could serve as potential diagnostic 
markers in a clinical setting. First, the detection of these low abundant proteins could be 
increased by depleting high abundant blood proteins such as albumin in order to reduce the 
range of protein abundance and sample complexity [51]. The ADP-ribosylated proteins 
detected in plasma samples from LPS-treated but not healthy pigs could subsequently be 
validated as early biomarkers for SIRS. However, time- and cost-intensive LC-MS/MS is not 
feasible for routine clinical diagnostics. Rather, an easily applicable, time- and cost-efficient 
test such as an ELISA could be designed for a such validated targets. Many of the biomarkers 
currently validated for sepsis are not able to distinguish between infected and non-infected SIRS 
patients, and as a result, these diagnostic tests are not able to predict clinical deterioration [52]. 
Our novel method could be used to analyze plasma ADP-ribosylation patterns at multiple 
timepoints throughout sepsis development to determine if certain modified target proteins 
predict impending sepsis. Ideally, blood samples would be collected using the optimized 
sampling method at various timepoints before clinical diagnosis of sepsis and the ADP-
ribosylome could be compared between patients that develop sepsis and those who do not. 
Furthermore, the survival rate relative to ADP-ribosylation abundance could be analyzed and 
potentially applied to determine prognosis on an individual patient basis.  
In conclusion, this study contributes to the rapidly developing field of ADP-
ribosylation. To the best of our knowledge, no whole blood or plasma ADP-ribosylomes have 
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been identified and published so far. The workflow developed in this study combined with the 
improved blood sampling technique has led to the identification of the first whole blood and 
plasma ADP-ribosylome using Sus scrofa domesticus as a model organism for human SIRS. 
Moreover, the novel method developed to identify the exact in vivo state of ADP-ribosylation 
can be used to investigate other highly relevant PTMs in blood samples such as phosphorylation 
and glycosylation. This study provides insights into the regulation of ADP-ribosylated proteins 
by writers and erasers that are present in the blood. Understanding the functions of ADP-
ribosylation of extracellular proteins in disease will help to unravel the mechanisms underlying 
SIRS and sepsis, two of the major health threats today. Using these findings to further 
characterize dynamics of plasma protein ADP-ribosylation will give rise to a vast array of new 
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Figure 1: Comparison of the standard and new workflow using HeLa H2O2 treated cell lysates. 
A: Comparison of number of unique peptides, unique modification sites (>95% localization confidence) and 
proteins identified in HeLa H2O2-treated cells via LC-MS/MS analyses when samples were prepare using either 
the standard and new workflow. Combined HCD and EThcD data is shown. B: Venn diagrams showing the overlap 
of ADP-ribosylated proteins that were identified in either the standard or new workflow. C: Comparison of the 
amount of missed cleavages in peptides from HeLa H2O2-treated cell lysates prepared for MS analysis using the 
standard (left panel) or new workflow (right panel).  
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Figure 2: Inducing ADP-ribosylation via heat-denaturing and assessing demodification potential ex vivo. 
A: Western blot analysis of auto-modified ARTD1 (Trevigen), with and without 5 µM NAD+, activated DNA and 
HPF1 using the Cell Signaling anti-ADPr-antibody. B: Western blot analysis of heat-denatured (95 °C, 10 min), 
GndHCl-denatured and native porcine plasma using the using the Cell Signaling anti-ADPr-antibody. C: To 
determine how stable ADPr-modifications were in plasma samples, porcine plasma samples were ADP-ribosylated 
ex vivo via incubation with ARTC1 expressing DC27.10 cells and NAD+. The cells were removed and the plasma 
incubated for 0 min, 15 min, 1 hour, 4 hours and overnight (16 h) at 37 °C. Western blot analysis of using the Cell 
Signaling anti-ADPr-antibody was then used to determine if ADP-ribosylation levels decreased during post-
modification incubation (left panel). To determine if the observed changes were enzymatically driven, 100 µM 
cAMP was added to the samples after removing the cells and the samples incubated as described above (right 
panel) before incubation. D: ARTD1 was auto-modified as described above and then porcine plasma from healthy 
pigs was added these samples and incubated for 1h, 4hrs, or overnight at 37°C to assess whether auto-modified 
ARTD1 could also be demodified by plasma. Western blot analysis with an anti-pan-ADPr-antibody (CST) was 
used to assess this.  
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Figure 3: The in vivo WBL ADP-ribosylome identified in healthy and LPS-treated pigs. 
A: Overview of unique ADP-ribosylated peptides, unique modification sites (> 95% localization confidence) and 
proteins found in the WBL ADP-ribosylome of control and LPS-treated pigs. B: Venn diagrams showing the 
overlap of ADP-ribosylated proteins identified in the WBL of healthy and LPS-treated pigs. C: Overview of unique 
ADP-ribosylated proteins found in control pigs only. D: Overview of unique ADP-ribosylated proteins found in 
LPS-treated pigs only. E: Overview of the unique ADP-ribosylated proteins identified in both control and LPS-
treated pigs. “C” denotes proteins belonging to the cellular fraction of the blood and “P” those belonging to the 
plasma. Significant differences were not identified due to small sample sizes for panels C-E.  
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Figure 4: The in vivo plasma ADP-ribosylome identified in healthy and LPS-treated pigs. 
A: Venn diagram showing the overlap of proteins found in the plasma samples of control and LPS-treated pigs. 
B: The plasma ADP-ribosylome of control and LPS-treated pigs was determined by cross-referencing the WBL 
ADP-ribosylome of both groups with the reference plasma proteome (generated by combining the plasma 
proteomes of both groups). C: Overview of unique ADP-ribosylated peptides, unique modification sites (> 95% 
localization confidence) and proteins found in the plasma ADP-ribosylome of control and LPS-treated pigs. D: 






Figure 5: Functional protein network analyses (STRING) of ADP-ribosylated proteins identified in healthy 
and LPS-treated pigs. 
STRING analysis of all ADP-ribosylated proteins identified here revealed network and functional enrichments for 
oxygen transport (red), nicotinamide nucleotide metabolic processes (blue), microtubule associated proteins 
(pink), organonitrogen compound metabolic process (green), and oxidation-reduction processes (yellow). “C” 
denotes proteins belonging to the cellular fraction of the blood and “P” those belonging to the plasma.  
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Supplementary Figure 1: Specific and significant increases in core body temperatures and leukocyte 
concentrations were observed after LPS injections. 
A: Mean core body temperature (°C) of pigs ± standard deviation after NaCl (control group) or LPS (treatment 
group) injections at indicated timepoints during the LPS trial. B: Mean leukocyte amounts (x 103/µl) ± standard 
deviation before and after NaCl (control group) or LPS (treatment group) injection during the LPS trial. C: Mean 
plasma protein concentration ± standard deviation before and after injection during the LPS trial. Significant 
differences (p < 0.05) are labeled with an asterisk (*) while non-significant differences are labeled “n.s.”.  
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Supplementary Figure 2: Overview of standard workflow and new workflow for MS sample preparation. 
The standard workflow includes tryptic digestion, C18-SepPak peptide purification/clean-up, PARG-based PAR 
chain digestion, Af1521-based ADPr-modified peptide enrichment and a final pre-MS C18 stage-tip clean-up (left 
column). For the new workflow, we moved the PARG/Benzonase forward to the first step of the sample 
preparation protocol, this was done to optimize tryptic digestions and eliminate free ADP-ribose from the samples 
prior to Af1521-based ADPr-modified peptide enrichment (right column).  
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Supplementary Figure 3: Comparison of the new workflow with and without LpH/HpH fractionation 
using HeLa H2O2-treated cell lysate. 
A: Comparison of number of unique peptides, unique modification sites (>95% localization confidence) and 
proteins identified in HeLa H2O2  treated cells when preparing samples for LC-MS/MS using the new workflow 
with and without fractionation. Combined HCD and EThcD data are shown. B: Venn diagrams showing the 




Supplementary Figure 4: Modification site distribution of the WBL and plasma protein ADP-ribosylome. 
A: Overview of the acceptor amino acids of unique sites > 95% in the WBL ADP-ribosylome. B: Overview of the 
acceptor amino acids of unique sites > 95% in the plasma ADP-ribosylome.  
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Supplementary Figure 5: Protein loading control via Ponceau staining for WB analyses (Figure 2).  
A: Ponceau stain of auto-modified ARTD1 (Trevigen), with and without NAD+, activated DNA and HPF1. B: 
Ponceau stain of heat-denatured (95 °C, 10 min) and non-heat-denatured porcine plasma. Samples were incubated 
overnight at 37 °C ± NAD+, 0.2M or 6M GndHCl as indicated. C: Ponceau stain of the ex vivo induced plasma 
ADP-ribosylation samples presented in Figure 2 C; left panel are the samples without cAMP and the right panel 
samples with cAMP. D: Ponceau stain of the auto-modified ARTD1 and then plasma incubated  samples presented 




Table 1: Experimental groups, animal experiment number, ear tag number, gender, weight and 
treatments of the pigs in the LPS trial. 
 
 
  Group Ear tag no. Gender Weight (kg) Treatment 
control 
1304 F 9.52 NaCl 
1296 M 10.62 NaCl 
1297 M 10.82 NaCl 
1295 F 11.14 NaCl 
1294 M 12.06 NaCl 
LPS 
1300 M 10.48 LPS 
1303 F 10.8 LPS 
1305 F 10.86 LPS 
1291 M 10.9 LPS 







Table 2: detailed information on peptides, modification sites and proteins identified during the MS workflow comparison. 
prot_acc prot_desc gene_name PEP_ADPr_site workflow pep_score pep_expect pep_var_mod_conf pep_var_mod pep_start pep_end mis_cleav
Q9NYF8 Bcl-2-associated transcription factor 1 BCLAF1 EYSGFAGVSRPR_E1 SWF 42.26 0.00035 87.57% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 785 796
Q9NYF8 Bcl-2-associated transcription factor 1 BCLAF1 SFATASHR_S1 SWF 31.78 0.013 100% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 422 429
Q9NYF8 Bcl-2-associated transcription factor 1 BCLAF1 EYSGFAGVSRPR_S3 SWF 21.44 0.0097 83.37% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 785 796
A0A0A0MRH8 Chromodomain-helicase-DNA-binding protein 1-like CHD1L SAVLHSQSSSSSSR_S1 SWF 40.38 0.00016 98.81% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 599 612
Q14011 Cold-inducible RNA-binding protein CIRBP SGGYGGSR_S1 SWF 24.05 0.04 95.02% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 132 139
Q9BTC0 Death-inducer obliterator 1 DIDO1 RPWLSATPSSGASAAR_R1 SWF 32.35 0.00093 97.74% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 597 612
Q9BTC0 Death-inducer obliterator 1 DIDO1 RPWLSATPSSGASAAR_S5 SWF 26.18 0.0054 94.53% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 597 612
P39748 Flap endonuclease 1 FEN1 VTGSLSSAK_S4 SWF 22.19 0.028 53.30% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 346 354
Q5TEC6;P68431;Q71DI3;Q16695 Histone H3;Histone H3.1;Histone H3.2;Histone H3.1t HIST2H3PS2;HIST1H3A;HIST2H3A;HIST3H3 SAPATGGVK_S1 SWF 38.49 0.0023 100% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 29 37
P05114 Non-histone chromosomal protein HMG-14 HMGN1 KVSSAEGAAKEEPK_K1 SWF 74.17 1.70E-07 99.30% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 5 18
P05114 Non-histone chromosomal protein HMG-14 HMGN1 KVSSAEGAAKEEPK_S3 SWF 41.7 0.00013 57.73% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 5 18
P05204 Non-histone chromosomal protein HMG-17 HMGN2 LSAKPAPPKPEPKPK_K4 SWF 24.95 0.0046 49.02% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 28 42
P05204 Non-histone chromosomal protein HMG-17 HMGN2 LSAKPAPPKPEPKPK_S2 SWF 28.48 0.0021 84.64% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 28 42
Q13151 Heterogeneous nuclear ribonucleoprotein A0 HNRNPA0 SGGGGGGGGSSWGGR_S1 SWF 79.36 3.60E-08 100.00% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 270 284
P09651 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 NQGGYGGSSSSSSYGSGR_Y5 SWF 53.67 9.30E-06 99.18% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 353 370
P09651 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 SGSGNFGGGR_S1 SWF 31.29 0.0021 84.74% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 197 206
P09651 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 SSGPYGGGGQYFAKPR_S1 SWF 52.3 1.20E-05 60.63% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 337 352
P09651 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 SSGPYGGGGQYFAKPR_S2 SWF 43.07 9.10E-05 46.04% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 337 352
P09651 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 NQGGYGGSSSSSSYGSGR_S11 SWF 43.17 8.90E-05 70.50% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 353 370
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 HNRNPA2B1 SGNFGGSR_S1 SWF 32.74 0.0058 100% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 318 325
P51991 Heterogeneous nuclear ribonucleoprotein A3 HNRNPA3 SSGSPYGGGYGSGGGSGGYGSR_S4 SWF 80.55 2.80E-08 48.43% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 355 376
Q9BUJ2 Heterogeneous nuclear ribonucleoprotein U-like protein 1 HNRNPUL1 SGGGGYSQNR_S1 SWF 23.2 0.0067 100% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 662 671
Q07666 KH domain-containing  RNA-binding  signal transduction-associated protein 1 KHDRBS1 SGSMDPSGAHPSVR_D4 SWF 44.65 6.50E-05 57.08% Oxidation (M); ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 18 31
Q07666 KH domain-containing  RNA-binding  signal transduction-associated protein 1 KHDRBS1 SGSMDPSGAHPSVR_S1 SWF 78.96 6.80E-08 99.48% Oxidation (M); ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 18 31
Q07666 KH domain-containing  RNA-binding  signal transduction-associated protein 1 KHDRBS1 SGSMDPSGAHPSVR_S3 SWF 39.49 0.00032 48.13% Oxidation (M); ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 18 31
P02545 Prelamin-A/C LMNA SGAQASSTPLSPTR_S1 SWF 39.78 0.00022 98.77% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 12 25
Q9Y6R4 Mitogen-activated protein kinase kinase kinase 4 MAP3K4 STQRAPR_S1 SWF 29.98 0.037 96.85% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 1395 1401
P46013 Antigen KI-67 MKI67 SGNLPSKR_S1 SWF 29.44 0.019 98.81% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 621 628
Q9BQG0 Myb-binding protein 1A MYBBP1A SPSLLQSGAK_S1 SWF 22.36 0.022 87.05% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 1308 1317
Q14978 Nucleolar and coiled-body phosphoprotein 1 NOLC1 SLGTQPPKK_S1 SWF 27.05 0.0041 100% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 303 311
Q14978 Nucleolar and coiled-body phosphoprotein 1 NOLC1 VAGGAAPSKPASAK_S12 SWF 29.13 0.0019 88.93% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 497 510
Q8TEM1 Nuclear pore membrane glycoprotein 210 NUP210 DSEADRFSDSHNALR_R6 SWF 33.38 0.00074 40.73% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 164 178
Q9BXS6 Nucleolar and spindle-associated protein 1 NUSAP1 SAHVTVSGGTPK_S1 SWF 27.67 0.0025 97.64% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 305 316
P09874 Poly [ADP-ribose] polymerase 1 PARP1 EEGINKSEK_E2 SWF 21.9 0.0095 63.68% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 513 521
P09874 Poly [ADP-ribose] polymerase 1 PARP1 EEGINKSEK_S7 SWF 38.69 0.0047 75.52% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 513 521
P09874 Poly [ADP-ribose] polymerase 1 PARP1 SKGQVKEEGINK_K2 SWF 34.05 0.0025 49.96% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 507 518
P30101 Protein disulfide-isomerase A3 PDIA3 RLAPEYEAAATR_R1 SWF 74.19 5.10E-07 100.00% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 62 73
Q8NEY8 Periphilin-1 PPHLN1 SYSFHQSQHR_Y2 SWF 22.56 0.013 45.59% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 161 170
Q8NEY8 Periphilin-1 PPHLN1 SYSFHQSQHR_S1 SWF 26.5 0.0033 74.08% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 161 170
P62136 Serine/threonine-protein phosphatase PP1-alpha catalytic subunit PPP1CA YGQFSGLNPGGRPITPPR_Y1 SWF 47.43 3.60E-05 99.79% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 306 323
P98179 RNA-binding protein 3 RBM3 NQGGYDRYSGGNYR_D6 SWF 20.07 0.013 43.56% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 139 152
P38159 RNA-binding motif protein  X chromosome RBMX SAPSGPVR_S1 SWF 32.25 0.013 99.24% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 165 172
P38159 RNA-binding motif protein  X chromosome RBMX SDLYSSGR_D2 SWF 21.48 0.021 47.78% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 332 339
P38159 RNA-binding motif protein  X chromosome RBMX SDLYSSGR_S1 SWF 31.42 0.0037 84.05% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 332 339
P38159 RNA-binding motif protein  X chromosome RBMX VEQATKPSFESGR_S11 SWF 38.08 0.0013 78.03% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 81 93
P61247 40S ribosomal protein S3a RPS3A KTSYAQHQQVR_K1 SWF 37.07 0.00033 72.94% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 152 162
P61247 40S ribosomal protein S3a RPS3A KTSYAQHQQVR_Y4 SWF 20.91 0.011 81.73% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 152 162
Q68D10 Protein SPT2 homolog SPTY2D1 GPGRPVSSPHELR_R4 SWF 23.49 0.03 67.43% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 464 476
Q68D10 Protein SPT2 homolog SPTY2D1 GPGRPVSSPHELR_S7 SWF 32.7 0.0019 86.13% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 464 476
Q92804 TATA-binding protein-associated factor 2N TAF15 SGGGYGGDR_S1 SWF 30.7 0.0022 99.62% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 423 431
Q92804 TATA-binding protein-associated factor 2N TAF15 SGGYGGDR_S1 SWF 26.77 0.041 97.74% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 546 553
P11388 DNA topoisomerase 2-alpha TOP2A RDPALNSGVSQKPDPAK_D14 SWF 29.65 0.0032 58.64% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 1443 1459
P11388 DNA topoisomerase 2-alpha TOP2A RDPALNSGVSQKPDPAK_S7 SWF 33.07 0.00079 97.78% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 1443 1459
Q8WZ42 Titin TTN ISLGARVVLTR_R6 SWF 22 0.01 94.87% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 12630 12640
O96028 Histone-lysine N-methyltransferase NSD2 WHSC1 LCSSAETLESHPDIGK_S3 SWF 23.05 0.0069 71.07% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 405 420
P25490 Transcriptional repressor protein YY1 YY1 KSYLSGGAGAAGGGGADPGNK_S5 SWF 69.09 4.90E-07 93.88% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 183 203
P25490 Transcriptional repressor protein YY1 YY1 SYLSGGAGAAGGGGADPGNK_S4 SWF 37.81 0.00028 77.86% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 184 203
P25490 Transcriptional repressor protein YY1 YY1 SYLSGGAGAAGGGGADPGNKK_S4 SWF 34.19 0.00062 24.89% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 184 204
P25490 Transcriptional repressor protein YY1 YY1 SYLSGGAGAAGGGGADPGNKK_Y2 SWF 64.82 4.50E-06 49.56% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 184 204
Q9NR48 Histone-lysine N-methyltransferase ASH1L ASH1L STAPSLALLADSEKPSHK_S1 NWF 70.05 2.70E-07 99.86% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 785 802
Q9NR48 Histone-lysine N-methyltransferase ASH1L ASH1L STAPSLALLADSEKPSHK_S5 NWF 30.11 0.0027 49.79% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 785 802
Q9UIG0 Tyrosine-protein kinase BAZ1B BAZ1B SLSGSPLK_S1 NWF 23.15 0.047 81.36% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 345 352
Q9NYF8 Bcl-2-associated transcription factor 1 BCLAF1 EYSGFAGVSRPR_E1 NWF 60.49 2.00E-05 91.22% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 785 796
Q9NYF8 Bcl-2-associated transcription factor 1 BCLAF1 EYSGFAGVSRPR_S3 NWF 38.73 0.00023 93.38% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 785 796
Q9NYF8 Bcl-2-associated transcription factor 1 BCLAF1 SFATASHR_S1 NWF 42.19 0.00012 100% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 422 429






Table 2: detailed information on peptides, modification sites and proteins identified during the MS workflow comparison (continued). 
prot_acc prot_desc gene_name PEP_ADPr_site workflow pep_score pep_expect pep_var_mod_conf pep_var_mod pep_start pep_end mis_cleav
P54132 Bloom syndrome protein BLM SSSIIGSSSASHTSQATSGANSK_S3 NWF 71.38 2.00E-07 33.29% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 1373 1395
Q7L1Q6 Basic leucine zipper and W2 domain-containing protein 1 BZW1 QQKPTLSGQR_K3 NWF 25.31 0.0055 100% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 6 15
Q7L1Q6 Basic leucine zipper and W2 domain-containing protein 1 BZW1 QQKPTLSGQR_S7 NWF 22.9 0.032 93.48% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 6 15
Q8NDD1 Uncharacterized protein C1orf131 C1orf131 SYVNYK_S1 NWF 23.78 0.025 84.39% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 207 212
Q9NWY4 UPF0609 protein C4orf27 C4orf27 TFHGAGLVVPVDKNDVGYR_R19 NWF 21.89 0.0088 33.94% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 221 239
Q9NWY4 UPF0609 protein C4orf27 C4orf27 TFHGAGLVVPVDKNDVGYR_Y18 NWF 26.45 0.0033 60.00% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 221 239
P45973 Chromobox protein homolog 5 CBX5 SNFSNSADDIK_S1 NWF 40.89 0.00015 82.75% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 92 102
Q9H6F5 Coiled-coil domain-containing protein 86 CCDC86 RFSQMLQDKPLR_R1 NWF 31.05 0.0058 79.44% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 253 264
Q9H6F5 Coiled-coil domain-containing protein 86 CCDC86 RFSQMLQDKPLR_S3 NWF 50.35 1.90E-05 99.00% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 253 264
Q7Z7K6-3 Isoform 3 of Centromere protein V CENPV SGASAAPAASAAAALAPSATR_S10 NWF 29.57 0.019 33.31% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 18 38
Q7Z7K6-3 Isoform 3 of Centromere protein V CENPV SGASAAPAASAAAALAPSATR_S4 NWF 21.26 0.01 34.41% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 18 38
Q7Z7K6 Centromere protein V CENPV SGASGASAAPAASAAAALAPSATR_S13 NWF 34.45 0.001 24.99% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 18 41
Q7Z7K6 Centromere protein V CENPV SGASGASAAPAASAAAALAPSATR_S7 NWF 36.44 0.00038 32.87% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 18 41
Q14011 Cold-inducible RNA-binding protein CIRBP SGGYGGSR_S1 NWF 33.4 0.03 98.88% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 132 139
Q14011 Cold-inducible RNA-binding protein CIRBP SQSGGYSDR_S1 NWF 23.52 0.0066 60.83% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 146 154
Q8N684 Cleavage and polyadenylation specificity factor subunit 7 CPSF7 SYSVGASGSSSR_Y2 NWF 29.05 0.0019 39.79% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 407 418
Q9H8H2 Probable ATP-dependent RNA helicase DDX31 DDX31 SHAVGPQEIR_S1 NWF 43.72 8.10E-05 99.93% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 678 687
Q08211 ATP-dependent RNA helicase A DHX9 YDNGSGYR_Y1 NWF 30.57 0.019 87.32% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 1167 1174
Q9BTC0 Death-inducer obliterator 1 DIDO1 RPWLSATPSSGASAAR_R1 NWF 45.95 9.80E-05 99.83% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 597 612
Q9BTC0 Death-inducer obliterator 1 DIDO1 SSFANVAAATPAIK_S2 NWF 32.81 0.0017 49.99% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 571 584
Q9UNQ2 Probable dimethyladenosine transferase DIMT1 SAGGLMFNTGIGQHILK_S1 NWF 28.39 0.0022 100% Oxidation (M); ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 24 40
O43768 Alpha-endosulfine ENSA SSLVTSK_S2 NWF 25.9 0.046 64.32% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 108 114
Q01780 Exosome component 10 EXOSC10 SMSFPTGK_S1 NWF 26.93 0.0052 94.68% Oxidation (M); ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 866 873
Q9BTL3 RNMT-activating mini protein FAM103A1 SWGNNYPQHR_S1 NWF 32.49 0.00094 99.87% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 86 95
Q5HYJ3 Protein FAM76B FAM76B SSATIQNETPK_S2 NWF 24.5 0.005 27.87% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 207 217
P39748 Flap endonuclease 1 FEN1 VTGSLSSAK_S7 NWF 25.35 0.0042 44.28% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 346 354
P39748 Flap endonuclease 1 FEN1 VTGSLSSAKR_S4 NWF 30.99 0.0022 94.43% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 346 355
P39748-2 Isoform FENMIT of Flap endonuclease 1 FEN1 VTGSLSSAKR_S7 NWF 51.51 6.00E-04 95.95% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 282 291
P35637 RNA-binding protein FUS FUS SSGGYEPR_S1 NWF 60.63 6.30E-05 94.39% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 235 242
P84243 Histone H3.3 H3F3A SAPSTGGVK_S1 NWF 27.82 0.018 97.36% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 29 37
P68431;Q5TEC6;Q16695 Histone H3.1;Histone H3;Histone H3.1t HIST1H3A;HIST2H3PS2;HIST3H3 SAPATGGVK_S1 NWF 21.52 0.023 100% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 29 37
P17096 High mobility group protein HMG-I/HMG-Y HMGA1 KQPPVSPGTALVGSQKEPSEVPTPK_K1 NWF 26.07 0.0036 90.03% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 31 55
P17096;A6NN90 High mobility group protein HMG-I/HMG-Y;Uncharacterized protein C2orf81 HMGA1;C2orf81 SSQPLASK_S1 NWF 29.91 0.034 84.86% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 8 15
P17096;A6NN90 High mobility group protein HMG-I/HMG-Y;Uncharacterized protein C2orf81 HMGA1;C2orf81 SSQPLASK_S2 NWF 33.43 0.029 49.87% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 8 15
P05114 Non-histone chromosomal protein HMG-14 HMGN1 KVSSAEGAAKEEPK_K1 NWF 76.06 6.80E-06 99.09% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 5 18
P05114 Non-histone chromosomal protein HMG-14 HMGN1 KVSSAEGAAKEEPK_S3 NWF 91.49 1.80E-08 97.78% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 5 18
P05204 Non-histone chromosomal protein HMG-17 HMGN2 LSAKPAPPKPEPKPK_K4 NWF 27.54 0.0026 48.62% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 28 42
P05204 Non-histone chromosomal protein HMG-17 HMGN2 LSAKPAPPKPEPKPK_S2 NWF 48.54 2.80E-05 97.38% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 28 42
Q13151 Heterogeneous nuclear ribonucleoprotein A0 HNRNPA0 SGGGGGGGGSSWGGR_S1 NWF 85.34 2.30E-08 100.00% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 270 284
P09651 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 NQGGYGGSSSSSSYGSGR_S11 NWF 63.26 1.20E-06 25.99% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 353 370
P09651 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 NQGGYGGSSSSSSYGSGR_S13 NWF 26.12 0.0036 42.41% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 353 370
P09651 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 NQGGYGGSSSSSSYGSGR_S16 NWF 70.45 2.50E-07 69.21% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 353 370
P09651 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 NQGGYGGSSSSSSYGSGR_Y5 NWF 72.21 1.70E-07 99.88% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 353 370
P09651 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 SESPKEPEQLR_E2 NWF 20.41 0.012 31.55% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 4 14
P09651 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 SGSGNFGGGR_S1 NWF 54.65 3.20E-05 98.73% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 197 206
P09651 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 SKSESPKEPEQLR_K2 NWF 22.4 0.01 47.15% Acetyl (Protein N-term); ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 2 14
P09651 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 SSGPYGGGGQYFAKPR_S1 NWF 118.91 7.10E-12 86.39% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 337 352
P09651 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 SSGPYGGGGQYFAKPR_S2 NWF 129.29 1.20E-12 50.00% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 337 352
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 HNRNPA2B1 NMGGPYGGGNYGPGGSGGSGGYGGR_Y2 NWF 90.36 3.40E-09 99.96% Oxidation (M); ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 326 350
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 HNRNPA2B1 NMGGPYGGGNYGPGGSGGSGGYGGR_Y6 NWF 37.1 0.00033 97.29% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 326 350
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 HNRNPA2B1 SGNFGGSR_S1 NWF 34.39 0.0048 100% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 318 325
P51991 Heterogeneous nuclear ribonucleoprotein A3 HNRNPA3 SSGSPYGGGYGSGGGSGGYGSR_S1 NWF 63.01 1.20E-06 87.81% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 355 376
P51991 Heterogeneous nuclear ribonucleoprotein A3 HNRNPA3 SSGSPYGGGYGSGGGSGGYGSR_S12 NWF 26.09 0.0036 66.65% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 355 376
P51991 Heterogeneous nuclear ribonucleoprotein A3 HNRNPA3 SSGSPYGGGYGSGGGSGGYGSR_S2 NWF 125.6 1.70E-12 49.15% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 355 376
P51991 Heterogeneous nuclear ribonucleoprotein A3 HNRNPA3 SSGSPYGGGYGSGGGSGGYGSR_S4 NWF 35.72 0.00045 50.85% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 355 376
P07910 Heterogeneous nuclear ribonucleoproteins C1/C2 HNRNPC SGFNSK_S1 NWF 21.74 0.046 95.75% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 171 176
P14866 Heterogeneous nuclear ribonucleoprotein L HNRNPL YYGGGSEGGR_Y1 NWF 28.25 0.0022 76.94% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 47 56
O43390 Heterogeneous nuclear ribonucleoprotein R HNRNPR STAYEDYYYHPPPR_S1 NWF 55.66 6.00E-06 90.16% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 428 441
Q00839 Heterogeneous nuclear ribonucleoprotein U HNRNPU SSGPTSLFAVTVAPPGAR_S6 NWF 36.64 0.00039 47.23% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 187 204
Q9BUJ2 Heterogeneous nuclear ribonucleoprotein U-like protein 1 HNRNPUL1 SGGGGYSQNR_S1 NWF 84.31 3.00E-07 100.00% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 662 671
Q1KMD3 Heterogeneous nuclear ribonucleoprotein U-like protein 2 HNRNPUL2 SRGQGYVGGQR_R2 NWF 43.31 0.00013 49.99% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 655 665
Q12906 Interleukin enhancer-binding factor 3 ILF3 SGGNSYGSGGASYNPGSHGGYGGGSGGGSSYQGK_Y6 NWF 59.02 2.90E-06 33.02% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 816 849
Q07666 KH domain-containing  RNA-binding  signal transduction-associated protein 1 KHDRBS1 SGSMDPSGAHPSVR_D4 NWF 34.32 0.0013 46.62% Oxidation (M); ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 18 31
Q07666 KH domain-containing  RNA-binding  signal transduction-associated protein 1 KHDRBS1 SGSMDPSGAHPSVR_S1 NWF 72.87 1.50E-07 99.56% Oxidation (M); ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 18 31







Table 2: detailed information on peptides, modification sites and proteins identified during the MS workflow comparison (continued). 
prot_acc prot_desc gene_name PEP_ADPr_site workflow pep_score pep_expect pep_var_mod_conf pep_var_mod pep_start pep_end mis_cleav
P02545 Prelamin-A/C LMNA SGAQASSTPLSPTR_S1 NWF 60.14 2.90E-06 99.95% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 12 25
P02545 Prelamin-A/C LMNA SVGGSGGGSFGDNLVTR_S1 NWF 71.12 2.20E-07 98.84% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 628 644
P02545 Prelamin-A/C LMNA SVGGSGGGSFGDNLVTR_S5 NWF 26.11 0.0036 48.45% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 628 644
O95243 Methyl-CpG-binding domain protein 4 MBD4 SCSGFVQSDSKR_S1 NWF 79.42 1.90E-06 98.57% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 253 264
P46013 Antigen KI-67 MKI67 SGGSGHAVAEPASPEQELDQNK_S1 NWF 94.97 1.70E-09 91.54% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 296 317
P46013 Antigen KI-67 MKI67 SGGSGHAVAEPASPEQELDQNK_S13 NWF 20.1 0.031 30.38% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 296 317
P46013 Antigen KI-67 MKI67 SGGSGHAVAEPASPEQELDQNK_S4 NWF 53.44 0.00018 49.81% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 296 317
P46013 Antigen KI-67 MKI67 SGLQTDYATEK_S1 NWF 36.95 0.0015 99.65% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 264 274
P46013 Antigen KI-67 MKI67 SGNLPSKR_S1 NWF 37.81 0.0068 99.63% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 621 628
Q96NY9 Crossover junction endonuclease MUS81 MUS81 AGGSGSYWPAR_S4 NWF 25.58 0.03 80.95% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 124 134
Q9BQG0 Myb-binding protein 1A MYBBP1A SPSLLQSGAK_S1 NWF 28.18 0.023 75.82% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 1308 1317
Q14978 Nucleolar and coiled-body phosphoprotein 1 NOLC1 SLGTQPPKK_S1 NWF 24.89 0.0063 100% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 303 311
Q14978 Nucleolar and coiled-body phosphoprotein 1 NOLC1 VAGGAAPSKPASAK_S12 NWF 37.94 0.00028 90.63% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 497 510
P06748 Nucleophosmin NPM1 SNQNGKDSKPSSTPR_S1 NWF 21.4 0.01 76.73% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 207 221
Q14980 Nuclear mitotic apparatus protein 1 NUMA1 KLGNSLLR_K1 NWF 23.77 0.044 100% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 2058 2065
Q14980 Nuclear mitotic apparatus protein 1 NUMA1 SAPASQASLR_S1 NWF 40.6 0.0018 99.81% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 1840 1849
Q8TEM1 Nuclear pore membrane glycoprotein 210 NUP210 DSEADRFSDSHNALR_R6 NWF 28.44 0.0022 35.55% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 164 178
Q9BXS6 Nucleolar and spindle-associated protein 1 NUSAP1 KSAHVTVSGGTPK_K1 NWF 52.12 6.50E-05 92.31% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 304 316
Q9BXS6 Nucleolar and spindle-associated protein 1 NUSAP1 KSAHVTVSGGTPK_S8 NWF 35.14 0.00051 98.42% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 304 316
Q9BXS6 Nucleolar and spindle-associated protein 1 NUSAP1 SAHVTVSGGTPK_S1 NWF 70.84 3.40E-06 100.00% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 305 316
Q9BXS6 Nucleolar and spindle-associated protein 1 NUSAP1 SCGPASQSTLGLK_S1 NWF 65.25 1.10E-05 99.99% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 255 267
Q9BXS6 Nucleolar and spindle-associated protein 1 NUSAP1 SLYTDESSKPGK_S1 NWF 30.98 0.0016 89.87% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 163 174
Q13415 Origin recognition complex subunit 1 ORC1 SSLHTLTK_S1 NWF 30.34 0.0094 93.78% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 449 456
P07237 Protein disulfide-isomerase P4HB VDATEESDLAQQYGVRGYPTIK_R16 NWF 23.24 0.0066 63.13% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 82 103
Q86U42 Polyadenylate-binding protein 2 PABPN1 AAAAAAAAAAGAAGGRGSGPGR_S18 NWF 31.37 0.0021 48.86% Acetyl (Protein N-term); ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 2 23
P09874 Poly [ADP-ribose] polymerase 1 PARP1 EEGINKSEK_E1 NWF 31.11 0.011 69.35% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 513 521
P09874 Poly [ADP-ribose] polymerase 1 PARP1 EEGINKSEK_E2 NWF 28.78 0.01 63.95% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 513 521
P09874 Poly [ADP-ribose] polymerase 1 PARP1 EEGINKSEK_S7 NWF 30.87 0.045 47.87% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 513 521
P09874 Poly [ADP-ribose] polymerase 1 PARP1 EEGINKSEKR_E2 NWF 20.67 0.036 49.35% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 513 522
P09874 Poly [ADP-ribose] polymerase 1 PARP1 EEGINKSEKR_S7 NWF 26.07 0.01 85.51% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 513 522
P09874 Poly [ADP-ribose] polymerase 1 PARP1 GKSGAALSK_K2 NWF 39.19 0.0033 87.32% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 497 505
P09874 Poly [ADP-ribose] polymerase 1 PARP1 GKSGAALSK_S3 NWF 30.43 0.016 49.86% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 497 505
P09874 Poly [ADP-ribose] polymerase 1 PARP1 GKSGAALSKK_S2 NWF 23.72 0.023 100% 2 ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 497 506
P09874 Poly [ADP-ribose] polymerase 1 PARP1 GQVKEEGINKSEK_E12 NWF 24.9 0.0064 25.01% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 509 521
P09874 Poly [ADP-ribose] polymerase 1 PARP1 GQVKEEGINKSEK_K10 NWF 23.53 0.0068 37.65% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 509 521
P09874 Poly [ADP-ribose] polymerase 1 PARP1 GQVKEEGINKSEK_S11 NWF 25.36 0.024 45.41% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 509 521
P09874 Poly [ADP-ribose] polymerase 1 PARP1 SGAALSK_S1 NWF 38.95 0.013 98.89% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 499 505
P09874 Poly [ADP-ribose] polymerase 1 PARP1 SKGQVKEEGINK_K1 NWF 60.97 4.80E-06 99.99% 2 ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 507 518
P09874 Poly [ADP-ribose] polymerase 1 PARP1 SKGQVKEEGINK_K2 NWF 24.25 0.0059 47.52% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 507 518
P09874 Poly [ADP-ribose] polymerase 1 PARP1 SKGQVKEEGINK_S1 NWF 78.49 3.20E-07 95.30% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 507 518
P09874 Poly [ADP-ribose] polymerase 1 PARP1 SKGQVKEEGINKSEK_K1 NWF 28.08 0.0043 82.05% 2 ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 507 521
O94913 Pre-mRNA cleavage complex 2 protein Pcf11 PCF11 SGWEENK_S1 NWF 24.67 0.034 96.60% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 599 605
P22061 Protein-L-isoaspartate(D-aspartate) O-methyltransferase PCMT1 SGGASHSELIHNLR_S1 NWF 35.08 0.00055 87.51% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 5 18
P30101 Protein disulfide-isomerase A3 PDIA3 RLAPEYEAAATR_R1 NWF 67.01 4.30E-06 100.00% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 62 73
Q9BY77 Polymerase delta-interacting protein 3 POLDIP3 SSGASVTTQPTEFK_S2 NWF 23.53 0.0062 48.27% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 405 418
Q8NEY8 Periphilin-1 PPHLN1 SVRPGASYK_S1 NWF 29.69 0.0021 95.38% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 172 180
Q8NEY8 Periphilin-1 PPHLN1 SYSFHQSQHR_S1 NWF 42.98 9.30E-05 80.99% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 161 170
Q8NEY8 Periphilin-1 PPHLN1 SYSFHQSQHR_S3 NWF 37.46 0.00078 42.47% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 161 170
Q8NEY8 Periphilin-1 PPHLN1 SYSFHQSQHR_Y2 NWF 24.31 0.0074 44.92% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 161 170
Q8WUA2 Peptidyl-prolyl cis-trans isomerase-like 4 PPIL4 SKYQTDLYER_K2 NWF 32.5 0.0016 46.47% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 459 468
Q8WUA2 Peptidyl-prolyl cis-trans isomerase-like 4 PPIL4 SKYQTDLYER_S1 NWF 58.25 6.30E-06 91.03% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 459 468
P62136 Serine/threonine-protein phosphatase PP1-alpha catalytic subunit PPP1CA YGQFSGLNPGGRPITPPR_Y1 NWF 45.61 5.30E-05 99.62% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 306 323
P98179 RNA-binding protein 3 RBM3 NQGGYDRYSGGNYR_Y5 NWF 23.52 0.0062 30.34% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 139 152
P98179 RNA-binding protein 3 RBM3 YSGGNYR_Y1 NWF 28.73 0.0089 89.70% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 146 152
P38159 RNA-binding motif protein  X chromosome RBMX AIKVEQATKPSFESGR_K3 NWF 54.78 7.30E-06 94.28% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 78 93
P38159 RNA-binding motif protein  X chromosome RBMX AIKVEQATKPSFESGR_R16 NWF 52.92 6.80E-05 47.35% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 78 93
P38159 RNA-binding motif protein  X chromosome RBMX DRDYSDHPSGGSYR_D1 NWF 34.98 0.00052 75.58% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 269 282
P38159 RNA-binding motif protein  X chromosome RBMX DYGHSSSRDDYPSR_D1 NWF 26.03 0.0036 44.33% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 245 258
P38159 RNA-binding motif protein  X chromosome RBMX GPPPSYGGSSR_S9 NWF 20.06 0.013 45.99% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 299 309
P38159 RNA-binding motif protein  X chromosome RBMX SAPSGPVR_S1 NWF 27.8 0.044 98.67% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 165 172
P38159 RNA-binding motif protein  X chromosome RBMX SDLYSSGR_D2 NWF 23.71 0.0082 47.33% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 332 339
P38159 RNA-binding motif protein  X chromosome RBMX SDLYSSGR_S1 NWF 39.68 0.00058 90.78% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 332 339
P38159 RNA-binding motif protein  X chromosome RBMX VEQATKPSFESGR_E10 NWF 31.56 0.0052 60.68% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 81 93
P38159 RNA-binding motif protein  X chromosome RBMX VEQATKPSFESGR_E2 NWF 27.7 0.01 52.69% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 81 93
P38159 RNA-binding motif protein  X chromosome RBMX VEQATKPSFESGR_S11 NWF 58.1 0.00035 83.85% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 81 93
P38159 RNA-binding motif protein  X chromosome RBMX VEQATKPSFESGRR_R13 NWF 40.01 0.00044 43.74% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 81 94







Table 2: detailed information on peptides, modification sites and proteins identified during the MS workflow comparison (continued). 
prot_acc prot_desc gene_name PEP_ADPr_site workflow pep_score pep_expect pep_var_mod_conf pep_var_mod pep_start pep_end mis_cleav
P35251 Replication factor C subunit 1 RFC1 SSADKIGEVSSPK_S1 NWF 32.99 0.00081 84.90% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 302 314
P35251 Replication factor C subunit 1 RFC1 SSADKIGEVSSPK_S2 NWF 47.66 0.00029 49.19% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 302 314
P83731 60S ribosomal protein L24 RPL24 VELCSFSGYK_E2 NWF 34.84 0.00054 98.29% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 3 12
P62917 60S ribosomal protein L8 RPL8 ASGNYATVISHNPETK_S2 NWF 60.14 2.30E-06 98.14% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 129 144
P62917 60S ribosomal protein L8 RPL8 ASGNYATVISHNPETK_Y5 NWF 46.41 1.00E-04 50.34% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 129 144
P61247 40S ribosomal protein S3a RPS3A KTSYAQHQQVR_K1 NWF 55.4 2.90E-05 97.27% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 152 162
P61247 40S ribosomal protein S3a RPS3A KTSYAQHQQVR_Y4 NWF 36.6 0.00037 92.58% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 152 162
H0Y8L7 40S ribosomal protein S3a (Fragment) RPS3A TSYAQHQQVR_Y3 NWF 38.85 0.00024 50.00% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 148 157
Q9NWH9 SAFB-like transcription modulator SLTM EVSGHSVR_E1 NWF 23.25 0.0076 82.92% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 907 914
Q9NWH9 SAFB-like transcription modulator SLTM GSGSGFKPFK_S2 NWF 30.24 0.0093 80.86% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 1018 1027
Q9NWH9 SAFB-like transcription modulator SLTM SSASGYGSR_S1 NWF 25.73 0.0043 83.55% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 922 930
Q68D10 Protein SPT2 homolog SPTY2D1 GPGRPVSSPHELR_R4 NWF 44.1 0.00039 78.14% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 464 476
Q68D10 Protein SPT2 homolog SPTY2D1 GPGRPVSSPHELR_S7 NWF 39.39 0.00023 93.53% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 464 476
Q68D10 Protein SPT2 homolog SPTY2D1 RPVSGLGPPGR_R1 NWF 36.85 0.00069 98.69% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 477 487
Q68D10 Protein SPT2 homolog SPTY2D1 TVSNSVPGRPVSSLGPGQTVSSSGPTIKPK_S5 NWF 54.9 7.10E-06 45.23% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 505 534
Q01130 Serine/arginine-rich splicing factor 2 SRSF2 SYGRPPPDVEGMTSLK_K16 NWF 28.76 0.0023 61.64% Acetyl (Protein N-term); ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 2 17
J3KP15 Serine/arginine-rich-splicing factor 2 (Fragment) SRSF2 SYGRPPPDVEGMTSLK_S1 NWF 40.29 0.00017 82.30% Acetyl (Protein N-term); ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 2 17
Q01130 Serine/arginine-rich splicing factor 2 SRSF2 SYGRPPPDVEGMTSLK_S14 NWF 20.98 0.011 60.44% Acetyl (Protein N-term); ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 2 17
Q92804 TATA-binding protein-associated factor 2N TAF15 SGGGYGGDR_S1 NWF 25.25 0.0078 100% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 423 431
Q92804 TATA-binding protein-associated factor 2N TAF15 SGGYGGDR_S1 NWF 33.06 0.018 99.50% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 546 553
Q92804 TATA-binding protein-associated factor 2N TAF15 SSGGGYSGDR_S1 NWF 35.78 0.00044 87.25% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 432 441
Q92804 TATA-binding protein-associated factor 2N TAF15 SSGGGYSGDR_S2 NWF 22.35 0.008 19.32% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 432 441
P11387 DNA topoisomerase 1 TOP1 SGDHLHNDSQIEADFR_S1 NWF 39.46 2.00E-04 78.08% Acetyl (Protein N-term); ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 2 17
P11387 DNA topoisomerase 1 TOP1 SMMNLQTK_S1 NWF 21.73 0.0096 100% 2 Oxidation (M); ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 643 650
P11388 DNA topoisomerase 2-alpha TOP2A DPALNSGVSQKPDPAK_D1 NWF 60.78 1.40E-05 99.84% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 1444 1459
P11388 DNA topoisomerase 2-alpha TOP2A DPALNSGVSQKPDPAK_S6 NWF 31.91 0.001 95.83% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 1444 1459
P11388 DNA topoisomerase 2-alpha TOP2A RDPALNSGVSQKPDPAK_D14 NWF 56.27 7.30E-06 56.74% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 1443 1459
P11388 DNA topoisomerase 2-alpha TOP2A RDPALNSGVSQKPDPAK_K17 NWF 43.29 0.00019 31.50% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 1443 1459
P11388 DNA topoisomerase 2-alpha TOP2A RDPALNSGVSQKPDPAK_S7 NWF 70.66 2.70E-07 99.90% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 1443 1459
P11388 DNA topoisomerase 2-alpha TOP2A SKGESDDFHMDFDSAVAPR_K2 NWF 57.98 3.70E-06 48.16% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 1491 1509
Q14669 E3 ubiquitin-protein ligase TRIP12 TRIP12 SGSGSESTGAEER_S1 NWF 44.78 6.30E-05 85.10% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 159 171
V9GYR5 Upstream stimulatory factor 2 USF2 SGGADSGGHHQRPAGGVR_S1 NWF 65.96 8.00E-07 99.80% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 70 87
Q96S55 ATPase WRNIP1 WRNIP1 SGQSYSPSR_S1 NWF 28.89 0.002 98.59% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 465 473
P25490 Transcriptional repressor protein YY1 YY1 KSYLSGGAGAAGGGGADPGNK_S5 NWF 68.28 4.00E-07 99.27% ADP-Ribosyl-EThcD (SRDEKY) (DEKRSY) 183 203
P25490 Transcriptional repressor protein YY1 YY1 KSYLSGGAGAAGGGGADPGNKK_K1 NWF 67.49 5.80E-07 84.40% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 183 204
P25490 Transcriptional repressor protein YY1 YY1 KSYLSGGAGAAGGGGADPGNKK_K21 NWF 32.88 0.0013 49.00% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 183 204
P25490 Transcriptional repressor protein YY1 YY1 SYLSGGAGAAGGGGADPGNK_S4 NWF 62.16 1.50E-06 88.18% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 184 203
P25490 Transcriptional repressor protein YY1 YY1 SYLSGGAGAAGGGGADPGNKK_S4 NWF 37.12 0.00061 48.08% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 184 204
P25490 Transcriptional repressor protein YY1 YY1 SYLSGGAGAAGGGGADPGNKK_Y2 NWF 81.24 7.20E-08 49.58% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 184 204
Q8IXZ2 Zinc finger CCCH domain-containing protein 3 ZC3H3 SGTSPAATAK_S1 NWF 22.05 0.0085 93.00% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 462 471
Q8IXZ2 Zinc finger CCCH domain-containing protein 3 ZC3H3 SVGSVGDSPREPR_S1 NWF 26.07 0.0075 91.56% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 204 216
Q9NR11 Zinc finger protein 302 ZNF302 SGAAFNQSK_S1 NWF 31.61 0.0083 93.98% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 258 266
Q96KM6 Zinc finger protein 512B ZNF512B SVPVTKPVPVTKPITVTK_S1 NWF 43.75 7.90E-05 98.45% ADP-Ribosyl-HCD_249_347_583 (DEKRSY) 263 280







Table 3: detailed information on peptides, modification sites and proteins identified in the WBL of control pigs.  
UniProt ID prot_desc gene_name plasma_prot PEP_ADPr_site pep_score pep_expect pep_var_mod_conf pep_var_mod pep_start pep_end
I3LEN2 Uncharacterized protein ADCYAP1R1 no KLHCTRNFIHMNLFVSFMLR_S11 18.45 0.026 81.92% Oxidation (M); ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 173 192
A0A287BRD8 BCL2 associated athanogene 5 BAG5 no TELQGLIGQLDEVSLEK_S14 16.41 0.036 85.97% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 327 343
F1S8V8 Dynamin binding protein DNMBP no GDEDSLMEK_S5 16.19 0.04 24.69% Oxidation (M); ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 986 994
F1SHL4 Uncharacterized protein F1SHL4 no AKVMKNDPVKKIFVGPR_K4 15.81 0.033 37.24% Oxidation (M); ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 140 156
A0A286ZZN9 Uncharacterized protein GFPT2 no REIIHGLK_K8 17.13 0.029 49.15% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 505 512
P01965 Hemoglobin subunit alpha HBA no AVGHLDDLPGALSALSDLHAHK_D17 27.2 0.0034 20.49% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 69 90
P01965 Hemoglobin subunit alpha HBA no AVGHLDDLPGALSALSDLHAHK_D6 99.67 4.50E-10 90.90% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 69 90
P01965 Hemoglobin subunit alpha HBA no AVGHLDDLPGALSALSDLHAHK_D7 80.32 4.10E-08 93.47% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 69 90
P01965 Hemoglobin subunit alpha HBA no AVGHLDDLPGALSALSDLHAHK_H21 38.44 0.00025 80.41% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 69 90
P01965 Hemoglobin subunit alpha HBA no AVGHLDDLPGALSALSDLHAHK_H4 95.29 1.30E-09 98.90% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 69 90
P01965 Hemoglobin subunit alpha HBA no AVGHLDDLPGALSALSDLHAHK_S13 28.32 0.0068 46.51% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 69 90
P01965 Hemoglobin subunit alpha HBA no AVGHLDDLPGALSALSDLHAHKLR_D6 121.08 4.40E-12 91.30% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 69 92
P01965 Hemoglobin subunit alpha HBA no AVGHLDDLPGALSALSDLHAHKLR_D7 49.12 2.50E-05 71.72% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 69 92
P01965 Hemoglobin subunit alpha HBA no AVGHLDDLPGALSALSDLHAHKLR_H4 89.13 4.40E-09 98.07% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 69 92
P01965 Hemoglobin subunit alpha HBA no FLANVSTVLTSK_K12 17.26 0.024 57.06% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 128 139
P01965 Hemoglobin subunit alpha HBA no FLANVSTVLTSK_S11 39.44 2.00E-04 93.33% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 128 139
P01965 Hemoglobin subunit alpha HBA no FLANVSTVLTSK_S6 17.37 0.023 100% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 128 139
P01965 Hemoglobin subunit alpha HBA no LLSHCLLVTLAAHHPDDFNPSVHASLDK_H13 46.71 4.20E-05 72.11% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 100 127
P01965 Hemoglobin subunit alpha HBA no LLSHCLLVTLAAHHPDDFNPSVHASLDK_H4 23.28 0.0066 28.00% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 100 127
P01965 Hemoglobin subunit alpha HBA no LLSHCLLVTLAAHHPDDFNPSVHASLDK_S3 86.26 8.20E-09 86.56% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 100 127
P01965 Hemoglobin subunit alpha HBA no MFLGFPTTKTYFPHFNLSHGSDQVK_Y11 45.52 6.50E-05 49.75% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 32 56
P01965 Hemoglobin subunit alpha HBA no TYFPHFNLSHGSDQVK_H10 60.5 2.20E-06 92.07% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 41 56
P01965 Hemoglobin subunit alpha HBA no TYFPHFNLSHGSDQVK_H5 74.06 1.10E-07 99.82% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 41 56
P01965 Hemoglobin subunit alpha HBA no TYFPHFNLSHGSDQVK_S12 49.84 2.10E-05 50.52% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 41 56
P01965 Hemoglobin subunit alpha HBA no TYFPHFNLSHGSDQVK_Y2 67.1 7.00E-07 99.87% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 41 56
P01965 Hemoglobin subunit alpha HBA no VGGQAGAHGAEALER_E14 25.02 0.0095 90.23% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 17 31
P01965 Hemoglobin subunit alpha HBA no VGGQAGAHGAEALER_H8 24.67 0.0049 94.25% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 17 31
P04246 Hemoglobin subunit theta HBE1 no LSELHCDKLHVDPENFR_E3 35.86 0.00043 41.06% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 88 104
P04246 Hemoglobin subunit theta HBE1 no LSELHCDKLHVDPENFR_H5 36.93 0.00034 82.68% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 88 104
F1REX8 Uncharacterized protein HIP1R no NSIKNVPAR_K4 22.54 0.03 100% Acetyl (Protein N-term); ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 2 10
A0A287BC41 Uncharacterized protein LMTK2 no LKEPDVEGKYLGK_K2 16.08 0.043 84.02% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 1251 1263
I3LCS1 Uncharacterized protein LOC100624559 no HLNDLK_K6 16.95 0.044 100% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 59 64
I3LCS1 Uncharacterized protein LOC100624559 no HLNDLKK_K7 25.1 0.04 88.94% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 59 65
F1REY1 Lon protease homolog 2  peroxisomal LONP2 no TRKHKQDDEKR_K5 18.14 0.039 82.14% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 231 241
A0A286ZMQ5 Uncharacterized protein MAGEB5 no DLVEFLWGPK_E4 17.05 0.026 85.08% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 173 182
F1RZG8 Uncharacterized protein MNS1 no MKTTQRYIEEFKK_R6 18.78 0.021 73.72% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 238 250
A0A287BGX8 Myin binding protein C  slow type MYBPC1 no MDLASKAGKHLQLK_K1 15.12 0.043 81.51% Oxidation (M); ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 1 14
A0A287B1L5 Uncharacterized protein OGFR no FQNLNWHSHNNLR_H7 24.04 0.039 80.71% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 179 191
A0A287B1L5 Uncharacterized protein OGFR no FQNLNWHSHNNLR_H9 28.87 0.0021 57.70% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 179 191
A0A287B1L5 Uncharacterized protein OGFR no FQNLNWHSHNNLR_R13 37.93 0.00064 56.27% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 179 191
A0A287B1L5 Uncharacterized protein OGFR no FQNLNWHSHNNLR_S8 23.55 0.0074 41.95% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 179 191
A0A287B1L5 Uncharacterized protein OGFR no RFQNLNWHSHNNLR_H10 38.26 0.00026 78.89% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 178 191
A0A287B1L5 Uncharacterized protein OGFR no RFQNLNWHSHNNLR_H8 18.8 0.022 57.89% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 178 191
A0A287B1L5 Uncharacterized protein OGFR no RFQNLNWHSHNNLR_R1 75.87 1.80E-07 99.99% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 178 191
A0A287B1L5 Uncharacterized protein OGFR no RFQNLNWHSHNNLR_R14 23.61 0.0073 47.84% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 178 191
I3LTG9 Uncharacterized protein RAD51D no ILQLLQARTSDEEEQAGALQRIQVVR_E14 18.33 0.019 18.58% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 159 184
A0A287A4Z9 Uncharacterized protein SENP5 no KYLLTEAR_Y2 19.12 0.042 46.23% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 649 656
F1RU38 Uncharacterized protein SF3B2 no QKKRKAQPQDSRGGSK_S15 18.15 0.025 82.35% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 873 888
F1SBK2 Uncharacterized protein SLX4IP no RALQEIVNR_E5 39.14 0.023 97.44% Acetyl (N-term); ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 164 172
A0A287BB26 Uncharacterized protein SMC1A no ALGAVESIAMKNPK_S7 22.77 0.0099 72.61% Acetyl (Protein N-term); Oxidation (M); ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 2 15
A0A287BMR4 SRP receptor alpha subunit SRPRA no LIDGIVLTKFDTIDDK_D15 18.8 0.037 45.71% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 581 596
A0A287BLR3 Uncharacterized protein USP53 no TGLLFHVDDNSASGK_H6 18.49 0.028 92.65% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 723 737
A0A287B900 Uncharacterized protein VPS26A no YFLNLVLVDEEDRR_R14 18.14 0.045 24.15% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 247 260
A0A287ATP7 Uncharacterized protein YTHDC2 no GILHPKRSADDR_S8 17.66 0.039 35.43% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 1124 1135
A0A287BKA2 Uncharacterized protein ZNF317 no WSILMEDIFGRGPSNGVTVER_S2 21.72 0.032 91.88% Oxidation (M); ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 58 78
P29700 Alpha-2-HS-glycoprotein (Fragment) AHSG yes HTLNQVDSVK_H1 40.94 0.00014 99.11% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 55 64
P29700 Alpha-2-HS-glycoprotein (Fragment) AHSG yes HTLNQVDSVK_S8 28.7 0.011 58.03% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 55 64
A0A286ZNV5 4-trimethylaminobutyraldehyde dehydrogenase ALDH9A1 yes ISFTGSVPTGSK_S2 58.78 6.00E-06 99.96% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 228 239
I3LQH7 Uncharacterized protein BLVRB yes YVAVMPPHIGDQPLTGAYTVTLDGR_Y1 68.42 3.80E-07 99.55% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 146 170
A0A287B6M0 Uncharacterized protein CA2 yes IVNNGHSFNVEFDSSQDK_H6 45.57 5.30E-05 88.06% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 59 76
F1SNS3 Uncharacterized protein CACHD1 yes GYLVAHPTLIDPK_D11 19.48 0.015 71.38% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 859 871
A0A287AK64 Uncharacterized protein CFAP54 yes GLLCVPVDVTDTLR_D11 21.28 0.018 87.92% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 1851 1864







Table 3: detailed information on peptides, modification sites and proteins identified in the WBL of control pigs (continued). 
 
UniProt ID prot_desc gene_name plasma_prot PEP_ADPr_site pep_score pep_expect pep_var_mod_conf pep_var_mod pep_start pep_end
P02067 Hemoglobin subunit beta HBB yes FFESFGDLSNADAVMGNPK_E3 109.91 5.00E-11 93.89% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 42 60
P02067 Hemoglobin subunit beta HBB yes FFESFGDLSNADAVMGNPK_S4 67.57 4.60E-07 61.29% Oxidation (M); ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 42 60
P02067 Hemoglobin subunit beta HBB yes FFESFGDLSNADAVMGNPK_S9 39.86 0.00018 96.64% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 42 60
P02067 Hemoglobin subunit beta HBB yes HLDNLK_H1 33.38 0.037 99.22% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 78 83
P02067 Hemoglobin subunit beta HBB yes HLDNLK_K6 16.95 0.044 100% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 78 83
P02067 Hemoglobin subunit beta HBB yes HLDNLKGTFAK_D3 22.83 0.0093 48.17% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 78 88
P02067 Hemoglobin subunit beta HBB yes HLDNLKGTFAK_H1 39.79 0.00019 98.81% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 78 88
P02067 Hemoglobin subunit beta HBB yes HLDNLKGTFAK_K11 28 0.0024 99.11% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 78 88
P02067 Hemoglobin subunit beta HBB yes KVLQSFSDGLK_K1 64.62 1.00E-05 100.00% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 67 77
P02067 Hemoglobin subunit beta HBB yes KVLQSFSDGLKHLDNLK_K1 91.92 1.30E-08 99.90% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 67 83
F1RII7 Hemoglobin subunit beta HBB yes LGHDFNPDVQAAFQK_D4 78.71 1.50E-06 99.20% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 119 133
F1RII7 Hemoglobin subunit beta HBB yes LGHDFNPDVQAAFQK_H3 63.05 6.10E-05 94.62% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 119 133
F1RII7 Hemoglobin subunit beta HBB yes LGHDFNPDVQAAFQK_K15 68.19 4.60E-06 99.80% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 119 133
P02067 Hemoglobin subunit beta HBB yes LSELHCDQLHVDPENFR_D7 19.67 0.029 34.48% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 89 105
P02067 Hemoglobin subunit beta HBB yes LSELHCDQLHVDPENFR_E14 27.01 0.0029 63.89% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 89 105
P02067 Hemoglobin subunit beta HBB yes LSELHCDQLHVDPENFR_E3 80.34 2.90E-08 91.93% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 89 105
P02067 Hemoglobin subunit beta HBB yes LSELHCDQLHVDPENFR_H10 62.33 1.40E-06 99.11% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 89 105
P02067 Hemoglobin subunit beta HBB yes LSELHCDQLHVDPENFR_H5 75.43 2.00E-07 91.99% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 89 105
P02067 Hemoglobin subunit beta HBB yes LSELHCDQLHVDPENFR_S2 90.98 1.70E-08 94.69% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 89 105
F1RII7 Hemoglobin subunit beta HBB yes RLGHDFNPDVQAAFQK_D5 41 0.0021 91.54% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 118 133
F1RII7 Hemoglobin subunit beta HBB yes RLGHDFNPDVQAAFQK_D9 27.67 0.02 55.04% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 118 133
F1RII7 Hemoglobin subunit beta HBB yes RLGHDFNPDVQAAFQK_H4 53.58 0.00023 89.82% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 118 133
F1RII7 Hemoglobin subunit beta HBB yes RLGHDFNPDVQAAFQK_K16 53.34 1.00E-05 99.96% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 118 133
F1RII7 Hemoglobin subunit beta HBB yes RLGHDFNPDVQAAFQK_R1 43.43 0.00047 91.85% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 118 133
P02067 Hemoglobin subunit beta HBB yes VHLSAEEK_E6 15.32 0.042 40.42% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 2 9
P02067 Hemoglobin subunit beta HBB yes VHLSAEEK_E7 22.53 0.025 62.78% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 2 9
P02067 Hemoglobin subunit beta HBB yes VHLSAEEK_H2 26.88 0.003 100% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 2 9
P02067 Hemoglobin subunit beta HBB yes VHLSAEEK_K8 25.73 0.014 80.55% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 2 9
P02067 Hemoglobin subunit beta HBB yes VHLSAEEK_S4 23.69 0.006 94.22% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 2 9
P02067 Hemoglobin subunit beta HBB yes VLQSFSDGLK_S4 26.72 0.035 96.26% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 68 77
P02067 Hemoglobin subunit beta HBB yes VLQSFSDGLKHLDNLK_D13 24.22 0.0054 38.29% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 68 83
P02067 Hemoglobin subunit beta HBB yes VLQSFSDGLKHLDNLK_H11 16.03 0.031 64.85% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 68 83
P02067 Hemoglobin subunit beta HBB yes VLQSFSDGLKHLDNLK_K16 26.83 0.003 48.88% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 68 83
P02067 Hemoglobin subunit beta HBB yes VLQSFSDGLKHLDNLK_S4 75.01 9.30E-08 99.31% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 68 83
P02067 Hemoglobin subunit beta HBB yes VLQSFSDGLKHLDNLKGTFAK_S4 85.06 1.10E-08 99.13% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 68 88
P02067 Hemoglobin subunit beta HBB yes VNVDEVGGEALGR_D4 24.04 0.0075 83.22% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 19 31
P02067 Hemoglobin subunit beta HBB yes VVAGVANALAHK_H11 32.92 0.0011 96.09% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 134 145
P02067 Hemoglobin subunit beta HBB yes VVAGVANALAHK_K12 48.12 3.50E-05 89.46% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 134 145
P02067 Hemoglobin subunit beta HBB yes VVAGVANALAHKYH_H11 48.26 2.00E-04 96.60% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 134 147
P02067 Hemoglobin subunit beta HBB yes VVAGVANALAHKYH_H14 40.76 0.00015 98.67% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 134 147
P02067 Hemoglobin subunit beta HBB yes VVAGVANALAHKYH_K12 30.54 0.0014 75.91% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 134 147
P02067 Hemoglobin subunit beta HBB yes VVAGVANALAHKYH_Y13 45.67 5.20E-05 83.11% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 134 147
P11708 Malate dehydrogenase  cytoplasmic MDH1 yes KLSSAMSAAK_K1 43.14 0.0036 98.55% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 239 248
P80895 Protein-L-isoaspartate(D-aspartate) O-methyltransferase PCMT1 yes SGGASHSELIHNLR_H11 18.3 0.019 87.86% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 5 18
P80895 Protein-L-isoaspartate(D-aspartate) O-methyltransferase PCMT1 yes SGGASHSELIHNLR_H6 33.83 0.012 31.21% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 5 18
P80895 Protein-L-isoaspartate(D-aspartate) O-methyltransferase PCMT1 yes SGGASHSELIHNLR_S1 65.14 4.20E-06 99.62% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 5 18
P80895 Protein-L-isoaspartate(D-aspartate) O-methyltransferase PCMT1 yes SGGASHSELIHNLR_S5 38.75 0.01 73.49% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 5 18
P80895 Protein-L-isoaspartate(D-aspartate) O-methyltransferase PCMT1 yes SGGASHSELIHNLRK_S1 46.04 4.80E-05 99.83% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 5 19







Table 4: detailed information on peptides, modification sites and proteins identified in the WBL of LPS-treated pigs. 
  
UniProt ID prot_desc gene_name plasma_prot PEP_ADPr_site pep_seq pep_score pep_expect pep_var_mod_conf pep_var_mod pep_start pep_end
A0A286ZKI5 Uncharacterized protein ABCC12 no TFMRDTIMK_D3 TFMRDTIMK 15.96 0.049 47.20% Oxidation (M); ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 1240 1248
A0A286ZUT6 Uncharacterized protein AKAP9 no NAVLDRMAESQEAELER_E7 NAVLDRMAESQEAELER 15.03 0.043 55.67% Oxidation (M); 2 ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 588 604
A0A287A3V7 Uncharacterized protein OS ARID5B no AAHGGHSGGASEGPK_S11 AAHGGHSGGASEGPK 19.54 0.026 41.43% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 1056 1070
V5PZZ6 Arrestin domain-containing 5 OS ARRDC5 no AERRSKVDSSELLR_R14 AERRSKVDSSELLR 20.77 0.015 91.48% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 225 238
A0A287ADS8 Uncharacterized protein BEND5 no RPEGRKPSEVAHK_S8 RPEGRKPSEVAHK 19.45 0.029 66.49% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 229 241
A0A287AJ04 Uncharacterized protein BICD1 no QTAEVALANLK_K11 QTAEVALANLK 17.6 0.022 100% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 699 709
F1S7X1 Uncharacterized protein F1S7X1 no SMLEEVIANWDR_E2 SMLEEVIANWDR 21.39 0.021 77.37% Oxidation (M); ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 606 617
A0A286ZL19 Uncharacterized protein F1SCQ1 no SFSRKTHLIRHR_R10 SFSRKTHLIRHR 22.91 0.022 82.78% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 509 520
P01965 Hemoglobin subunit alpha HBA no AVGHLDDLPGALSALSDLHAHK_D6 AVGHLDDLPGALSALSDLHAHK 90.13 4.40E-09 89.28% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 69 90
P01965 Hemoglobin subunit alpha HBA no AVGHLDDLPGALSALSDLHAHK_D7 AVGHLDDLPGALSALSDLHAHK 62.16 3.80E-06 98.70% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 69 90
P01965 Hemoglobin subunit alpha HBA no AVGHLDDLPGALSALSDLHAHK_H21 AVGHLDDLPGALSALSDLHAHK 50.08 2.00E-05 92.42% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 69 90
P01965 Hemoglobin subunit alpha HBA no AVGHLDDLPGALSALSDLHAHK_H4 AVGHLDDLPGALSALSDLHAHK 70.07 3.30E-07 98.09% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 69 90
P01965 Hemoglobin subunit alpha HBA no AVGHLDDLPGALSALSDLHAHK_K22 AVGHLDDLPGALSALSDLHAHK 23.21 0.0067 44.82% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 69 90
P01965 Hemoglobin subunit alpha HBA no AVGHLDDLPGALSALSDLHAHK_S13 AVGHLDDLPGALSALSDLHAHK 61.03 1.90E-06 90.52% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 69 90
P01965 Hemoglobin subunit alpha HBA no AVGHLDDLPGALSALSDLHAHKLR_D6 AVGHLDDLPGALSALSDLHAHKLR 103.83 1.90E-10 92.34% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 69 92
P01965 Hemoglobin subunit alpha HBA no AVGHLDDLPGALSALSDLHAHKLR_D7 AVGHLDDLPGALSALSDLHAHKLR 99.54 5.20E-10 49.85% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 69 92
P01965 Hemoglobin subunit alpha OS HBA no AVGHLDDLPGALSALSDLHAHKLR_H4 AVGHLDDLPGALSALSDLHAHKLR 93.39 1.80E-09 98.87% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 69 92
P01965 Hemoglobin subunit alpha HBA no FLANVSTVLTSK_S11 FLANVSTVLTSK 36.03 0.00042 96.26% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 128 139
P01965 Hemoglobin subunit alpha HBA no FLANVSTVLTSK_S6 FLANVSTVLTSK 15.7 0.034 100% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 128 139
P01965 Hemoglobin subunit alpha HBA no LLSHCLLVTLAAHHPDDFNPSVHASLDK_H13 LLSHCLLVTLAAHHPDDFNPSVHASLDK 81.93 2.10E-08 64.25% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 100 127
P01965 Hemoglobin subunit alpha OS HBA no LLSHCLLVTLAAHHPDDFNPSVHASLDK_H14 LLSHCLLVTLAAHHPDDFNPSVHASLDK 22.36 0.016 22.22% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 100 127
P01965 Hemoglobin subunit alpha HBA no LLSHCLLVTLAAHHPDDFNPSVHASLDK_H4 LLSHCLLVTLAAHHPDDFNPSVHASLDK 80.07 3.10E-08 39.46% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 100 127
P01965 Hemoglobin subunit alpha HBA no LLSHCLLVTLAAHHPDDFNPSVHASLDK_S25 LLSHCLLVTLAAHHPDDFNPSVHASLDK 69.5 3.00E-07 80.50% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 100 127
P01965 Hemoglobin subunit alpha HBA no LLSHCLLVTLAAHHPDDFNPSVHASLDK_S3 LLSHCLLVTLAAHHPDDFNPSVHASLDK 79.58 3.50E-08 71.97% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 100 127
P01965 Hemoglobin subunit alpha OS HBA no LRVDPVNFK_R2 LRVDPVNFK 17.02 0.025 85.77% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 91 99
P01965 Hemoglobin subunit alpha HBA no TYFPHFNLSHGSDQVK_D13 TYFPHFNLSHGSDQVK 24.41 0.0051 29.03% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 41 56
P01965 Hemoglobin subunit alpha OS HBA no TYFPHFNLSHGSDQVK_H10 TYFPHFNLSHGSDQVK 63.05 1.20E-06 95.27% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 41 56
P01965 Hemoglobin subunit alpha HBA no TYFPHFNLSHGSDQVK_H5 TYFPHFNLSHGSDQVK 38.89 0.00023 98.95% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 41 56
P01965 Hemoglobin subunit alpha HBA no TYFPHFNLSHGSDQVK_S12 TYFPHFNLSHGSDQVK 19.48 0.015 38.74% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 41 56
P01965 Hemoglobin subunit alpha HBA no TYFPHFNLSHGSDQVK_Y2 TYFPHFNLSHGSDQVK 77.1 5.90E-08 99.90% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 41 56
P01965 Hemoglobin subunit alpha HBA no VGGQAGAHGAEALER_E14 VGGQAGAHGAEALER 34.44 0.0048 91.82% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 17 31
P01965 Hemoglobin subunit alpha OS HBA no VGGQAGAHGAEALER_H8 VGGQAGAHGAEALER 20.32 0.012 92.76% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 17 31
A0A287ANC5 Uncharacterized protein HEATR5B no SALTLVMGALDNPNPILR_S1 SALTLVMGALDNPNPILR 16.47 0.049 100% Oxidation (M); ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 852 869
A0A287A5I8 Uncharacterized protein HES2 no KNLKPLLEK_K1 KNLKPLLEK 20.89 0.011 63.58% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 15 23
A0A286ZIK8 Uncharacterized protein HSPA4L no LKVLATTFDPYLGGR_K2 LKVLATTFDPYLGGR 18.32 0.036 92.06% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 220 234
A0A286ZTE8 Uncharacterized protein LOC100517659 no KLRVLSMDKK_K1_R3 KLRVLSMDKK 15.68 0.046 100% Oxidation (M); 2 ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 183 192
A0A287AWP4 Uncharacterized protein LOC100624559 no HLNDLKK_K7 HLNDLKK 25.11 0.024 87.49% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 147 153
A0A286ZN09 Uncharacterized protein LOC102158372 no RPPKVNR_K4 RPPKVNR 17.37 0.03 72.63% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 241 247
A0A286ZMQ5 Uncharacterized protein MAGEB5 no DLVEFLWGPK_E4 DLVEFLWGPK 17.53 0.048 49.54% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 173 182
A0A286ZMJ9 Alpha-mannidase MAN2A2 no SNVLLVPLGDDFR_D11 SNVLLVPLGDDFR 22.1 0.043 48.86% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 416 428
F1RZ25 Uncharacterized protein MPP1 no RKTLVLIGASGVGR_S10 RKTLVLIGASGVGR 17.41 0.023 100% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 236 249
A0A287AAY6 Uncharacterized protein MYBPC1 no MDLASKAGKHLQLK_K1 MDLASKAGKHLQLK 19.35 0.016 87.49% Oxidation (M); ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 1 14
A0A287A0Y3 Uncharacterized protein MYO3B no VYKVTNKRDGSLAAVK_Y2 VYKVTNKRDGSLAAVK 20.11 0.033 61.19% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 28 43
F1S9A4 Uncharacterized protein NUCB2 no EHVMNEVDTNK_E6 EHVMNEVDTNK 16.81 0.03 74.42% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 350 360
A0A287B051 Uncharacterized protein ODF2 no LKASFAPMEDK_D8 LKASFAPMEDK 20.41 0.018 46.68% Oxidation (M); ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 506 516
A0A286ZQ96 Uncharacterized protein OS OGFR no FQNLNWHSHNNLR_H7 FQNLNWHSHNNLR 18.15 0.04 87.55% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 186 198
A0A286ZQ96 Uncharacterized protein OGFR no FQNLNWHSHNNLR_H9 FQNLNWHSHNNLR 45.92 4.90E-05 88.51% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 186 198
A0A286ZQ96 Uncharacterized protein OGFR no FQNLNWHSHNNLR_R13 FQNLNWHSHNNLR 24.57 0.005 36.85% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 186 198
A0A286ZQ96 Uncharacterized protein OGFR no FQNLNWHSHNNLR_S8 FQNLNWHSHNNLR 21.61 0.0098 41.26% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 186 198
A0A286ZQ96 Uncharacterized protein OGFR no RFQNLNWHSHNNLR_H10 RFQNLNWHSHNNLR 24.23 0.0053 33.39% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 185 198
A0A286ZQ96 Uncharacterized protein OGFR no RFQNLNWHSHNNLR_H8 RFQNLNWHSHNNLR 16.35 0.033 52.56% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 185 198
A0A286ZQ96 Uncharacterized protein OGFR no RFQNLNWHSHNNLR_R1 RFQNLNWHSHNNLR 75.42 3.10E-07 99.91% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 185 198
I3LRU7 DNA-binding protein SATB OS SATB2 no KEEDPRTASQSLLVNLR_S9 KEEDPRTASQSLLVNLR 20.49 0.035 36.59% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 400 416
F1RU38 Uncharacterized protein SF3B2 no QKKRKAQPQDSRGGSK_S15 QKKRKAQPQDSRGGSK 18.51 0.037 82.62% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 873 888
F1RMN6 Sphingomyelin phosphodiesterase OS SMPD1 no LDSFLRVPSLR_S3 LDSFLRVPSLR 40.31 0.011 88.75% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 21 31
A0A287BMR4 SRP receptor alpha subunit OS SRPRA no LIDGIVLTKFDTIDDK_D15 LIDGIVLTKFDTIDDK 20.3 0.03 46.46% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 581 596
A0A287B900 Uncharacterized protein OS VPS26A no YFLNLVLVDEEDRR_R13 YFLNLVLVDEEDRR 19.07 0.039 31.13% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 247 260
I3LE67 Zinc finger protein 518B ZNF518B no RESADGGSAPR_D5 RESADGGSAPR 17.55 0.032 46.33% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 860 870
P29700 Alpha-2-HS-glycoprotein (Fragment) AHSG yes HTLNQVDSVK_H1 HTLNQVDSVK 19.43 0.015 100% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 55 64
A0A286ZNV5 4-trimethylaminobutyraldehyde dehydrogenase OS ALDH9A1 yes ISFTGSVPTGSK_S2 ISFTGSVPTGSK 70.53 5.80E-07 99.99% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 228 239
A0A287AI92 Uncharacterized protein CA1 yes HDTSLKPISVSYNPATAK_S4 HDTSLKPISVSYNPATAK 51.62 1.40E-05 66.09% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 41 58
A0A287B6M0 Uncharacterized protein CA2 yes IVNNGHSFNVEFDSSQDK_H6 IVNNGHSFNVEFDSSQDK 46.22 4.60E-05 64.36% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 59 76
A0A287AK64 Uncharacterized protein CFAP54 yes GLLCVPVDVTDTLR_D11 GLLCVPVDVTDTLR 16.83 0.04 85.75% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 1851 1864







Table 4: detailed information on peptides, modification sites and proteins identified in the WBL of LPS-treated pigs (continued). 
UniProt ID prot_desc gene_name plasma_prot PEP_ADPr_site pep_seq.1 pep_score pep_expect pep_var_mod_conf pep_var_mod pep_start pep_end
P02067 Hemoglobin subunit beta HBB yes FFESFGDLSNADAVMGNPK_D7 FFESFGDLSNADAVMGNPK 59.95 3.30E-06 32.71% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 42 60
P02067 Hemoglobin subunit beta HBB yes FFESFGDLSNADAVMGNPK_E3 FFESFGDLSNADAVMGNPK 67.2 5.00E-07 95.12% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 42 60
P02067 Hemoglobin subunit beta HBB yes FFESFGDLSNADAVMGNPK_S4 FFESFGDLSNADAVMGNPK 48.92 2.60E-05 50.86% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 42 60
P02067 Hemoglobin subunit beta HBB yes FFESFGDLSNADAVMGNPK_S9 FFESFGDLSNADAVMGNPK 15.48 0.035 45.72% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 42 60
P02067 Hemoglobin subunit beta HBB yes HLDNLKGTFAK_D3 HLDNLKGTFAK 21.99 0.0087 49.23% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 78 88
P02067 Hemoglobin subunit beta HBB yes HLDNLKGTFAK_H1 HLDNLKGTFAK 38.58 0.00031 88.05% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 78 88
P02067 Hemoglobin subunit beta HBB yes HLDNLKGTFAK_K11 HLDNLKGTFAK 47.69 1.00E-04 99.88% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 78 88
P02067 Hemoglobin subunit beta HBB yes HLDNLKGTFAK_K6 HLDNLKGTFAK 23.28 0.0066 96.28% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 78 88
P02067 Hemoglobin subunit beta HBB yes KVLQSFSDGLK_K1 KVLQSFSDGLK 74.66 4.70E-06 100.00% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 67 77
P02067 Hemoglobin subunit beta HBB yes KVLQSFSDGLKHLDNLK_K1 KVLQSFSDGLKHLDNLK 82.37 1.60E-07 99.91% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 67 83
F1RII7 Hemoglobin subunit beta HBB yes LGHDFNPDVQAAFQK_D4 LGHDFNPDVQAAFQK 86.43 2.80E-07 99.57% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 119 133
F1RII7 Hemoglobin subunit beta HBB yes LGHDFNPDVQAAFQK_H3 LGHDFNPDVQAAFQK 43.14 0.00027 90.05% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 119 133
F1RII7 Hemoglobin subunit beta HBB yes LGHDFNPDVQAAFQK_K15 LGHDFNPDVQAAFQK 72.69 2.60E-06 99.24% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 119 133
P02067 Hemoglobin subunit beta HBB yes LSELHCDQLHVDPENFR_D7 LSELHCDQLHVDPENFR 25.16 0.041 47.88% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 89 105
P02067 Hemoglobin subunit beta OS HBB yes LSELHCDQLHVDPENFR_E14 LSELHCDQLHVDPENFR 60.54 2.70E-06 51.25% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 89 105
P02067 Hemoglobin subunit beta HBB yes LSELHCDQLHVDPENFR_E3 LSELHCDQLHVDPENFR 80.93 6.00E-08 84.31% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 89 105
P02067 Hemoglobin subunit beta OS HBB yes LSELHCDQLHVDPENFR_H10 LSELHCDQLHVDPENFR 50.63 3.00E-05 97.88% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 89 105
P02067 Hemoglobin subunit beta HBB yes LSELHCDQLHVDPENFR_H5 LSELHCDQLHVDPENFR 72.16 6.70E-07 89.40% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 89 105
P02067 Hemoglobin subunit beta HBB yes LSELHCDQLHVDPENFR_S2 LSELHCDQLHVDPENFR 61.58 1.70E-06 84.35% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 89 105
F1RII7 Hemoglobin subunit beta HBB yes RLGHDFNPDVQAAFQK_D5 RLGHDFNPDVQAAFQK 50.68 0.00017 86.98% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 118 133
F1RII7 Hemoglobin subunit beta HBB yes RLGHDFNPDVQAAFQK_D9 RLGHDFNPDVQAAFQK 22.97 0.045 24.25% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 118 133
F1RII7 Hemoglobin subunit beta HBB yes RLGHDFNPDVQAAFQK_H4 RLGHDFNPDVQAAFQK 40.06 0.00018 87.54% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 118 133
F1RII7 Hemoglobin subunit beta HBB yes RLGHDFNPDVQAAFQK_K16 RLGHDFNPDVQAAFQK 15.76 0.033 100% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 118 133
F1RII7 Hemoglobin subunit beta OS HBB yes RLGHDFNPDVQAAFQK_R1 RLGHDFNPDVQAAFQK 48.47 0.00015 98.75% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 118 133
P02067 Hemoglobin subunit beta HBB yes VHLSAEEK_E6 VHLSAEEK 15.93 0.048 40.75% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 2 9
P02067 Hemoglobin subunit beta HBB yes VHLSAEEK_E7 VHLSAEEK 23.72 0.02 65.64% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 2 9
P02067 Hemoglobin subunit beta HBB yes VHLSAEEK_H2 VHLSAEEK 22.12 0.02 100% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 2 9
P02067 Hemoglobin subunit beta HBB yes VHLSAEEK_K8 VHLSAEEK 26.54 0.037 82.41% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 2 9
P02067 Hemoglobin subunit beta HBB yes VLQSFSDGLK_K10 VLQSFSDGLK 17.13 0.044 39.28% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 68 77
P02067 Hemoglobin subunit beta HBB yes VLQSFSDGLK_S4 VLQSFSDGLK 30.1 0.017 96.08% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 68 77
P02067 Hemoglobin subunit beta HBB yes VLQSFSDGLKHLDNLK_D13 VLQSFSDGLKHLDNLK 23.06 0.0069 45.91% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 68 83
P02067 Hemoglobin subunit beta HBB yes VLQSFSDGLKHLDNLK_H11 VLQSFSDGLKHLDNLK 20.65 0.021 66.36% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 68 83
P02067 Hemoglobin subunit beta OS HBB yes VLQSFSDGLKHLDNLK_S4 VLQSFSDGLKHLDNLK 76.74 7.40E-08 99.11% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 68 83
P02067 Hemoglobin subunit beta HBB yes VLQSFSDGLKHLDNLKGTFAK_S4 VLQSFSDGLKHLDNLKGTFAK 104.15 1.70E-10 99.19% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 68 88
P02067 Hemoglobin subunit beta HBB yes VNVDEVGGEALGR_D4 VNVDEVGGEALGR 22.23 0.012 81.53% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 19 31
P02067 Hemoglobin subunit beta HBB yes VVAGVANALAHK_H11 VVAGVANALAHK 32.74 0.0018 97.15% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 134 145
P02067 Hemoglobin subunit beta HBB yes VVAGVANALAHK_K12 VVAGVANALAHK 55.4 9.20E-06 90.24% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 134 145
P02067 Hemoglobin subunit beta HBB yes VVAGVANALAHKYH_H11 VVAGVANALAHKYH 63.08 5.90E-05 98.18% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 134 147
P02067 Hemoglobin subunit beta OS HBB yes VVAGVANALAHKYH_H14 VVAGVANALAHKYH 62.86 1.30E-06 92.35% ADP-Ribosyl-EThcD (DEHKRSY) (DEHKRSY) 134 147
P02067 Hemoglobin subunit beta HBB yes VVAGVANALAHKYH_K12 VVAGVANALAHKYH 42.86 9.60E-05 80.46% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 134 147
P02067 Hemoglobin subunit beta OS HBB yes VVAGVANALAHKYH_Y13 VVAGVANALAHKYH 46.79 4.10E-05 86.30% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 134 147
F1RKY6 Uncharacterized protein LOC100153093 yes QARELQRQLAEELVNR_E12 QARELQRQLAEELVNR 20.74 0.017 89.04% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 18 33
P11708 Malate dehydrogenase  cytoplasmic MDH1 yes KLSSAMSAAK_K1 KLSSAMSAAK 43.51 0.00067 98.92% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 239 248
P80895 Protein-L-isoaspartate(D-aspartate) O-methyltransferase PCMT1 yes SGGASHSELIHNLR_S1 SGGASHSELIHNLR 57.08 7.70E-06 99.67% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 5 18
P80895 Protein-L-isoaspartate(D-aspartate) O-methyltransferase PCMT1 yes SGGASHSELIHNLR_S5 SGGASHSELIHNLR 51.74 0.0011 47.34% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 5 18
P80895 Protein-L-isoaspartate(D-aspartate) O-methyltransferase PCMT1 yes SGGASHSELIHNLRK_H11 SGGASHSELIHNLRK 19.73 0.014 50.75% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 5 19
P80895 Protein-L-isoaspartate(D-aspartate) O-methyltransferase PCMT1 yes SGGASHSELIHNLRK_S1 SGGASHSELIHNLRK 36.24 4.00E-04 67.98% ADPr_HCD_249_347_583 (DEHKRSY) (DEHKRSY) 5 19
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prot_acc prot_desc gene_name pep_query pep_start pep_end pep_score pep_expect group
A0A287A333 Alpha-1B-glycoprotein A1BG 19 350 354 23.06 0.045 both
F1SLX2 Uncharacterized protein A2M 1066 1335 1340 37.88 0.016 both
A0A287A6F6 Uncharacterized protein ABCC4 851 257 262 30.24 0.046 ctrl only
A0A286ZJ87 Uncharacterized protein ABCC5 14885 22 31 19.81 0.04 LPS only
A0A286ZKN8 Uncharacterized protein ABCC8 874 15 19 18.94 0.041 both
F1RGB5 Uncharacterized protein ACACB 32499 924 937 17.88 0.047 ctrl only
A0A287B863 Aggrecan core protein ACAN 35790 498 511 34.56 0.00057 both
F1RRW4 Angiotensin-converting enzyme ACE 6143 236 243 22.71 0.02 both
A0A287B1V5 Uncharacterized protein ACOT11 27550 80 91 19.96 0.05 ctrl only
P81693 Low molecular weight phosphotyrosine protein phosphatase ACP1 5980 20 28 33.89 0.0056 ctrl only
A0A287AAR4 Actin cytoplasmic 1 ACTB 1643 329 335 26.97 0.018 LPS only
A0A287A4R1 Uncharacterized protein ACTBL2 1643 330 336 26.97 0.018 both
A0A287A5G1 Actin gamma 1 ACTG1 1643 207 213 26.97 0.018 both
A0A286ZWJ1 Uncharacterized protein ACTG2 1643 330 336 26.97 0.018 both
A0A287A4Q7 Actinin alpha 4 ACTN4 38307 883 899 17.55 0.023 ctrl only
A0A286ZYY7 Uncharacterized protein ADAM20 84 81 85 28.79 0.048 both
I3LKV5 Uncharacterized protein ADAMTS13 29545 400 412 57.66 6.80E-06 both
A0A287B327 Uncharacterized protein ADAMTS3 8771 653 661 29.79 0.0043 LPS only
I3L5B0 Uncharacterized protein ADD2 25195 65 76 22.24 0.017 ctrl only
A0A287AQV7 Uncharacterized protein ADGRV1 14913 5522 5532 16.91 0.026 both
A0A287AHI7 Uncharacterized protein ADIPOQ 7306 166 174 28.81 0.002 both
A0A287A363 Uncharacterized protein AFM 1148 501 506 48.8 0.00059 both
Q8MJ76 Alpha-fetoprotein AFP 3226 366 373 40.2 0.00016 both
F1RT17 N(4)-(Beta-N-acetylglucosaminyl)-L-asparaginase AGA 38260 115 131 15.82 0.033 both
A0A287ABP5 Uncharacterized protein AGT 395 253 258 33.99 0.035 both
F1SPS7 Acylamino-acid-releasing enzyme AHSG 9334 119 126 40.92 0.0028 both
A0A287B4J2 Adenosylhomocysteinase AHCY 11469 264 275 37.46 0.00062 ctrl only
A0A286ZPY1 Uncharacterized protein AHNAK 16394 1028 1038 33.19 0.00077 both
P29700 Alpha-2-HS-glycoprotein (Fragment) AHSG 3137 216 222 45.9 0.002 both
A0A287AK38 Uncharacterized protein AHSP 25974 72 84 60.59 2.10E-06 ctrl only
A0A286ZQ79 Adenylate kinase isoenzyme 1 AK1 16771 173 183 19.38 0.02 both
A0A287BDC1 Uncharacterized protein AKIRIN2 21176 76 86 15.25 0.037 LPS only
A0A287A3Y9 Alcohol dehydrogenase [NADP(+)] AKR1A1 10747 36 45 35.91 0.0061 ctrl only
A0A287BGW4 Delta-aminolevulinic acid dehydratase ALAD 15540 287 297 45.67 5.20E-05 ctrl only
P08835 Serum albumin ALB 360 205 209 38.68 0.0047 both
A0A287AEA5 Aldehyde dehydrogenase family 16 member A1 ALDH16A1 32400 309 321 17.87 0.021 ctrl only
A0A286ZNV5 4-trimethylaminobutyraldehyde dehydrogenase ALDH9A1 11264 317 326 57.72 1.60E-05 both
A0A286ZYX8 Fructose-bisphosphate aldolase ALDOA 8012 61 69 46.1 0.00013 both
A0A287B8Z2 Fructose-bisphosphate aldolase ALDOC 52344 182 204 104.31 1.70E-10 both
A0A287AV93 Uncharacterized protein ALG5 5219 52 59 33.8 0.018 LPS only
A0A286ZSH7 Arachidonate 15-lipoxygenase ALOX15 40993 571 586 15.84 0.033 ctrl only
Q1KS52 Acid-labile subunit ALS 7797 270 277 16.87 0.026 both
F1SN71 Protein AMBP AMBP 7192 158 165 31.95 0.0019 both
F1SL93 Uncharacterized protein AMOTL2 24180 523 536 19.63 0.014 ctrl only
P00690 Pancreatic alpha-amylase AMY2 21259 26 35 40.71 0.00017 LPS only
T1UNN8 Angiopoietin like 8 ANGPTL8 36716 93 106 18.33 0.019 both
A0A287A126 Ankyrin 1 ANK1 36 591 595 41.51 0.00055 ctrl only
A0A287AEE1 Uncharacterized protein ANK3 2463 394 400 30.08 0.016 ctrl only
A0A286ZN01 Uncharacterized protein ANKRD12 2222 1224 1230 31.78 0.047 both
A0A287ABU8 Uncharacterized protein ANKS3 20793 490 500 21.33 0.025 both
A0A286ZR09 Uncharacterized protein ANLN 4478 660 667 31.03 0.016 both
F1SK03 Aminopeptidase ANPEP 46360 864 877 33.69 0.00069 ctrl only
A0A286ZJV6 Annexin ANXA2 9694 113 122 40.33 0.00045 ctrl only
A0A287A531 Annexin ANXA5 10403 277 285 27.97 0.0063 both
F1S1G7 Amine oxidase AOC2 4609 103 111 58.23 8.20E-05 both
A0A286ZZR5 Uncharacterized protein APC2 3621 1539 1546 53.24 0.00017 both
O19063 Serum amyloid P-component APCS 5598 77 84 20.54 0.028 both
A0A286ZI19 Uncharacterized protein APLP2 13199 467 475 32.42 0.045 LPS only
A0A287A6K7 Uncharacterized protein APMAP 10754 377 385 31.22 0.0012 both
P18648 Apolipoprotein A-I APOA1 6047 142 150 62.55 2.60E-05 both
F1S1A9 Uncharacterized protein APOA2 12390 68 77 38.64 0.00047 both
O46409 Apolipoprotein A-IV APOA4 897 288 293 40.13 0.0099 both
A0A287AG13 Uncharacterized protein APOB 357 1694 1699 36.7 0.015 both
D3Y264 Apolipoprotein C-II APOC2 4604 53 60 38.91 0.0028 both
P27917 Apolipoprotein C-III APOC3 4822 72 78 19.78 0.039 both
A0A286ZPG0 Uncharacterized protein APOC4 13469 58 66 39.56 0.0054 both
A0A287BS37 Apolipoprotein D APOD 1984 38 44 34.67 0.0012 both
P18650 Apolipoprotein E APOE 368 132 136 29.1 0.047 both
A0A140TAK8 Uncharacterized protein APOH 1704 238 243 26.58 0.0043 both
A0A287AVQ5 Apolipoprotein M APOM 1946 172 178 39.61 0.0046 both
Q68RU1 Ovarian and testicular apolipoprotein N ApoN 889 233 239 32.95 0.05 both
Q03472 Apolipoprotein R APOR 26938 160 171 30.25 0.0015 both
A0A287AT23 Aquaporin-1 AQP1 52829 246 265 92.5 2.10E-09 ctrl only
A0A286ZTI3 Uncharacterized protein ARF1 9662 20 30 26.24 0.0073 ctrl only
A0A287BM57 Uncharacterized protein ARF2 9662 20 30 26.24 0.0073 ctrl only
A0A287A1L1 Uncharacterized protein ARF4 9662 20 30 26.24 0.0073 ctrl only
B9V4F0 ADP-ribosylation factor 5 ARF5 9662 20 30 26.24 0.0073 ctrl only
A0A287B2D9 Uncharacterized protein ARHGAP27 10165 2 10 18.53 0.037 both
A0A287ART1 Uncharacterized protein ARHGAP31 5955 795 802 22.14 0.034 ctrl only
E7EI20 Rho GDP dissociation inhibitor alpha ARHGDIA 33158 59 74 77.01 6.00E-08 ctrl only
A0A287AFI5 Uncharacterized protein ARHGEF3 461 362 367 15.56 0.035 ctrl only
I3LG01 Uncharacterized protein ARHGEF38 47996 617 633 17.38 0.025 LPS only
A0A286ZZJ2 Uncharacterized protein ARHGEF7 15128 671 680 27.96 0.018 ctrl only
A0A287AS03 Uncharacterized protein ARID5A 18319 31 41 29.61 0.014 LPS only
A0A287A0M2 Uncharacterized protein ARSG 13570 343 352 39.48 0.0002 LPS only
F1RYU5 NAD(P)(+)--arginine ADP-ribosyltransferase ART3 4553 84 91 20.22 0.022 both
A5GFT7 AS complex locus AS 9431 169 178 26.05 0.018 LPS only
A0A287AIE6 ATPase ASNA1 ASNA1 14185 176 185 34.23 0.0029 LPS only
F1RSA3 Uncharacterized protein ASTE1 45734 658 675 17.87 0.029 LPS only
D0G0C7 Antioxidant protein 1 homolog (Yeast) ATOX1 23788 26 38 36.65 0.00096 ctrl only
A0A287AX66 Phospholipid-transporting ATPase ATP10D 26659 1306 1318 17.49 0.046 both
P11607 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 ATP2A2 68144 353 371 17.49 0.028 LPS only
A0A287AGU2 ATP synthase subunit alpha ATP5F1A 7309 192 201 15.93 0.032 ctrl only
A0A287BET3 Uncharacterized protein ATP5F1B 33624 137 151 34.07 0.00064 ctrl only
A0A287BCX5 V-type proton ATPase catalytic subunit A ATP6V1A 37940 366 382 18.89 0.017 ctrl only
F1RGL1 Phospholipid-transporting ATPase ATP8B2 45942 141 156 16.8 0.027 LPS only
F1SKG2 Uncharacterized protein ATR 13776 1956 1965 23.55 0.02 both
A0A286ZI01 Uncharacterized protein ATXN2 35003 751 764 16 0.039 LPS only
A0A286ZLH6 Uncharacterized protein AVL9 53504 477 494 15.97 0.032 ctrl only
A0A286ZX01 Vasopressin V1a receptor AVPR1A 29819 21 33 19.75 0.03 ctrl only
A0A286ZVC3 Uncharacterized protein AZGP1 9965 91 99 49 0.00019 both
A0A287B7B9 Beta-2-microglobulin B2M 21179 88 99 77.82 5.10E-08 both
A0A287AIG3 Uncharacterized protein B4GALT1 4400 181 188 18.75 0.017 both
F1RFK7 Uncharacterized protein BAIAP2L1 39355 177 190 17.44 0.023 LPS only
A0A287BKD3 Uncharacterized protein BAZ2B 28265 1548 1559 16.4 0.035 LPS only
I3LT30 Bardet-Biedl syndrome 2 protein homolog BBS2 1555 276 282 40.05 0.0022 LPS only
A0A287AGY0 Uncharacterized protein BBX 39846 345 358 26.85 0.0054 LPS only
I3LQH7 Uncharacterized protein BLVRB 3773 6 14 47.89 0.001 both
F1RKG8 Uncharacterized protein BP1 11576 29 39 73.04 2.00E-07 LPS only
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A0A286ZQ31 Phosphoglycerate mutase BPGM 4016 173 181 32.58 0.0015 ctrl only
F1S505 BPI fold-containing family A member 1 BPIFA1 25052 73 88 15.04 0.039 LPS only
F1S033 Bromodomain containing 3 BRD3 18696 689 701 16.32 0.049 LPS only
A0A287BBE7 Uncharacterized protein BRD8 5751 1 9 22.3 0.042 ctrl only
A0A287BBB8 Uncharacterized protein BRPF3 2009 685 692 31.3 0.027 LPS only
A0A287AJV7 Uncharacterized protein BSDC1 36782 156 170 24.61 0.048 LPS only
A0A287ADJ5 Uncharacterized protein BTBD3 12587 305 314 32.99 0.012 ctrl only
F1RS82 Biotinidase BTD 10487 335 344 46.54 0.00015 both
A0A287AB51 Uncharacterized protein C12H17orf100 395 1 6 33.99 0.035 ctrl only
F1SIC7 Uncharacterized protein C15orf59 34613 277 290 18.52 0.033 ctrl only
A0A287BKX0 Uncharacterized protein C1D 7010 129 138 23.19 0.043 both
A0A287B0Z7 Complement C1q subcomponent subunit A C1QA 37631 159 173 50.43 1.90E-05 both
A0A286ZKA5 Uncharacterized protein C1QB 174 115 120 26.89 0.04 both
A0A286ZSJ7 Uncharacterized protein C1QC 6878 201 210 67.02 7.90E-06 both
A0A287BFU6 Uncharacterized protein C1R 6538 25 33 31.29 0.014 both
A0A286ZMS2 Uncharacterized protein C1S 2498 444 451 33.07 0.0083 both
F1RQW7 Uncharacterized protein C2 8641 828 835 22.17 0.044 both
F1SBS4 Complement C3 C3 1434 599 605 30.41 0.047 both
F1RQW2 Uncharacterized protein C4A 230 1663 1667 36.63 0.015 both
A0A286ZU55 Uncharacterized protein C4BPA 8879 262 270 29.34 0.0024 both
A0A287AL92 Uncharacterized protein C4BPB 6181 228 235 49.01 4.10E-05 both
F1S8R6 Uncharacterized protein C4orf48 15759 78 87 20.86 0.017 both
A0A286ZKB4 Complement C5a anaphylatoxin C5 1222 1143 1149 32.72 0.041 both
F1SMI8 Uncharacterized protein C6 1298 405 410 25.55 0.035 both
Q9TUQ3 Complement component C7 C7 399 373 378 22.28 0.025 both
A0A287B5F3 Uncharacterized protein C7orf57 39200 191 206 15.57 0.037 both
F1S788 Uncharacterized protein C8A 9401 475 484 34.06 0.00079 ctrl only
A0A287AT36 Uncharacterized protein C8B 3791 252 259 73.06 1.70E-06 both
A0A287AFQ4 Uncharacterized protein C8G 10613 162 170 30.93 0.0045 both
A0A287BH90 Uncharacterized protein C9 1106 329 335 27.68 0.024 both
A0A287AI92 Uncharacterized protein CA1 27746 101 114 64.38 9.20E-07 both
A0A287B6M0 Uncharacterized protein CA2 6405 159 167 39.24 0.00036 both
A0A287ARG0 Uncharacterized protein CABS1 17719 9 19 16.15 0.031 ctrl only
F1SNS3 Uncharacterized protein CACHD1 1337 334 339 32.36 0.048 LPS only
A0A287BJU2 Uncharacterized protein CACTIN 4305 157 163 19.08 0.043 both
F1S710 Uncharacterized protein CACYBP 940 11 16 36.29 0.025 both
A0A0G2KBD0 Calcitonin gene-related peptide type 1 receptor CALCRL 29959 324 335 17.18 0.046 both
A0A287BCG9 Uncharacterized protein CALM1 1766 32 38 28.89 0.017 ctrl only
F1RYI3 Uncharacterized protein CAND1 19847 1027 1039 48.17 0.00013 ctrl only
F1SMC0 Adenylyl cyclase-associated protein CAP1 42836 255 272 30.67 0.004 ctrl only
P35750 Calpain-1 catalytic subunit CAPN1 17613 37 46 48.15 4.70E-05 ctrl only
Q9N2I1 Caspase-1 CASP1 11099 1 9 21.49 0.045 ctrl only
O62839 Catalase CAT 1695 493 499 35.59 0.017 both
A0A286ZUF4 Uncharacterized protein CB2 22302 435 445 25.51 0.034 LPS only
Q28960 Carbonyl reductase [NADPH] 1 CBR1 35139 160 174 46.94 4.00E-05 ctrl only
A0A287AXW1 Uncharacterized protein CCDC121 10657 201 209 15.39 0.045 LPS only
F1SP97 Uncharacterized protein CCDC191 2345 619 625 37.07 0.025 LPS only
A0A286ZPZ0 Uncharacterized protein CCDC30 12449 553 561 25.74 0.02 ctrl only
F1SGC2 Uncharacterized protein CCDC39 7090 408 415 23.97 0.04 LPS only
F1RZ80 Uncharacterized protein CCDC40 56338 489 506 15.72 0.034 ctrl only
F1RUT6 Uncharacterized protein CCDC87 814 153 159 47.81 0.0014 LPS only
A0A287AMZ2 T-complex protein 1 subunit gamma CCT3 12802 439 449 34.77 0.00055 ctrl only
A0A287AKF5 Uncharacterized protein CCT7 22404 289 300 18.79 0.017 ctrl only
I3LCA2 Uncharacterized protein CCT8 21914 283 297 32.52 0.00089 ctrl only
F1RQH9 Uncharacterized protein CD109 24233 1131 1143 56.91 1.80E-05 both
A2SW51 Monocyte differentiation antigen CD14 CD14 5631 65 72 40.06 0.0056 both
A0A286ZZK6 Uncharacterized protein CD180 401 254 258 40.43 0.0031 both
F1SGT4 Uncharacterized protein CD44 9782 42 50 38.18 0.0013 both
A0A286ZPI8 Uncharacterized protein CD55 30620 75 88 29.28 0.037 ctrl only
A0A287AE58 Uncharacterized protein CD5L 4081 512 518 29.55 0.023 both
F1SAT8 Uncharacterized protein CD93 51580 70 88 28.66 0.0069 cb
A0A287AEC2 Uncharacterized protein CDH1 25202 309 322 74.33 3.90E-07 both
F1RFU7 Uncharacterized protein CDH11 24376 430 441 31.1 0.0012 both
A0A286ZU93 Uncharacterized protein CDH17 15257 157 168 56.61 0.00011 c
Q8WNW5 Cadherin-5 CDH5 10281 270 280 50.55 0.00011 both
A0A286ZX45 Uncharacterized protein CELSR1 50695 1866 1883 16.5 0.028 both
I3LRD3 Uncharacterized protein CENPE 4541 1251 1258 40.53 0.0093 both
A0A287BAP4 Uncharacterized protein CEP112 3375 261 267 18.06 0.049 LPS only
F1SF36 Uncharacterized protein CEP85L 4841 117 125 24.6 0.033 both
A0A287AK64 Uncharacterized protein CFAP54 16039 2866 2875 18.9 0.042 LPS only
Q03710 Complement factor B (Fragment) CFB 65393 52 76 63.18 1.20E-06 both
P51779 Complement factor D CFD 19448 167 177 42.59 0.0001 both
A0A286ZJK1 Uncharacterized protein CFH 2357 519 525 16.7 0.032 both
A0A287AQ20 Uncharacterized protein CFI 2495 446 452 41.56 0.0027 both
P10668 Cofilin-1 CFL1 11859 2 13 43.99 0.00017 both
Q5G6V9 Cofilin-2 CFL2 20366 82 92 40.28 0.00021 both
F1RWV1 Uncharacterized protein CFP 35474 438 451 15.28 0.037 both
A0A286ZJL1 Uncharacterized protein CHD3 45246 50 64 19.68 0.014 LPS only
A0A286ZN07 Uncharacterized protein CHMP4A 1031 61 67 34.61 0.0085 both
F1S6Q3 Uncharacterized protein CILP2 11890 714 723 36.21 0.0029 LPS only
A0A287A2B5 Uncharacterized protein CINP 37923 150 162 16.76 0.031 both
I3LPB5 Creatine kinase B-type CKB 16302 237 247 20.44 0.033 c
Q5XLD3 Creatine kinase M-type CKM 3928 359 365 24.3 0.031 both
A0A287AAI1 Uncharacterized protein CLEC11A 13219 195 205 45.1 0.00011 both
F1SRC8 C-type lectin domain family 3 member B CLEC3B 9515 81 89 33.2 0.0026 both
A0A287B250 Chloride intracellular channel protein CLIC1 40086 103 120 19.38 0.015 c
A0A287A988 Uncharacterized protein CLIC3 7453 193 201 24.14 0.047 both
A0A287ADH9 Chloride intracellular channel protein CLIC4 15012 239 249 22.77 0.024 both
C0MHR2 Clathrin heavy chain CLTC 43374 228 245 35.04 0.00052 c
K7GND8 Clusterin CLU 3888 216 223 46.09 0.00043 both
A0A2C9F3A4 UMP-CMP kinase CMPK1 26574 59 71 18.01 0.04 ctrl only
A0A287BCC0 Uncharacterized protein CNIH2 45775 2 17 15.59 0.036 ctrl only
A0A287AJ55 Uncharacterized protein CNKSR2 67924 343 367 15.82 0.046 LPS only
A0A287A9Q5 Uncharacterized protein CNTNAP2 4820 173 180 36.43 0.032 ctrl only
A0A286ZK31 Uncharacterized protein COBLL1 3848 1093 1101 26.35 0.048 ctrl only
A0A286ZXJ1 Uncharacterized protein COG5 6981 106 115 17.94 0.03 ctrl only
A0A287A8R0 Uncharacterized protein COL10A1 25293 521 533 41.73 0.00012 LPS only
F1RQI0 Uncharacterized protein COL12A1 31235 540 553 15.13 0.038 ctrl only
A0A287BGV6 Uncharacterized protein COL14A1 51692 899 916 65.43 5.20E-06 LPS only
A0A286ZIL9 Uncharacterized protein COL18A1 16910 1244 1256 20.33 0.047 both
A0A287A1S6 Uncharacterized protein COL1A1 13610 1239 1248 41.63 0.0081 both
I3L781 Uncharacterized protein COL1A2 30989 1273 1286 37.73 0.00029 both
A0A286ZWS8 Uncharacterized protein COL2A1 13425 1444 1452 25.24 0.0043 both
A0A286ZLV2 Uncharacterized protein COL6A3 25385 444 456 19.82 0.014 both
A0A287ATF0 Uncharacterized protein COLEC10 12604 207 216 26.31 0.0051 both
A0A287ADL0 Uncharacterized protein COLEC11 13183 250 259 37.93 0.0016 both
A0A287AXP9 Collagen beta(1-O)galactosyltransferase 1 COLGALT1 3478 55 62 20.5 0.03 both
F1S902 Uncharacterized protein COMP 20433 485 496 24.11 0.031 both
A0A286ZQ12 Coatomer subunit gamma COPG2 35106 516 527 21.08 0.024 LPS only
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F1SKB1 Uncharacterized protein CP 401 44 49 34.37 0.05 both
F1RU03 Uncharacterized protein CPA6 31550 96 109 19.94 0.02 ctrl only
F1RK01 Uncharacterized protein CPB2 1609 291 297 37.3 0.024 both
A0A287A983 Carboxypeptidase N subunit 1 CPN1 37997 107 121 102.62 3.40E-09 both
I3LF89 Uncharacterized protein CPN2 628 348 354 38.89 0.013 both
F1SSS0 Carbamoyl-phosphate synthase 1 CPS1 31940 533 547 76.21 7.10E-08 ctrl only
I3LVL5 Uncharacterized protein CRISP3 25247 62 74 55 1.10E-05 both
A0A287B1U0 Uncharacterized protein CRLF3 13162 60 69 26.25 0.043 LPS only
A0A287AL32 Uncharacterized protein CROCC 5373 1498 1504 28.41 0.033 LPS only
A0A286ZT09 Uncharacterized protein CROT 48445 228 245 15.9 0.032 ctrl only
A0A287AL17 Uncharacterized protein CRTAC1 35323 156 168 32.79 0.021 LPS only
A0A287BE96 Uncharacterized protein CRYBG2 36934 434 448 22.49 0.017 LPS only
F1SRD7 Uncharacterized protein CSDC2 17743 117 126 31.37 0.024 LPS only
F1RL77 Uncharacterized protein CSF1R 31470 110 124 65.4 2.90E-06 both
Q0Z8R0 Cystatin CST3 53962 102 119 25.09 0.0044 both
F1RU34 Cystatin CST6 56813 126 143 15.84 0.048 ctrl only
F1S1L9 Uncharacterized protein CSTF2 11846 419 428 19.78 0.046 LPS only
F1SC70 Carboxypeptidase CTSA 55634 421 439 22.65 0.0075 ctrl only
A0A287BF94 Cathepsin B CTSB 7501 270 277 22.71 0.038 both
A0A286ZX26 Cathepsin D CTSD 24304 330 343 20.8 0.013 both
A0A286ZNU3 Uncharacterized protein CTSV 22951 50 61 22.36 0.02 ctrl only
A0A286ZZB0 Uncharacterized protein CWF19L2 29178 613 624 18.75 0.034 LPS only
A0A286ZRH9 Uncharacterized protein CXADR 62538 133 150 17.64 0.022 LPS only
A0A287AQ90 Uncharacterized protein CXorf57 8980 77 84 28.28 0.047 LPS only
P00172 Cytochrome b5 CYB5A 23620 78 89 40.84 0.00017 ctrl only
A0A286ZPR0 Aromatase 3 CYP19A3 33817 178 190 15.67 0.047 both
A0A287BAM0 Dystroglycan DAG1 32701 80 95 41.73 0.00012 both
A0A287A3D1 Uncharacterized protein DBF4 1030 474 479 36.35 0.025 both
A0A287BJR8 Acyl-CoA-binding protein DBI 43182 17 34 28 0.0024 ctrl only
A0A287B1T7 Uncharacterized protein DDAH1 14276 71 81 51.98 3.20E-05 ctrl only
A0A286ZLI8 Uncharacterized protein DDX17 15153 390 401 30.11 0.0071 both
A0A287A3P8 Uncharacterized protein DDX50 17934 559 569 18.17 0.047 ctrl only
A0A286ZPQ4 Uncharacterized protein DENND4C 18376 300 310 24.37 0.0052 LPS only
A0A286ZR82 Uncharacterized protein DERA 34695 107 122 70.53 2.40E-07 ctrl only
P02540 Desmin DES 4488 409 416 27.53 0.023 ctrl only
F1S1B9 Uncharacterized protein DHRS11 13856 241 251 47.98 0.00067 ctrl only
I3LRU8 Uncharacterized protein DHX36 3487 209 215 33.4 0.017 ctrl only
A0A287AIF6 Death inducer-obliterator 1 DIDO1 26558 2 14 16.46 0.037 both
A0A286ZRB0 Uncharacterized protein DIP2C 7082 126 134 24.41 0.016 LPS only
A0A287ALV3 Uncharacterized protein DLC1 7101 267 274 31.46 0.035 ctrl only
A0A287BRM0 Uncharacterized protein DLG5 31 961 965 36.62 0.0091 ctrl only
A0A287AF97 Uncharacterized protein DNAH10 17609 645 654 18.96 0.035 LPS only
A0A287AHL5 Uncharacterized protein DNAH7 15112 2330 2340 17.18 0.032 LPS only
A0A286ZSC6 Uncharacterized protein DNAH8 42713 419 432 15.14 0.038 ctrl only
F1RIJ5 Uncharacterized protein DNAJC11 3699 444 450 33.38 0.046 LPS only
F1SB54 Uncharacterized protein DNAJC2 36879 521 533 19.14 0.022 ctrl only
F1SU72 Uncharacterized protein DNAJC9 36248 38 52 17.38 0.045 LPS only
F1SDY3 Deoxyribonuclease-2-alpha DNASE2 27861 66 80 20.29 0.036 LPS only
F1RGE0 Uncharacterized protein DND1 8889 226 234 23.23 0.03 ctrl only
A0A286ZL45 Uncharacterized protein DOCK2 59655 230 249 18.44 0.043 ctrl only
A0A287A8X2 Uncharacterized protein DOCK4 5857 1712 1719 16.25 0.034 both
A0A2C9F3H7 Dipeptidyl peptidase 4 DPP4 40148 685 699 30.82 0.0013 both
F1SSP9 Uncharacterized protein DPP6 70203 59 81 22.11 0.019 LPS only
I3LG81 Uncharacterized protein DPY19L1 13872 196 205 20.56 0.033 LPS only
A0A287AQA5 Uncharacterized protein DSEL 68208 597 619 15.08 0.038 LPS only
A0A287ATF2 Uncharacterized protein DSG2 34199 38 51 25.84 0.0038 both
I3LRN0 Uncharacterized protein DTX3L 35024 284 298 16.43 0.029 ctrl only
F1S252 Uncharacterized protein DUSP27 22950 844 853 32.24 0.0054 LPS only
A0A287B3I2 Uncharacterized protein DYTN 5656 96 104 21.48 0.014 LPS only
A0A287BNU9 Uncharacterized protein E2F3 26600 156 169 25.56 0.012 LPS only
A0A287AU20 Uncharacterized protein E2F4 53027 1 20 15.6 0.034 ctrl only
F1RYJ9 Uncharacterized protein E2F7 12273 1 9 17.35 0.025 LPS only
A0A287A262 Uncharacterized protein EARS2 38 309 313 31.7 0.011 both
A0A287BHL7 Uncharacterized protein ECM1 6396 507 516 36.77 0.0024 both
A0A286ZUI3 Uncharacterized protein EEF1A1 4052 402 410 34.44 0.0031 ctrl only
A0A286ZNV2 Uncharacterized protein EEF1A2 4052 556 564 34.44 0.0031 ctrl only
F1SDP1 EEF1A lysine methyltransferase 2 EEF1AKMT2 16606 2 15 18.23 0.019 LPS only
F1SHD6 Uncharacterized protein EEF1B2 31780 8 22 62.1 1.90E-06 ctrl only
Q29387 Elongation factor 1-gamma (Fragment) EEF1G 25160 397 409 46.12 4.70E-05 ctrl only
A0A287A1E0 Uncharacterized protein EEF2 10462 400 410 40.29 0.00017 ctrl only
A0A287B922 Uncharacterized protein EHBP1 10866 1 9 18.88 0.042 ctrl only
A0A287B1T2 Uncharacterized protein EHD3 21721 77 87 27.87 0.025 ctrl only
I3LDA5 Uncharacterized protein EHD4 21721 80 90 27.87 0.025 ctrl only
I3LUM9 Eukaryotic translation initiation factor 2 subunit 3 EIF2S3 31275 2 17 39.5 0.00075 ctrl only
A0A286ZPS5 Eukaryotic translation initiation factor 5A EIF5A2 18459 56 67 21.37 0.011 ctrl only
A0A287B6A2 Uncharacterized protein ELF2 13053 532 542 16.04 0.041 LPS only
A0A286ZKS3 Engulfment and cell motility 2 ELMO2 12012 252 261 15.59 0.039 ctrl only
A0A287AJA7 Elongation of very long chain fatty acids protein 1 ELOVL1 979 258 263 31.44 0.015 ctrl only
A0A287B6S5 Uncharacterized protein ENO1 1915 222 228 58.76 0.00014 both
A0A287ANH6 Uncharacterized protein ENO2 23339 16 28 44.5 0.00043 both
Q1KYT0 Beta-enolase ENO3 29926 240 253 39.47 0.0005 both
A0A286ZKF8 Uncharacterized protein ENPP2 9561 988 996 16.53 0.029 both
A0A287A0X7 Uncharacterized protein EPB41 12645 394 403 20.63 0.04 ctrl only
A0A286ZJ88 Uncharacterized protein EPB41L1 37358 175 189 61.08 3.70E-06 ctrl only
A0A287BJX0 Uncharacterized protein EPB42 28274 411 423 52.07 5.90E-05 ctrl only
A0A286ZNB6 Uncharacterized protein EPHA3 10021 280 289 15.42 0.036 ctrl only
I3LPX6 Uncharacterized protein ERICH6 42164 172 188 16.15 0.031 ctrl only
Q9GJT2 S-formylglutathione hydrolase ESD 33007 210 224 25.23 0.0043 ctrl only
F1RHL1 ETS variant 3 ETV3 29404 381 393 15.94 0.041 both
A0A287AJ08 Uncharacterized protein ETV7 20678 193 205 17.79 0.047 LPS only
F1RW07 Uncharacterized protein EVPL 17745 731 741 22.28 0.022 ctrl only
A0A287AET8 Exocyst complex component EXOC6 13814 508 517 16.06 0.031 LPS only
A0A287BES5 Uncharacterized protein EXPH5 54391 1759 1777 15.2 0.037 ctrl only
A0A286ZNT6 Uncharacterized protein EXTL2 5028 209 215 40.75 0.0035 ctrl only
A0A286ZVZ2 Uncharacterized protein EXTL3 50 422 426 29.53 0.046 ctrl only
F1RN41 Uncharacterized protein F10 3530 415 423 17.42 0.03 both
A0A286ZR66 Uncharacterized protein F11 38328 535 548 32.3 0.00094 ctrl only
O97507 Coagulation factor XII F12 130 578 582 42.3 0.0023 both
K7GQL2 Coagulation factor XIII A chain F13A1 934 539 544 19.61 0.014 both
A0A287AFP8 Uncharacterized protein F13B 15989 300 309 22.83 0.0087 both
F1SIB1 Prothrombin F2 391 463 468 33.73 0.035 both
Q9GLP1 Coagulation factor V F5 927 1030 1035 36.8 0.0045 both
P16293 Coagulation factor IX (Fragment) F9 654 330 335 32.71 0.025 both
A0A2C9F382 Fatty acid-binding protein liver FABP1 17470 44 54 18.57 0.018 LPS only
A0A286ZKB9 Uncharacterized protein FAM120B 60367 32 50 16.49 0.037 LPS only
A0A287ACV7 Uncharacterized protein FAM213A 23792 91 103 23.86 0.0058 ctrl only
A0A287B4D4 Uncharacterized protein FAM81A 23129 166 177 18.01 0.02 ctrl only
F1RUH9 Uncharacterized protein FAM8A1 7436 1 9 17.61 0.022 LPS only
A0A287BMP6 Fanconi anemia group C protein homolog FANCC 3865 47 53 27.42 0.038 LPS only
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A0A287A8Z0 Uncharacterized protein FANCD2OS 32350 165 176 17.71 0.022 ctrl only
I3LC73 Uncharacterized protein FASN 58541 1704 1722 16.51 0.047 LPS only
A0A286ZYP1 Uncharacterized protein FBH1 1130 530 535 26.89 0.046 ctrl only
A0A287AL89 Fibulin-1 FBLN1 11985 502 511 31.49 0.0036 both
Q29042 Ficolin-1 FCN1 3728 38 46 60.87 7.30E-06 both
Q29041 Ficolin-2 FCN2 3728 35 43 60.87 7.30E-06 both
I3LCL4 Uncharacterized protein FER1L5 48869 650 665 19.11 0.048 ctrl only
F1SFI6 Uncharacterized protein FETUB 7107 59 67 15.52 0.035 both
P14460 Fibrinogen alpha chain (Fragment) FGA 9779 7 17 31.59 0.029 both
P14477 Fibrinogen beta chain (Fragment) FGB 28454 1 13 52.93 1.10E-05 both
F1RX35 Uncharacterized protein FGG 1696 155 161 31.87 0.041 both
A0A287BKJ2 Fibrinogen like 1 FGL1 5810 55 62 46.14 0.001 both
A0A287ACQ1 Uncharacterized protein FHAD1 17528 397 406 22 0.031 ctrl only
Q2VTP6 Peptidylprolyl isomerase FKBP1A 28933 59 72 28.01 0.0024 ctrl only
A0A286ZRM3 Uncharacterized protein FLII 42349 43 57 16.41 0.046 both
A0A286ZPG4 Uncharacterized protein FLNB 52861 1577 1595 16.46 0.048 LPS only
F1RNA6 Uncharacterized protein FLOT2 36463 64 78 35.48 0.00047 ctrl only
F1S5Q6 Uncharacterized protein FLT4 45169 708 723 35.35 0.00048 both
A0A286ZY95 Uncharacterized protein FN1 1202 1028 1034 43.65 0.0042 both
F1RZZ3 Uncharacterized protein FN3KRP 49327 83 103 21.73 0.0092 ctrl only
A0A287A309 Formin binding protein 4 FNBP4 2810 197 204 28.63 0.042 LPS only
A0A287BLX2 Uncharacterized protein FOLR1 6001 216 223 31.48 0.0029 LPS only
A0A287AKZ2 Uncharacterized protein FRAS1 117 1843 1848 37.36 0.014 LPS only
A0A287A840 Uncharacterized protein FRMPD2 33551 9 25 37.81 0.0024 both
F1RYK8 Uncharacterized protein FSIP2 39016 5766 5779 19.19 0.029 both
A0A287AZC9 Uncharacterized protein FSTL1 43049 235 249 15.69 0.049 both
F1S715 Alpha-L-fucosidase FUCA2 24389 28 38 31.24 0.0012 both
A0A287BIT3 Alpha-(13)-fucosyltransferase FUT11 2619 129 136 18.87 0.047 LPS only
A0A286ZS04 Uncharacterized protein FXR1 22889 475 488 20.1 0.036 ctrl only
A0A286ZLD3 FYN binding protein 1 FYB1 26549 228 242 21.27 0.039 both
A0A286ZY10 Glucose-6-phosphate 1-dehydrogenase G6PD 13744 499 508 35.42 0.00048 ctrl only
Q9GKX6 Aldose 1-epimerase GALM 59022 1 21 18.31 0.035 both
A0A286ZQE4 Glyceraldehyde-3-phosphate dehydrogenase GAPDH 1637 226 232 36.11 0.0021 both
F1RM74 Glyceraldehyde-3-phosphate dehydrogenase GAPDHS 1637 217 223 36.11 0.0021 ctrl only
A0A287BIU0 Uncharacterized protein GARNL3 26273 840 853 19.92 0.014 LPS only
I3LN42 GC vitamin D binding protein GC 1888 364 370 32.72 0.024 LPS only
A0A287ADA9 Uncharacterized protein GCLC 38132 2 17 81.2 2.40E-08 ctrl only
A0A287AA47 Uncharacterized protein GCLM 36799 50 64 20.01 0.027 ctrl only
I3L5N5 Uncharacterized protein GCSAM 11731 2 10 26.32 0.017 LPS only
Q6Q7J2 Rab GDP dissociation inhibitor beta GDI2 10525 90 98 21.24 0.037 ctrl only
A0A287A1W4 Uncharacterized protein GFAP 20889 353 363 58.97 1.70E-05 LPS only
I3LDM7 Lactoylglutathione lyase GLO1 2585 61 67 27.11 0.0082 ctrl only
F1SLB4 Uncharacterized protein GLS2 80305 415 453 18.03 0.032 LPS only
A0A287AY75 Uncharacterized protein GOLM1 2460 142 148 34.63 0.043 both
F1RPA7 Glycoprotein 2 GP2 6354 489 497 26.65 0.0039 both
P08059 Glucose-6-phosphate isomerase GPI 14809 242 252 15.95 0.037 ctrl only
A0A287AHX3 Uncharacterized protein GPLD1 4571 800 808 74.82 2.50E-06 both
A0A287AG70 Glutathione peroxidase GPX1 6239 7 17 50.82 0.00037 ctrl only
A0A287AIJ3 Glutathione peroxidase GPX3 1969 147 152 29.85 0.045 both
O18994 Epididymal secretory glutathione peroxidase GPX5 17771 184 195 39.21 0.0032 both
A0A287BN68 Uncharacterized protein GRIN2A 51032 783 802 16.15 0.031 both
A0A287AD92 GrpE protein homolog GRL1 22071 1 11 15.96 0.045 LPS only
F1SBX5 Uncharacterized protein GRM3 1637 673 679 25.19 0.026 LPS only
A0A286ZLK2 Uncharacterized protein GRXCR2 11765 122 130 21.6 0.021 both
P20305 Gelsolin (Fragment) GSN 336 555 559 29.84 0.043 both
Q9N1F5 Glutathione S-transferase omega-1 GSTO1 1810 123 129 20.39 0.023 ctrl only
A0A287AZ91 Glutathione S-transferase P GSTP1 36834 84 99 80.81 7.10E-08 ctrl only
A0A286ZI87 Uncharacterized protein GZMB 7220 202 211 32.44 0.0024 both
A0A287A1S9 Histone H2A H2AFV 2560 77 83 22.34 0.04 LPS only
A0A286ZYN1 Uncharacterized protein H6PD 21504 263 273 29.3 0.0018 both
A0A287AZ81 Uncharacterized protein HABP2 28855 374 386 51.59 0.00016 both
P02067 Hemoglobin subunit beta HBB 5026 2 9 35.44 0.005 both
P02101 Hemoglobin subunit epsilon HBE1 17106 32 41 37.63 0.0015 both
K7GNR8 Uncharacterized protein HBQ1 873 74 79 33.67 0.019 both
F1RGX7 Uncharacterized protein HBZ 1955 93 99 30.99 0.038 ctrl only
A0A287AU98 Uncharacterized protein HCFC2 49087 191 207 15.9 0.032 LPS only
A0A286ZSH3 Heme-binding protein 1 HEBP1 44468 126 143 46.27 4.60E-05 ctrl only
F1SHF6 Uncharacterized protein HECTD1 553 696 701 35.69 0.024 ctrl only
A0A287AHB3 Uncharacterized protein HECW1 3313 1 8 25.56 0.025 LPS only
A0A287AQV2 Uncharacterized protein HELZ 5383 937 944 23.18 0.036 ctrl only
A0A286ZKQ1 Beta-hexosaminidase HEXB 7267 362 370 17.78 0.036 LPS only
A0A286ZMW3 Uncharacterized protein HGFAC 13774 557 567 42.82 0.00084 both
F1SAH3 Uncharacterized protein HINFP 7245 355 363 16.16 0.03 ctrl only
F1RKI3 Uncharacterized protein HINT1 57646 59 82 62.35 1.40E-06 ctrl only
A0A286ZZB7 Histone cluster 1 H1 family member e HIST1H1E 10446 65 75 66.76 1.80E-06 ctrl only
P06348 Histone H1t HIST1H1T 10446 68 78 66.76 1.80E-06 ctrl only
F2Z581 Histone cluster 1 H2B family member n HIST1H2BN 11578 36 44 22.35 0.016 ctrl only
A0A286ZRQ1 Histone H2B HIST2H2BE 5014 113 121 38.45 0.003 ctrl only
A0A286ZPE3 Uncharacterized protein HNRNPA1 14808 131 140 51.72 0.00015 ctrl only
A0A286ZI52 Heterogeneous nuclear ribonucleoprotein A2/B1 HNRNPA2B1 9638 55 62 25.47 0.0061 ctrl only
A0A286ZK74 Uncharacterized protein HNRNPC 19447 18 29 25.92 0.024 both
A0A286ZQN9 Heterogeneous nuclear ribonucleoprotein H1 HNRNPH1 20227 88 98 16.46 0.029 ctrl only
A0A286ZWW2 Uncharacterized protein HNRNPH2 39959 151 167 58.13 3.50E-06 ctrl only
A0A287A699 Uncharacterized protein HNRNPK 3099 373 381 24.63 0.02 ctrl only
A0A286ZJR3 Heterogeneous nuclear ribonucleoprotein U HNRNPU 18039 123 132 40.42 0.00023 ctrl only
A0A2C9F356 Haptoglobin HP 3112 170 176 39.53 0.011 both
Q45FY6 Hypoxanthine-guanine phosphoribosyltransferase HPRT1 24440 129 141 51.98 0.00013 ctrl only
P50828 Hemopexin HPX 925 204 209 31.22 0.0081 both
F1SFI5 Uncharacterized protein HRG 1540 37 43 40.91 0.0054 both
F1SMZ6 Uncharacterized protein HS1 3824 9 15 26.25 0.021 LPS only
K7GP28 Uncharacterized protein HSD17B10 6368 285 293 17.21 0.043 LPS only
O02705 Heat shock protein HSP 90-alpha HSP90AA1 10479 348 356 15.4 0.036 both
A0A286ZR68 Uncharacterized protein HSP90AB1 12555 482 491 36.9 0.0013 both
Q29092 Endoplasmin HSP90B1 17180 103 114 28 0.0024 both
P34930 Heat shock 70 kDa protein 1A HSPA1A 14013 160 171 38.56 0.0081 LPS only
Q6S4N2 Heat shock 70 kDa protein 1B HSPA1B 14013 160 171 38.56 0.0081 LPS only
A5A8V7 Heat shock 70 kDa protein 1-like HSPA1L 14013 162 173 38.56 0.0081 both
F1SA70 Uncharacterized protein HSPA2 15213 27 37 62.78 3.80E-06 both
A0A287B6J6 Uncharacterized protein HSPA4 27308 20 33 39.2 0.00027 ctrl only
P34935 Endoplasmic reticulum chaperone BiP (Fragment) HSPA5 39808 92 108 88.89 4.60E-09 both
Q04967 Heat shock 70 kDa protein 6 HSPA6 15213 28 38 62.78 3.80E-06 ctrl only
A0A286ZPN4 Uncharacterized protein HSPA8 6108 129 137 18.35 0.019 both
A0A287ADJ2 Stress-70 protein mitochondrial HSPA9 15751 207 218 33.42 0.0046 LPS only
A0A287ATN8 Uncharacterized protein HSPD1 3997 293 301 52.92 0.00013 ctrl only
A0A286ZHV7 Uncharacterized protein HSPG2 42000 4164 4181 35.8 0.00088 both
A0A287AA97 Uncharacterized protein HUWE1 2526 2115 2121 41.84 0.002 LPS only
Q29545 Inhibitor of carbonic anhydrase ICA 946 554 560 34.17 0.03 both
F1SHE9 Islet cell autoantigen 1 like ICA1L 67043 98 118 16.83 0.05 LPS only
A0A287A4X6 Uncharacterized protein ICOSLG 13155 171 180 32.75 0.006 both
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Q6IED5 Interferon alpha inducible protein 6 IFI6 13770 110 120 23.65 0.044 LPS only
K7GNR1 Uncharacterized protein IFIT2 1715 236 242 31.64 0.031 both
F1RNN4 Uncharacterized protein IFT81 8840 493 501 19.62 0.029 LPS only
A0A286ZP75 Uncharacterized protein IGDCC4 24565 75 86 18.83 0.02 both
P24853 Insulin-like growth factor-binding protein 2 IGFBP2 929 178 183 27.71 0.015 both
A0A286ZX24 Immunoglobulin heavy constant delta IGHD 5162 354 361 34.37 0.0088 both
A0A287B6H1 Uncharacterized protein IL1RAP 11564 94 103 34.73 0.012 ctrl only
K7GS49 Uncharacterized protein ILF2 23509 128 141 28.66 0.0021 ctrl only
K7GL83 Uncharacterized protein ILF3 42238 183 200 45.21 5.80E-05 ctrl only
F1SKI5 Inosine-5~-monophosphate dehydrogenase IMPDH2 52369 517 535 20.33 0.012 both
A0A287BPF5 Inhibin beta B chain INHBB 2153 101 108 29.29 0.046 both
A0A287B0Z8 Uncharacterized protein INMT 30314 79 91 75.19 1.80E-07 ctrl only
A0A287BAN0 Uncharacterized protein INO80 41115 496 512 19.34 0.044 ctrl only
F1SFW4 Uncharacterized protein INTS3 46032 53 67 18.66 0.018 LPS only
A0A286ZVK8 Uncharacterized protein INTU 220 529 533 36.45 0.039 LPS only
F1RP44 Uncharacterized protein IPO5 38136 442 457 83.1 1.90E-08 ctrl only
A0A286ZVD9 Uncharacterized protein IQCA1 32873 279 290 15.73 0.033 both
F1RM42 Uncharacterized protein IRF2BP1 13236 428 438 15.36 0.048 ctrl only
I3LLF1 Uncharacterized protein IRS1 23036 627 638 19.64 0.028 LPS only
F1RVE7 Integrin beta ITGB1 7247 182 190 24.16 0.012 LPS only
K7GP66 Uncharacterized protein ITGB4 447 758 763 34.1 0.034 LPs only
A0A287AG27 Integrin beta ITGB8 8073 495 502 31.46 0.0044 both
Q29052 Inter-alpha-trypsin inhibitor heavy chain H1 ITIH1 2138 39 46 29.11 0.0057 both
F1RUM4 Inter-alpha-trypsin inhibitor heavy chain H2 ITIH2 2457 324 330 41.48 0.0079 both
A0A287AP73 Uncharacterized protein ITIH3 2503 538 544 40.49 0.0052 both
A0A286ZN24 Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4 2134 369 375 31.16 0.036 both
A0A287AT14 Uncharacterized protein ITIH6 20651 649 659 16.29 0.03 both
A0A287BHZ5 Uncharacterized protein IWS1 12089 834 843 16.73 0.036 ctrl only
A0A287BAD0 Uncharacterized protein JAKMIP3 73933 637 658 18.3 0.019 LPS only
A0A287BCR9 Uncharacterized protein JCAD 1824 1072 1078 15.84 0.049 ctrl only
A0A287B5V2 Uncharacterized protein JCHAIN 4627 77 84 37.9 0.0013 both
A0A286ZVV5 KAT8 regulatory NSL complex subunit 3 KANSL3 1032 2 7 24.96 0.05 both
I3LEM5 Katanin p60 ATPase-containing subunit A-like 2 KATNAL2 13060 289 300 21.42 0.0098 ctrl only
F1RZ97 Uncharacterized protein KCNG2 122 292 297 31.57 0.027 both
A0A286ZSP9 Uncharacterized protein KCNK2 8964 1 10 22.18 0.014 LPS only
A0A286ZIZ1 Uncharacterized protein KCNT1 36758 927 940 19.18 0.022 ctrl only
I3LMF8 Uncharacterized protein KCTD1 22843 32 44 24.23 0.016 LPS only
F1RHE6 Potassium channel tetramerization domain containing 12 KCTD12 58799 186 206 52.54 1.20E-05 LPS only
F1S4N3 Lysine (K)-specific demethylase 5B KDM5B 5048 254 261 23.6 0.044 LPS only
K7GNY3 Uncharacterized protein KHDRBS3 5020 2 8 16.45 0.038 ctrl only
A0A286ZYF1 Uncharacterized protein KIAA1109 26031 4273 4284 17.78 0.029 LPS only
A0A287BIC6 Uncharacterized protein KIAA1522 32114 216 230 15.92 0.032 LPS only
I3LUB8 Kinesin-like protein KIF5C 7504 596 604 30.26 0.041 ctrl only
A0A287BR34 Kinesin-like protein KIF9 34399 622 634 18.95 0.02 ctrl only
F1RZN7 Uncharacterized protein KLKB1 492 36 40 34.15 0.022 both
A0A287B3E8 Uncharacterized protein KLRB1 49579 15 30 16.59 0.037 LPS only
A0A287A6Z4 Uncharacterized protein KMT2C 64423 3119 3138 20.61 0.012 both
A0A287AHT8 Uncharacterized protein KNG1 3075 306 314 40.73 0.0017 both
A0A287AML8 Uncharacterized protein KNTC1 4745 705 712 24.02 0.039 LPS only
F1RWJ5 Importin subunit beta-1 KPNB1 21193 526 537 66.6 9.90E-07 ctrl only
F1SGG3 Uncharacterized protein KRT1 3116 67 75 35.92 0.0048 both
I3LDS3 Uncharacterized protein KRT10 1794 241 247 34.44 0.011 both
A0A286ZP27 Uncharacterized protein KRT12 1828 135 141 40.58 0.0026 both
F1S0K1 Uncharacterized protein KRT13 1963 183 189 34.97 0.012 both
A0A287AEL2 Uncharacterized protein KRT14 1794 238 244 34.44 0.011 both
A0A286ZYN0 Uncharacterized protein KRT15 1794 192 198 34.44 0.011 both
F1SGG1 Uncharacterized protein KRT18 1794 152 158 34.44 0.011 both
A0A287BHY5 Uncharacterized protein KRT2 15619 275 283 43.71 0.00056 both
A0A286ZVQ5 Uncharacterized protein KRT24 1794 141 147 34.44 0.011 both
F1RXF9 Uncharacterized protein KRT25 9742 83 91 53.64 6.20E-05 both
F1RXG2 Uncharacterized protein KRT28 1794 170 176 34.44 0.011 both
I3LDM6 Uncharacterized protein KRT3 11500 381 389 23.5 0.022 both
A0A286ZPQ6 Uncharacterized protein KRT4 20991 425 435 58.31 1.80E-05 both
A0A287AZL3 Keratin 5 KRT5 15583 359 368 37.24 0.0033 both
A0A287AG48 Keratin 7 KRT7 4488 398 405 27.53 0.023 ctrl only
A0A286ZIX1 Uncharacterized protein KRT71 2790 143 149 39.93 0.0052 LPS only
A0A287APM4 Uncharacterized protein KRT75 2798 150 156 40.16 0.0049 LPS only
A0A286ZJM8 Uncharacterized protein KRT77 26411 173 184 25.02 0.024 both
A0A287B7K6 Uncharacterized protein KRT78 4488 445 452 27.53 0.023 both
A0A287A2X0 Uncharacterized protein KRT79 21282 232 241 38.84 0.0015 both
A0A287A784 Uncharacterized protein KRT8 4488 402 409 27.53 0.023 both
A0A286ZL11 Uncharacterized protein KRT80 20199 374 384 24.14 0.028 LPS only
F1SBB3 Uncharacterized protein LAMA3 19381 2069 2079 16.95 0.041 ctrl only
F1SAE9 Uncharacterized protein LAMB1 36664 194 208 55.96 5.70E-06 both
A0A287ACS7 Uncharacterized protein LAMB4 2663 1556 1562 26.14 0.023 ctrl only
A0A287B5Y6 Uncharacterized protein LBP 12610 469 478 34.27 0.023 both
I3LK29 Phosphatidylcholine-sterol acyltransferase LCAT 34822 203 214 59.77 2.90E-05 both
F1RRX1 Uncharacterized protein LCN2 24490 102 113 25.45 0.015 LPS only
A0A287ANV7 Uncharacterized protein LCP1 5364 245 253 37.12 0.00033 both
A0A286ZNX3 L-lactate dehydrogenase LDHA 32992 145 158 61.19 1.20E-05 both
A0A287AQS1 L-lactate dehydrogenase B chain LDHB 5118 163 170 37.11 0.0086 both
A0A286ZRI5 Galectin LGALS1 30205 101 112 19.21 0.016 both
A0A287A604 Uncharacterized protein LGALS3BP 3128 346 352 28.03 0.0079 both
A0A287BCT6 Uncharacterized protein LGMN 31215 301 314 38.43 0.0011 both
A0A287A3S0 Pellino E3 ubiquitin protein ligase family member 2 LI2 30761 90 101 19.46 0.015 LPS only
A0A287B925 Protein lin-7 homolog LIN7B 2612 16 22 39 0.016 ctrl only
F1RPQ9 Uncharacterized protein LIPG 50163 130 147 27.64 0.003 LPS only
Q3ZD69 Prelamin-A/C LMNA 24535 299 311 57.92 2.10E-05 ctrl only
F1SLY4 Uncharacterized protein LMOD2 8435 343 351 19.87 0.026 ctrl only
F1RKY6 Uncharacterized protein LOC100153093 4867 148 156 24.34 0.036 LPS only
F1S573 Alpha-amylase LOC100153854 29168 285 297 31.08 0.0012 both
A0A287AT48 Uncharacterized protein LOC100153899 1616 152 157 40.4 0.0085 both
F1SR80 Tubulin alpha chain LOC100158003 23543 81 92 36.11 0.00072 ctrl only
A0A287AMU6 Uncharacterized protein LOC100158011 9434 93 101 24.72 0.012 ctrl only
A0A287B5W2 Uncharacterized protein LOC100302368 2406 123 130 49.75 0.00054 both
A0A286ZK96 Histone H2B LOC100512420 5014 90 98 38.45 0.003 ctrl only
A0A286ZYP5 Uncharacterized protein LOC100513601 32817 43 56 54.32 1.30E-05 both
F1SPW2 Uncharacterized protein LOC100513636 10106 270 277 19.96 0.05 LPS only
A0A286ZJ89 Uncharacterized protein LOC100514282 14863 89 98 25.3 0.011 LPS only
F1RII5 Uncharacterized protein LOC100515788 7161 134 144 64.9 8.20E-07 both
A0A287A5Z8 Uncharacterized protein LOC100517145 2241 839 845 28.03 0.029 both
A0A286ZSA5 Uncharacterized protein LOC100519130 3079 202 209 24.25 0.035 ctrl only
A0A286ZI83 Amine oxidase LOC100520329 332 349 353 44.22 0.0032 both
A0A287A8N4 C-X-C motif chemokine LOC100520680 3081 83 90 26.81 0.025 both
F1RL06 Uncharacterized protein LOC100523213 32916 171 185 105.37 5.00E-10 both
F1SCU8 Uncharacterized protein LOC100523732 15311 375 383 24.4 0.047 LPS only
F1SQ28 Uncharacterized protein LOC100523789 63415 213 230 16.87 0.026 ctrl only
A0A287A5S9 Uncharacterized protein LOC100524773 18724 985 994 22.08 0.032 both
F1RJE4 Uncharacterized protein LOC100525876 13679 16 25 26.83 0.041 LPS only
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A0A286ZIH3 Elongation factor 1-alpha LOC100620900 4052 424 432 34.44 0.0031 ctrl only
A0A287BS91 Uncharacterized protein LOC100621288 8169 1 10 22.47 0.027 ctrl only
A0A287ALA1 Uncharacterized protein LOC100621494 6886 273 282 49.2 0.00097 both
I3LK01 Uncharacterized protein LOC100621639 1917 131 137 25.73 0.015 LPS only
A0A287A665 Uncharacterized protein LOC100624628 41467 137 152 25.34 0.0042 ctrl only
A0A287A0J1 Tubulin beta chain LOC100624785 170 179 42.97 0.0002 ctrl only
K7GLE5 Uncharacterized protein LOC100626157 4901 127 135 31.52 0.016 ctrl only
A0A286ZPQ9 Uncharacterized protein LOC100736765 43496 1150 1166 15.93 0.032 LPS only
A0A287AHM5 Uncharacterized protein LOC100737030 1963 174 180 34.97 0.012 both
A0A287AVL4 Uncharacterized protein LOC100738425 26279 265 277 15.58 0.049 ctrl only
A0A286ZJQ0 Histone H3 LOC102161782 2221 58 64 40.06 0.0048 ctrl only
A0A287AAR6 Uncharacterized protein LOC102164346 23123 1041 1051 22.29 0.0081 both
F1RUL9 Uncharacterized protein LOC102166306 19140 58 68 32.7 0.00086 ctrl only
A0A286ZYZ5 Uncharacterized protein LOC106504545 1616 68 73 40.4 0.0085 both
A0A286ZTU7 Uncharacterized protein LOC106504547 931 199 204 30.53 0.043 both
A0A286ZKZ0 Uncharacterized protein LOC106507258 1917 116 122 25.73 0.015 LPS only
A0A286ZS98 Uncharacterized protein LOC110255205 126 163 168 37.29 0.014 ctrl only
I3LHA3 Uncharacterized protein LOC110255463 47824 393 409 15.1 0.043 ctrl only
F1S1G8 Amine oxidase LOC110256000 332 278 282 44.22 0.0032 both
A0A287AE80 Uncharacterized protein LOC110256481 13205 99 109 18.49 0.028 ctrl only
A0A286ZVG3 Thymosin beta LOC110257905 18751 2 12 19.15 0.016 ctrl only
K7GSY4 Uncharacterized protein LOC110257929 75899 122 145 15.67 0.034 LPS only
I3LHC3 Alpha-amylase LOC110258046 29464 211 222 25.6 0.0053 both
A0A287BRF1 Uncharacterized protein LOC110258309 14242 164 173 44.3 0.0012 both
A0A286ZQJ9 Uncharacterized protein LOC110258310 1753 144 151 31.61 0.012 both
A0A287AAW7 Uncharacterized protein LOC110258312 2025 179 184 31.57 0.036 both
F1RGX4 Uncharacterized protein LOC110259958 656 2 8 48.91 0.0015 both
A0A287AVR0 Eukaryotic translation initiation factor 3 subunit C LOC110260088 23942 878 889 16.83 0.045 ctrl only
A0A287BH91 Uncharacterized protein LOC110261286 30253 488 500 23.51 0.016 LPS only
A0A287BM11 Uncharacterized protein LOC396684 1361 225 231 26.7 0.046 both
F1S7K2 Uncharacterized protein LRG1 5484 320 327 31.64 0.0079 both
K7GS03 Uncharacterized protein LRP1 19590 771 783 33.83 0.0011 LPS only
A0A287B5N0 Uncharacterized protein LRRC31 55906 1 16 17.68 0.042 LPS only
F1S3V9 Uncharacterized protein LRRC41 81521 1 28 21.23 0.015 LPS only
A0A287AG02 Uncharacterized protein LRRIQ3 18447 511 520 32.44 0.0038 both
F1SQR8 Leukotriene A(4) hydrolase LTA4H 12918 547 556 20.61 0.017 both
P14632 Lactotransferrin LTF 10029 538 546 20.29 0.014 both
F1SQ09 Uncharacterized protein LUM 5250 176 184 45.34 0.0021 both
A0A2C9F343 Lysozyme LYZ 45190 99 113 78.91 1.90E-07 both
A0A287A837 Uncharacterized protein LZIC 1206 100 105 34.67 0.018 LPS only
A0A287AEG1 Uncharacterized protein MACF1 59961 1609 1630 19.05 0.04 LPS only
A0A287AG74 Uncharacterized protein MAGI2 47067 594 606 19.13 0.025 LPS only
I3L826 alpha-1 2-Mannosidase MAN1C1 25597 285 297 19.06 0.016 LPS only
A0A287BHP5 Alpha-mannosidase MAN2B1 35277 822 837 21.51 0.0096 both
F1S106 Uncharacterized protein MANBA 6719 191 199 15.89 0.048 ctrl only
E0YLM4 Mesencephalic astrocyte-derived neurotrophic factor MANF 22587 161 171 26.29 0.04 ctrl only
A0A287B4Y9 Uncharacterized protein MAP2K4 21348 145 155 18.1 0.039 ctrl only
A0A287A5U6 Uncharacterized protein MAP2K5 608 263 269 30.42 0.022 both
K7GKU8 Uncharacterized protein MASP2 34674 223 237 39.39 0.0002 both
F1S3V0 Uncharacterized protein MAST2 55504 1530 1549 15.56 0.04 ctrl only
A0A287AEL3 Uncharacterized protein MAX 29341 2 13 18.75 0.036 LPS only
Q5U9S1 Mannose-binding protein A MBL1 6796 106 114 32.12 0.014 both
I3LCF4 Uncharacterized protein MCM3AP 70459 624 646 19.22 0.03 LPS only
P11708 Malate dehydrogenase cytoplasmic MDH1 13304 221 230 47.16 0.00037 LPS only
I3LP41 Malate dehydrogenase MDH2 15408 223 233 22.46 0.03 ctrl only
Q29558 NADP-dependent malic enzyme (Fragment) ME1 8522 108 116 28.98 0.0045 both
A0A287ABG5 Methionine aminopeptidase METAP1D 574 206 211 36.38 0.016 ctrl only
A0A286ZL87 Uncharacterized protein MGA 27842 924 936 17.05 0.032 ctrl only
A0A287A042 Uncharacterized protein MGAM 4808 1057 1064 52.71 0.0007 both
A0A287A375 Uncharacterized protein MGAM2 45195 1495 1511 47.71 3.40E-05 both
P80928 Macrophage migration inhibitory factor MIF 8014 79 87 46.9 0.00087 ctrl only
F1RL22 Matrix metalloproteinase MMP11 1019 375 379 23.81 0.028 both
F1SV56 Matrix metalloproteinase MMP13 26969 69 81 18.34 0.019 ctrl only
F1RF11 Uncharacterized protein MMP2 47848 52 70 34.26 0.00061 both
A0A287B8S7 Uncharacterized protein MOGS 286 325 329 32.24 0.029 both
A0A286ZSV9 Uncharacterized protein MORC2 14658 453 463 15.3 0.041 ctrl only
F1RYC6 Uncharacterized protein MORF4L2 1440 87 92 35.02 0.032 LPS only
A0A287AYL1 Uncharacterized protein MPP6 7530 480 488 28.89 0.016 ctrl only
F1RWA3 Uncharacterized protein MRC1 11359 944 952 19.49 0.025 both
A0A287AEW3 Uncharacterized protein MRPS23 37467 1 15 20.05 0.013 ctrl only
A0A286ZZB9 Uncharacterized protein MSI1 8204 137 146 25.3 0.035 ctrl only
A0A287AK19 Moesin MSN 10307 239 247 28.36 0.015 ctrl only
F1SPS6 Uncharacterized protein MST1 14356 711 720 45.99 4.90E-05 ctrl only
F1SNK3 S-methyl-5~-thioadenosine phosphorylase MTAP 39322 12 29 55.68 1.10E-05 ctrl only
F1RWE3 Uncharacterized protein MTPAP 295 164 168 32.36 0.019 ctrl only
K9IVW4 Myotrophin MTPN 36940 98 114 34.28 0.00061 ctrl only
F1RXM4 MUM1 like 1 MUM1L1 39900 416 429 17.87 0.033 LPS only
A0A287AAA1 Uncharacterized protein MYCBP2 26056 4012 4024 26.16 0.0072 ctrl only
I3LIE3 Uncharacterized protein MYH14 35885 1048 1060 17.09 0.045 LPS only
F1SKJ1 Uncharacterized protein MYH9 32251 328 341 29.48 0.0018 ctrl only
A0A2C9F331 Myosin light polypeptide 6 MYL6 29413 91 103 30.05 0.0031 ctrl only
F1SRM1 Uncharacterized protein MYO10 24932 1912 1924 20.06 0.018 ctrl only
F1SA47 Uncharacterized protein MYO1F 8073 762 770 21.39 0.027 ctrl only
A0A286ZQ42 Uncharacterized protein MYO5C 15756 346 356 15 0.039 LPS only
A0A287AHC3 Uncharacterized protein MYOF 25254 1704 1714 16.39 0.029 LPS only
A0A287A887 Uncharacterized protein MYOM2 2014 168 174 29.48 0.033 ctrl only
P02009 Hemoglobin subunit zeta n/a 1955 93 99 30.99 0.038 LPS only
P62802 Histone H4 n/a 5991 61 68 27.11 0.038 LPS only
P01846 Ig lambda chain C region n/a 32916 65 79 105.37 5.00E-10 LPS only
Q29126 Protein WAP-3 n/a 24675 52 63 60.95 2.80E-05 ctrl only
P16225 Sodium/potassium ATPase inhibitor SPAI-2 n/a 21375 94 105 25.14 0.026 LPS only
A0A287BE02 Sulfotransferase n/a 19970 2 12 16.31 0.035 LPS only
P02554 Tubulin beta chain n/a 11323 242 251 42.97 0.0002 ctrl only
A0A075B7J0 Uncharacterized protein n/a 3212 64 72 29.01 0.036 both
F1STC5 Uncharacterized protein n/a 2557 199 206 28.26 0.025 both
A0A287AE24 Uncharacterized protein n/a 2160 198 205 27.93 0.01 both
I3LJA6 Uncharacterized protein n/a 8076 66 74 51.76 0.0002 both
F1STC2 Uncharacterized protein n/a 18719 66 78 75.73 1.40E-07 both
I3L6U3 Uncharacterized protein n/a 18719 66 78 75.73 1.40E-07 both
F2Z5K9 Uncharacterized protein n/a 2221 58 64 40.06 0.0048 both
F1S5N8 Uncharacterized protein n/a 4678 100 107 34.45 0.00059 both
A0A075B7H9 Uncharacterized protein n/a 3212 86 94 29.01 0.036 both
F1S144 Uncharacterized protein n/a 12100 82 91 21 0.033 both
A0A286ZJ78 Uncharacterized protein n/a 8561 71 80 28.95 0.012 both
I3L728 Uncharacterized protein n/a 11206 31 40 50.57 0.0002 both
A0A286ZKW3 Uncharacterized protein N4BP2L2 33786 534 546 25.56 0.034 LPS only
K7GNZ3 Uncharacterized protein NACA 25800 180 192 39.88 0.01 ctrl only
F1ST62 Uncharacterized protein NACAD 14610 1059 1069 19.04 0.039 LPS only
Q0QVW6 Nicotinamide phosphoribosyltransferase NAMPT 53513 1 19 16.66 0.027 LPS only
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A0A287AFP4 Uncharacterized protein NAP1L1 20333 54 63 33.08 0.0024 ctrl only
A0A287AEQ6 Uncharacterized protein NAP1L4 20333 84 93 33.08 0.0024 ctrl only
F1RLB6 Uncharacterized protein NAPA 23267 7 19 38.84 0.00051 ctrl only
A0A286ZV25 Uncharacterized protein NAV3 17295 940 951 24.26 0.013 ctrl only
A0A287AU28 Uncharacterized protein NCAM1 14442 474 485 30.68 0.0038 ctrl only
F1SLS9 Condensin complex subunit 1 NCAPD2 15342 234 243 32.35 0.0046 LPS only
A0A286ZI22 Uncharacterized protein NCAPG2 31619 160 172 16.52 0.039 LPS only
A0A287B069 Uncharacterized protein NDFIP1 48735 1 18 17.26 0.024 LPS only
F1SLR1 Uncharacterized protein NDUFA8 765 97 103 22.45 0.014 LPS only
A0A287BMW6 Uncharacterized protein NDUFB11 5908 2 11 30.95 0.0067 ctrl only
A0A287AWH6 Uncharacterized protein NDUFV3 4102 1 8 37.57 0.021 LPS only
A0A286ZRQ6 Uncharacterized protein NEB 38320 1534 1547 37.24 0.0041 ctrl only
A0A287B1U6 Uncharacterized protein NELL2 9928 57 65 27.85 0.039 ctrl only
A0A287BP79 Uncharacterized protein NEU4 24062 84 94 32.21 0.0032 LPS only
A0A287AVR3 Uncharacterized protein NFKB1 38757 117 130 15.18 0.038 LPS only
A0A286ZL08 Uncharacterized protein NID1 13207 648 658 22.97 0.022 ctrl only
F1SMG7 Uncharacterized protein NIM1K 52309 225 244 17.57 0.022 ctrl only
F1SAS0 Uncharacterized protein NINL 13 505 509 35.46 0.014 LPS only
A0A287AS29 Nucleoside diphosphate kinase NME1 13368 40 49 64.24 3.80E-06 ctrl only
Q2EN76 Nucleoside diphosphate kinase B NME2 13185 57 66 24.38 0.048 ctrl only
F1RG17 Nucleoside diphosphate kinase NME3 20087 24 35 32.15 0.044 ctrl only
F1SUF5 Nucleolar protein 8 NOL8 16917 208 218 16.39 0.038 ctrl only
A0A287A770 Uncharacterized protein NPTN 405 160 164 17.07 0.047 LPS only
A0A287B2K4 Neuropilin NRP2 34807 288 303 32.92 0.00082 ctrl only
A0A287AX72 Uncharacterized protein NSMF 1764 2 8 17.13 0.038 ctrl only
I3L713 NOP2/Sun RNA methyltransferase family member 7 NSUN7 50729 15 36 20.65 0.019 LPS only
A0A286ZWM0 5~-nucleotidase NT5C3B 6111 121 128 23.94 0.045 LPS only
A0A287AHD5 Uncharacterized protein NUCB1 20620 150 160 19.39 0.025 LPS only
A0A287ALQ1 Uncharacterized protein NUP210 29694 129 140 50.29 0.001 LPS only
F1SCL8 Uncharacterized protein NUTM1 16357 277 285 25.95 0.01 LPS only
I3LNX4 Uncharacterized protein NXF1 9023 347 355 24.25 0.032 LPS only
Q29599 2~-5~-oligoadenylate synthase 1 OAS1 8681 116 124 27.41 0.0066 both
F1SUE2 Osteomodulin OMD 14828 167 176 30.91 0.01 both
F1RNC1 Olfactory receptor OR6K3 9004 132 139 19.24 0.042 LPS only
F1SN68 Alpha-1-acid glycoprotein ORM1 4457 181 188 30.48 0.0015 both
A0A2C9F365 Osteoclast-stimulating factor 1 OSTF1 2112 117 124 30.03 0.013 both
O19072 Ornithine carbamoyltransferase mitochondrial (Fragment) OTC 2373 1 8 24.72 0.016 ctrl only
A0A287A1K0 Uncharacterized protein OXR1 16323 10 19 18.29 0.048 ctrl only
I3L7I0 Uncharacterized protein P3H1 4469 688 695 22.9 0.037 LPS only
G9F6X8 Protein disulfide-isomerase P4HB 14345 317 326 27.49 0.0095 ctrl only
A0A287AZY8 Uncharacterized protein PABPC5 29664 1 14 18.77 0.017 ctrl only
F1SUK2 P21 (RAC1) activated kinase 1 PAK1 45512 2 16 15.3 0.037 LPS only
F1SQW0 Non-specific serine/threonine protein kinase PAK2 13007 227 235 16.98 0.037 both
A0A286ZVD4 Pantothenate kinase 4 PANK4 30483 142 153 19.54 0.03 LPS only
Q0R678 DJ-1 protein PARK7 1916 33 41 35.57 0.0044 ctrl only
I3LDH3 Poly [ADP-ribose] polymerase PARP1 58363 601 618 18.34 0.028 LPS only
I3LDB1 Poly [ADP-ribose] polymerase PARP4 12269 97 107 17.76 0.032 ctrl only
A0A287A992 Polysaccharide biosynthesis domain containing 1 PBDC1 26802 157 168 21.45 0.031 LPS only
A0A287BHL0 Uncharacterized protein PCBP2 21308 20 32 20.16 0.013 ctrl only
A0A287AV49 Protein-L-isoaspartate(D-aspartate) O-methyltransferase PCMT1 26483 63 76 52.12 0.00074 ctrl only
I3LEE6 Uncharacterized protein PCOLCE 33796 92 107 68.88 5.30E-07 both
A0A286ZVI0 Uncharacterized protein PCSK9 14862 124 134 35.38 0.00048 both
F1RNW4 Uncharacterized protein PD 10363 188 196 42.54 0.0028 both
A0A287A5B4 Uncharacterized protein PDCD6IP 42424 170 187 29.1 0.0019 ctrl only
E1CAJ6 Protein disulfide isomerase P5 pdi-p5 28715 217 231 39.86 0.00029 both
F6QA08 Protein disulfide-isomerase PDIA3 13025 335 343 19.63 0.014 ctrl only
A0A286ZSB7 Uncharacterized protein PDS5B 18757 1042 1051 27.14 0.0054 LPS only
I3LRP4 Uncharacterized protein PDZD2 7253 1611 1619 18.31 0.045 ctrl only
P30034 Platelet factor 4 PF4 22134 66 76 26.11 0.0054 ctrl only
F1RFY1 Profilin PFN1 3124 109 116 43.71 0.0025 both
I3L660 Profilin PFN2 58325 71 89 15.02 0.039 ctrl only
A0A287AJQ2 Phosphoglycerate mutase PGAM1 38 6 10 31.7 0.011 both
F1RIF8 6-phosphogluconate dehydrogenase decarboxylating PGD 31274 120 136 33.15 0.00078 ctrl only
F1RPH0 Phosphoglycerate kinase PGK1 14183 221 230 51.18 0.00091 both
Q6RI85 Phosphoglycerate kinase 2 PGK2 33048 157 171 60.58 2.10E-06 ctrl only
A0A286ZI97 Peptidoglycan-recognition protein PGLYRP1 57752 199 216 35.03 0.00052 both
A0A287BRX5 N-acetylmuramoyl-L-alanine amidase PGLYRP2 58828 368 392 26.97 0.003 both
I3LQN4 Uncharacterized protein PHB2 4569 290 298 24.69 0.031 both
A0A286ZKL5 Uncharacterized protein PHC3 96 848 852 37.14 0.0085 both
F1RQK4 Pleckstrin homology domain interacting protein PHIP 12441 1761 1769 19.73 0.017 LPS only
A0A287B268 Uncharacterized protein PHLPP1 41137 562 576 18.55 0.018 LPS only
F1RVS9 Uncharacterized protein PI16 30421 34 44 43.08 0.00014 both
A0A287A0N2 Polymeric immunoglobulin receptor PIGR 25329 535 546 69.05 7.50E-07 both
A0A287AST2 Uncharacterized protein PIP5K1A 31069 2 14 16.01 0.031 ctrl only
F1RRZ1 Uncharacterized protein PIP5KL1 17107 220 229 15.37 0.04 ctrl only
A0A286ZWV0 Uncharacterized protein PKHD1 16110 315 326 21.06 0.046 ctrl only
A0A286ZYV7 Pyruvate kinase PKLR 11725 325 335 21.14 0.026 ctrl only
A0A287ACX9 Pyruvate kinase PKM 6017 126 135 41.76 0.0074 both
A0A287A0U1 Platelet-activating factor acetylhydrolase PLA2G7 24752 357 368 54.78 9.70E-06 both
F1SU38 Urokinase-type plasminogen activator PLAU 12050 261 269 18.62 0.018 both
A0A287ADQ6 Phosphoinositide phospholipase C PLCH2 132 784 788 41.86 0.0025 ctrl only
A0A287BPI8 Uncharacterized protein PLEKHG6 18546 593 604 16.03 0.041 ctrl only
P06867 Plasminogen PLG 1860 720 726 27.53 0.014 both
I3LA84 Uncharacterized protein PLOD3 6822 414 422 35.14 0.024 LPS only
A0A286ZJH2 Uncharacterized protein PLS1 8961 266 274 29.72 0.0018 both
F1RWT2 Plastin 3 PLS3 10698 207 215 30.95 0.0055 both
F1SC57 Uncharacterized protein PLTP 14445 295 304 22.29 0.011 both
A0A287B8U7 Plexin domain containing 2 PLXDC2 20735 278 289 21.22 0.01 ctrl only
F1SLI0 Uncharacterized protein PLXNB1 86 1610 1614 29.56 0.036 ctrl only
A0A286ZKJ1 Uncharacterized protein PMAP-23 28899 45 56 27.42 0.0047 LPS only
A0A286ZR10 Uncharacterized protein PNKD 27157 129 141 15.74 0.041 ctrl only
A0A287A2Y1 Purine nucleoside phosphorylase PNP 25436 92 102 29.04 0.0027 ctrl only
A0A287BD23 Uncharacterized protein POFUT2 3044 345 351 28.9 0.015 both
A0A287B813 Uncharacterized protein POLA2 24819 2 13 15.6 0.034 ctrl only
F1RMB0 Uncharacterized protein POLR3D 39507 242 256 16.15 0.031 LPS only
F1SRD5 Uncharacterized protein POMT2 18385 468 479 20.03 0.025 ctrl only
A0A287AWR7 Uncharacterized protein PON1 2061 139 145 40.91 0.0052 both
A0A286ZN21 Uncharacterized protein POSTN 3012 682 689 31.8 0.023 both
P43030 Platelet basic protein PPBP 3081 83 90 26.81 0.025 both
A0A287A0R3 Uncharacterized protein PPFIA1 13458 716 726 16.86 0.046 ctrl only
P62936 Peptidyl-prolyl cis-trans isomerase A PPIA 8413 20 28 44.42 0.00032 both
A0A286ZJY9 Peptidyl-prolyl cis-trans isomerase E PPIE 12980 244 252 30.61 0.015 ctrl only
A0A286ZL42 Serine/threonine-protein phosphatase PPP1CA 14045 114 122 24.54 0.0053 ctrl only
F1SDW9 Uncharacterized protein PPP1R16B 6541 17 24 23.11 0.0068 both
F1RX68 Serine/threonine-protein phosphatase PPP2CB 38298 75 89 30.67 0.0013 ctrl only
A0A287AHX5 Uncharacterized protein PPP2R3B 22457 36 46 24.75 0.046 ctrl only
A0A287B775 Uncharacterized protein PRDM15 4226 656 662 16.72 0.04 ctrl only
A0A286ZND5 Uncharacterized protein PRDX1 3565 146 153 39.78 0.0065 ctrl only
P52552 Peroxiredoxin-2 (Fragment) PRDX2 1282 54 61 45.07 0.0015 both
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F1SQ01 Uncharacterized protein PRDX4 4169 202 209 40.66 0.00061 ctrl only
Q9TSX9 Peroxiredoxin-6 PRDX6 3796 156 162 36.25 0.0053 ctrl only
A0A286ZUE0 Uncharacterized protein PREX1 34169 411 422 16.19 0.048 LPS only
A0A286ZSP2 Uncharacterized protein PREX2 5879 1158 1165 21.1 0.046 ctrl only
I3L5Z3 Uncharacterized protein PRG4 25553 339 349 44.82 6.30E-05 both
F1SGF0 Prickle planar cell polarity protein 2 PRICKLE2 24573 1 11 18.2 0.02 both
A0A287A287 Protein kinase C PRKCD 1082 1 6 29.86 0.045 ctrl only
I3LRJ4 Vitamin K-dependent protein C PROC 6953 278 285 29.64 0.014 both
I3LQA4 Uncharacterized protein PROCR 7112 108 116 22.28 0.028 LPS only
A0A287A6Q0 Uncharacterized protein PROS1 875 317 322 33.07 0.019 both
A0A287AP63 Uncharacterized protein PRPF3 9937 466 475 25.31 0.033 ctrl only
A0A287B1I2 Uncharacterized protein PRPH 4488 398 405 27.53 0.023 ctrl only
A0A286ZVG0 Saposin-B-Val PSAP 19917 295 306 35.71 0.0013 LPS only
F2Z5L7 Proteasome subunit alpha type PSMA1 1927 108 115 42.02 0.0042 both
I3LAB6 Proteasome subunit alpha type PSMA2 56853 93 113 24.32 0.0052 ctrl only
F1SSL6 Proteasome subunit alpha type PSMA3 14779 30 41 37.46 0.00099 both
A0A287BIV4 Proteasome subunit alpha type PSMA4 15143 55 64 38.6 0.00067 both
F2Z5K2 Proteasome subunit alpha type PSMA5 8696 11 20 21.21 0.022 both
F2Z5N0 Proteasome subunit alpha type PSMA6 12382 12 21 32.42 0.042 both
A0A287AT18 Proteasome subunit alpha type PSMA7 2589 228 234 23.75 0.036 both
F1SBA5 Proteasome subunit alpha type PSMA8 10174 196 206 41.52 0.00039 both
A0A287BPP9 Proteasome subunit beta PSMB1 29468 147 160 20.87 0.022 ctrl only
A0A286ZN52 Proteasome subunit beta PSMB3 29766 178 192 68.42 9.50E-07 both
A0A287B088 Proteasome subunit beta PSMB4 28859 46 60 41.25 0.00024 both
A0A287AGG3 Proteasome subunit beta PSMB5 24338 179 191 18.62 0.018 ctrl only
F1RFV5 Proteasome subunit beta PSMB6 10738 212 222 36.36 0.00095 both
A0A287A1Z0 Proteasome subunit beta PSMB8 19948 80 91 18.84 0.024 both
A0A287B4P8 Uncharacterized protein PSMC4 2382 115 121 45.96 0.0027 both
F1RPQ3 Proteasome 26S subunit non-ATPase 14 PSMD14 70063 224 246 19.03 0.016 ctrl only
F1SGM1 Proteasome activator complex subunit 1 PSME1 23624 46 58 58.88 1.30E-05 ctrl only
F1S870 Uncharacterized protein PSMF1 5107 205 213 26.14 0.04 ctrl only
A0A287AAP9 Uncharacterized protein PSTK 1969 294 300 26.39 0.025 ctrl only
A0A287APX1 Prostaglandin-H2 D-isomerase PTGDS 20973 187 198 63.85 1.00E-06 both
C3VVV8 Prothymosin alpha PTMA 26007 2 15 51.98 1.30E-05 ctrl only
A0A286ZTF3 Serine/threonine-protein phosphatase 2A activator PTPA 12435 77 86 33.34 0.0024 ctrl only
A0A287AUM0 Uncharacterized protein PTPN13 23563 1432 1443 21.75 0.047 both
A0A287BMT5 Uncharacterized protein PTPN18 39685 425 440 15.23 0.04 ctrl only
A0A287AR65 Tyrosine-protein phosphatase non-receptor type PTPN3 22338 356 366 16.68 0.047 ctrl only
A0A286ZIH1 Uncharacterized protein PTPRF 36403 586 600 18.07 0.02 both
A0A287BL66 Uncharacterized protein PTPRG 22762 94 106 59.41 2.70E-06 both
A0A287BN06 Uncharacterized protein PZP 295 901 905 32.36 0.019 both
F1S682 Sulfhydryl oxidase QSOX1 4566 318 325 37.12 0.0041 both
F1SIU9 Uncharacterized protein R2 6147 737 744 23.39 0.043 both
A0A287BKW2 Uncharacterized protein RAB44 44924 130 147 17.8 0.024 ctrl only
F2Z5I8 Uncharacterized protein RAB8A 20535 134 145 47.66 7.10E-05 ctrl only
F1RJI2 Uncharacterized protein RABGEF1 33158 116 129 15.76 0.045 ctrl only
A0A287B104 Uncharacterized protein RACGAP1 4831 424 430 20.24 0.018 LPS only
A0A287ARC6 Uncharacterized protein RAD23A 57651 178 204 17.07 0.025 ctrl only
F1RFQ7 GTP-binding nuclear protein Ran RAN 5156 30 37 29.36 0.013 ctrl only
A0A286ZJ82 Uncharacterized protein RANBP1 2405 138 144 41 0.004 ctrl only
F1S0W0 Uncharacterized protein RAPGEF1 38823 335 349 19.3 0.023 LPS only
A0A286ZLM3 Uncharacterized protein RAPGEF2 1334 621 626 34.06 0.016 both
F1S067 Uncharacterized protein RAPGEF4 63162 476 497 17.56 0.023 ctrl only
A0A286ZY53 Uncharacterized protein RARRES2 44785 49 67 55.35 6.80E-06 both
A0A287A0N9 Uncharacterized protein RB1CC1 13041 1314 1322 37.71 0.0092 LPS only
A0A286ZL66 RNA binding protein fox-1 homolog RBFOX2 45383 221 237 15.2 0.037 ctrl only
F1SIZ8 Uncharacterized protein RBM15B 34057 80 98 16.43 0.04 LPS only
A0A287A0L7 Uncharacterized protein RBM28 219 11 16 28.48 0.043 LPS only
A0A286ZQ71 Uncharacterized protein RBM45 2438 28 34 25.93 0.021 both
F1SC80 Retinol-binding protein RBP4 7041 174 181 46.73 0.00042 both
A0A287BMD1 Uncharacterized protein RC3H2 4800 998 1005 35.42 0.037 ctrl only
I3LMU6 Reticulocalbin 3 RCN3 30420 89 102 97.5 1.00E-08 both
F1SA10 Uncharacterized protein RCOR1 38539 1 15 20.76 0.029 ctrl only
P26044 Radixin RDX 10307 238 246 28.36 0.015 ctrl only
F1REY7 Uncharacterized protein RFESD 35523 87 102 34.96 0.00053 ctrl only
A0A287AKP3 Uncharacterized protein RFX1 2155 550 557 29.69 0.041 LPS only
F1SBD9 RIPOR family member 3 RIPOR3 27564 674 686 23.86 0.034 ctrl only
I3LBP8 GTP-binding protein Rit1 RIT1 7061 187 195 29.01 0.0093 ctrl only
P15468 Ribonuclease 4 RNASE4 35501 70 82 40.31 0.00034 both
A0A287B8W4 Uncharacterized protein RNF44 2895 341 348 25.51 0.006 ctrl only
A0A287AM26 Uncharacterized protein RNP 25420 15 28 24.8 0.0047 ctrl only
A0A286ZKM4 Uncharacterized protein ROBO3 24011 190 200 18.5 0.047 both
F1STC1 Ribose-5-phosphate isomerase RPIA 35997 133 147 16.38 0.029 ctrl only
Q29205 60S ribosomal protein L11 RPL11 29522 39 52 48.46 0.00012 ctrl only
A0A287B929 60S ribosomal protein L13a RPL13A 16140 150 160 34.64 0.0016 ctrl only
A0A286ZW72 60S ribosomal protein L14 RPL14 21123 24 35 57.06 4.50E-06 ctrl only
Q95342 60S ribosomal protein L18 RPL18 20732 86 98 56.05 2.80E-05 ctrl only
A0A287A5S4 Ribosomal protein L19 RPL19 43283 22 38 55.19 6.70E-06 ctrl only
A0A287A286 Uncharacterized protein RPL24 16491 141 153 44.85 0.00088 ctrl only
A0A287AWS4 60S ribosomal protein L27a RPL27A 10618 58 68 30.14 0.037 ctrl only
A0A287B5V1 60S ribosomal protein L3 RPL3 5767 11 19 29.83 0.024 ctrl only
A0A287AE76 60S ribosomal protein L4 RPL4 16822 223 234 48.51 3.20E-05 ctrl only
A0A287A8T0 Uncharacterized protein RPL7 12962 169 179 30.62 0.025 ctrl only
A0A286ZQA5 60S ribosomal protein L7a RPL7A 20731 174 186 66.69 2.10E-06 ctrl only
A0A287BGL3 60S acidic ribosomal protein P0 RPLP0 14782 17 26 55.41 0.00022 ctrl only
Q29315 60S acidic ribosomal protein P2 RPLP2 16317 50 61 47.49 4.50E-05 ctrl only
F1RZ28 Uncharacterized protein RPS10 25003 140 153 49.62 2.20E-05 ctrl only
K7GKC0 40S ribosomal protein S16 RPS16 13612 5 15 23.28 0.015 ctrl only
P62272 40S ribosomal protein S18 RPS18 4871 26 34 32.84 0.0018 ctrl only
I3LJ87 Uncharacterized protein RPS2 22515 247 257 37.03 0.001 ctrl only
A0A287ACL6 40S ribosomal protein S24 RPS24 34741 69 83 20.18 0.013 ctrl only
A0A287AZA7 Uncharacterized protein RPS27A 8862 64 72 49.49 0.00039 both
Q0Z8U2 40S ribosomal protein S3 RPS3 12425 188 197 25.57 0.0075 ctrl only
A0A287B771 40S ribosomal protein S4 RPS4X 14712 117 127 34.4 0.0022 ctrl only
A0A287BCW5 40S ribosomal protein S6 RPS6 17641 82 93 29.49 0.0045 ctrl only
A0A287A993 Non-specific serine/threonine protein kinase RPS6KA2 4720 44 52 34.91 0.0077 both
A0A287A9Y6 40S ribosomal protein S7 RPS7 7413 170 178 28.86 0.017 ctrl only
F2Z5F5 40S ribosomal protein S8 RPS8 27773 158 170 53.54 1.50E-05 ctrl only
A0A287B2M3 40S ribosomal protein SA RPSA 10305 2 11 50.25 4.30E-05 ctrl only
P80310 Protein S100-A12 S100A12 41854 57 72 64.12 9.70E-07 both
F1SFV7 Protein S100 S100A4 8170 58 66 45.57 5.30E-05 ctrl only
C3S7K5 Protein S100 S100A8 24150 78 89 27.42 0.0034 both
C3S7K6 Calcium-binding protein A9 S100A9 19670 86 96 36.28 0.00065 both
F1SQR2 Protein S100 S100G 22520 63 74 30.85 0.0013 both
I3LIS0 Sphingosine-1-phosphate receptor 1 S1PR1 12547 284 292 28.21 0.018 ctrl only
F1S8F0 Uncharacterized protein S1PR4 32351 88 103 16.94 0.049 ctrl only
A0A287AKL0 Serum amyloid A protein SAA3 1897 60 68 29.86 0.0028 both
F1S9B8 Serum amyloid A protein SAA4 15308 27 37 57.12 8.20E-05 both
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A0A286ZLW6 Uncharacterized protein SAFB 5626 673 679 16.44 0.042 both
A0A287A7Z0 Uncharacterized protein SAPCD2 3250 291 298 27.08 0.018 ctrl only
A0A287AR98 Uncharacterized protein SBSN 30344 403 416 20.8 0.027 LPS only
A0A286ZNJ7 Uncharacterized protein SEC63 9344 303 311 16.52 0.032 LPS only
A0A286ZRR3 Uncharacterized protein SELENBP1 8271 394 401 20.45 0.024 ctrl only
I3LJP2 Uncharacterized protein SELENOP 8434 132 139 27.77 0.0039 both
A0A288CG53 L-selectin SELL 53265 82 98 27.28 0.0028 both
A0A287AX45 Uncharacterized protein SEMA3D 46 82 87 24.77 0.041 both
A0A286ZJ16 Uncharacterized protein SEPTIN7 53811 314 328 22.97 0.012 ctrl only
P50447 Alpha-1-antitrypsin SERPINA1 1057 245 250 23.92 0.049 both
F1SCD1 Uncharacterized protein SERPINA3-2 931 190 195 30.53 0.043 both
A0A287BHS2 Uncharacterized protein SERPINA5 9255 47 54 25.65 0.008 both
F1SCF1 Uncharacterized protein SERPINA6 25710 290 302 15.71 0.04 both
F1RXM6 Thyroxine-binding globulin SERPINA7 1436 399 405 30.5 0.027 both
A0A287B7P2 Leukocyte elastase inhibitor SERPINB1 27462 179 193 46.82 4.10E-05 both
F2Z5E2 Uncharacterized protein SERPINC1 2348 141 147 45.12 0.0018 both
F1RKY2 Serpin family D member 1 SERPIND1 1997 428 434 33.91 0.0076 both
Q0PM28 Pigment epithelium-derived factor SERPINF1 3742 239 246 27.29 0.013 both
A0A287AJI4 Uncharacterized protein SERPINF2 4170 75 82 37.78 0.0049 both
F1SJW8 Uncharacterized protein SERPING1 2631 479 485 21.38 0.039 both
A0A286ZRU9 Uncharacterized protein SERPINH1 20387 320 332 22.69 0.033 ctrl only
F1RR69 Uncharacterized protein SET 39910 124 137 22.69 0.013 ctrl only
A0A287A4F2 Uncharacterized protein SFPQ 37380 475 488 22.86 0.0094 ctrl only
A0A287BPZ1 Pulmonary surfactant-associated protein D SFTPD 27413 153 167 21.88 0.025 LPS only
A0A287A0P2 Small glutamine rich tetratricopeptide repeat containing beta SGTB 909 145 151 34.45 0.022 ctrl only
A0A286ZWS0 SH3 domain-binding glutamic acid-rich-like protein SH3BGRL3 37784 33 47 20.07 0.036 ctrl only
A0A286ZK02 Uncharacterized protein SH3TC1 46815 319 334 18.68 0.032 ctrl only
F1RYS7 Uncharacterized protein SHROOM3 42168 412 426 18.97 0.037 LPS only
A0A287B920 Sucrase-isomaltase intestinal SI 767 596 601 22.49 0.041 ctrl only
A0A286ZKF2 Uncharacterized protein SKIV2L 18330 672 682 19.45 0.015 ctrl only
F1SE25 Phosphate transporter SLC20A2 9593 425 434 21.06 0.046 both
I3LPU7 Uncharacterized protein SLC22A14 33885 1 12 27.38 0.035 both
F1RK74 Uncharacterized protein SLC25A1 5217 9 19 21.71 0.043 ctrl only
A0A287BR27 Uncharacterized protein SLC25A27 5959 153 160 17.58 0.035 ctrl only
A0A286ZIE8 Uncharacterized protein SLC25A4 14864 11 23 29.05 0.005 ctrl only
F1RLI6 Uncharacterized protein SLC25A46 10884 215 223 15.27 0.037 LPS only
F2Z565 Uncharacterized protein SLC25A5 10977 64 72 26.51 0.012 ctrl only
Q6QRN9 ADP/ATP translocase 3 SLC25A6 10977 64 72 26.51 0.012 ctrl only
I3LCQ6 Uncharacterized protein SLC39A2 1420 79 84 27.39 0.023 both
A0A2C9F351 Choline transporter-like protein 4 SLC44A4 2046 413 420 17.4 0.047 ctrl only
F1RQY6 Anion exchange protein SLC4A1 1210 326 332 35.55 0.027 both
A0A287AMX1 Anion exchange protein SLC4A2 897 368 373 40.13 0.0099 both
F1S024 Transporter SLC6A3 1679 20 27 16.08 0.044 both
K9J4W3 Transporter SLC6A6 28501 576 587 17.34 0.034 ctrl only
A0A287BFZ4 Uncharacterized protein SLF2 33478 414 426 15.22 0.037 LPS only
A0A287BR93 Structural maintenance of chromosomes protein SMC1B 2343 593 599 20.65 0.043 LPS only
A0A287AGI4 Uncharacterized protein SMC2 16946 910 919 25.38 0.033 ctrl only
I3LCG7 Small integral membrane protein 26 SMIM26 5907 6 12 15.5 0.035 LPS only
A0A287BQT0 Uncharacterized protein SMPDL3B 50940 283 298 34.78 0.00055 both
A7YX24 Gamma-synuclein SNCG 5004 35 43 46.27 0.00022 both
A0A287A447 Uncharacterized protein SNX30 1726 355 361 41.11 0.003 LPS only
P04178 Superoxide dismutase [Cu-Zn] SOD1 4472 28 36 51.91 0.00039 ctrl only
I3LUD1 Superoxide dismutase [Cu-Zn] SOD3 28817 101 112 17.32 0.024 both
A0A286ZZ32 Uncharacterized protein SOGA3 702 59 66 16.5 0.028 LPS only
A0A1P0REP6 Spastin SPAST 24844 266 279 19.96 0.028 ctrl only
A0A286ZT43 Uncharacterized protein SPATA13 16228 1070 1078 30.81 0.008 LPS only
I3LER8 Uncharacterized protein SPG11 216 2 6 37.38 0.0091 LPS only
P14287 Osteopontin SPP1 20539 206 217 22.43 0.0086 both
Q711S8 Secreted phosphoprotein 24 SPP2 4494 121 127 59.55 4.80E-05 both
F1RNB8 Uncharacterized protein SPTA1 6341 718 726 25.47 0.035 both
A0A287A113 Spectrin beta chain SPTB 3199 681 687 40.1 0.0061 ctrl only
A0A286ZNC7 Spectrin beta chain SPTBN1 16267 215 224 24.91 0.035 both
I3LKI1 Uncharacterized protein SR 23141 53 65 52.99 0.00013 ctrl only
A0A286ZM20 Uncharacterized protein SRRM1 7130 103 110 20.74 0.041 both
A0A286ZSZ6 Uncharacterized protein SRRM2 6196 2723 2730 27.01 0.046 both
A0A286ZX74 Uncharacterized protein SRSF5 8268 2 10 21.34 0.011 both
A0A287ASZ5 Uncharacterized protein SRSF7 32446 45 58 31.15 0.0012 ctrl only
A0A287AT90 Uncharacterized protein SSH1 13029 934 944 18.73 0.05 both
A0A287B8B1 Uncharacterized protein ST13 21804 211 222 23.96 0.0057 both
A0A286ZSQ8 ST6 beta-galactoside alpha-2 6-sialyltransferase 1 ST6GAL1 67108 50 73 19.64 0.014 ctrl only
A0A286ZTH4 Uncharacterized protein STIL 10515 1199 1207 16.33 0.045 ctrl only
I3LNG8 Stress induced phosphoprotein 1 STIP1 10177 534 543 36.84 0.00081 ctrl only
A5A8W9 Serine/threonine kinase 19 STK19 28863 8 19 21.67 0.018 LPS only
F1ST91 Uncharacterized protein STK31 62352 337 355 18.18 0.028 both
A0A287AE47 Uncharacterized protein STOM 4074 145 152 19.92 0.014 ctrl only
K9J6J2 Erythrocyte band 7 integral membrane protein isoform a STOM_tv1 4074 145 152 19.92 0.014 ctrl only
A0A287AD21 Small ubiquitin-related modifier SUMO3 15439 21 32 29.07 0.0023 ctrl only
F1S8K5 SPT16 homolog facilitates chromatin remodeling subunit SUPT16H 19862 383 393 19.92 0.019 ctrl only
F1SNY4 Uncharacterized protein TAB1 7091 218 227 23.41 0.046 ctrl only
A0A287BAJ9 Transcriptional adapter TADA2A 5166 106 112 16.64 0.045 ctrl only
F1RJ93 Transgelin TAGLN2 14714 128 139 71.77 9.70E-07 ctrl only
A0A287BQ72 Transaldolase TALDO1 30608 72 86 57.76 3.80E-06 ctrl only
F1SP18 Uncharacterized protein TARS 19030 541 552 21.35 0.0099 ctrl only
I3LCT3 Uncharacterized protein TAS2R39 16881 1 10 19.15 0.016 ctrl only
F1RWJ4 TBK1 binding protein 1 TBKBP1 6741 95 103 24.27 0.031 ctrl only
A0A287AJY2 Uncharacterized protein TCP1 14321 494 504 71.48 1.20E-06 ctrl only
A0A287AZ97 Uncharacterized protein TDRD7 15637 258 268 16.43 0.029 ctrl only
P09571 Serotransferrin TF 946 537 543 34.17 0.03 both
A0A287A3E7 Transferrin receptor protein 1 TFRC 41329 448 461 41.8 0.00014 both
F1RHA7 Transforming growth factor-beta-induced protein ig-h3 TGFBI 1941 179 185 28.79 0.02 both
F1SS26 Uncharacterized protein THBS1 8680 75 83 31.82 0.039 both
A0A287AQ98 Uncharacterized protein THBS2 5932 1035 1041 26.09 0.0047 both
A0A287AK31 Uncharacterized protein THBS3 33734 811 823 69.28 1.60E-06 both
F1RF27 Uncharacterized protein THBS4 33734 817 829 69.28 1.60E-06 both
F1SHM4 Uncharacterized protein TIAM1 3013 2 8 39.06 0.0048 both
A8U4R4 Transketolase tkt 4810 335 343 44.03 0.00041 ctrl only
A0A287AC34 Uncharacterized protein TLN1 34364 2215 2227 19.13 0.029 LPS only
I3LPE4 Uncharacterized protein TLR10 3889 188 194 19.95 0.013 LPS only
F1SN29 Uncharacterized protein TMEFF2 3343 2 8 15.96 0.036 ctrl only
A0A287AKT1 Transmembrane protein 161A TMEM161A 3067 150 156 16.8 0.027 LPS only
F1RLI7 Uncharacterized protein TMEM232 61501 368 388 17.03 0.025 both
A0A286ZYQ9 Transmembrane protein 52B TMEM52B 29 133 137 30.9 0.025 both
A0A287BJ41 Tropomodulin 1 TMOD1 35080 256 271 71.12 8.70E-07 ctrl only
I3LN91 Uncharacterized protein TMTC2 73487 599 621 16.17 0.044 both
A0A286ZR70 Tenascin TNC 27166 253 264 30.53 0.0043 LPS only
P02587 Troponin C skeletal muscle TNNC2 1766 38 44 28.89 0.017 ctrl only
K7GRK7 Uncharacterized protein TNXB 71669 4017 4039 37.93 0.00028 both
A0A288CFT0 Triosephosphate isomerase TPI1 19889 244 256 61.98 4.40E-06 both
P42639 Tropomyosin alpha-1 chain TPM1 15795 92 101 72.59 3.30E-06 both
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A0A287AD38 Uncharacterized protein TPM2 12961 169 178 34.68 0.00056 ctrl only
A1XQV4 Tropomyosin alpha-3 chain TPM3 12389 169 178 39.1 0.0045 ctrl only
P67937 Tropomyosin alpha-4 chain TPM4 7971 2 11 29.67 0.0035 both
A0A287B4E6 Translationally-controlled tumor protein TPT1 35721 6 19 30.35 0.0014 ctrl only
A0A286ZLB1 Uncharacterized protein TRAP1 28098 387 400 90.08 1.10E-08 ctrl only
A0A286ZR41 Uncharacterized protein TRAPPC10 10066 724 731 15.16 0.045 ctrl only
A0A287BNT0 Uncharacterized protein TRPC1 50611 51 65 16.8 0.044 ctrl only
A0A287A4K8 Transient receptor potential cation channel subfamily M member 4 TRPM4 52438 195 213 16.54 0.028 ctrl only
F1S497 Uncharacterized protein TTC9 7831 203 210 21.01 0.031 both
F1SAY2 Uncharacterized protein TTF2 25593 991 1003 18.5 0.039 LPS only
P50390 Transthyretin TTR 388 36 41 36.6 0.016 both
P02550 Tubulin alpha-1A chain TUBA1A 23543 85 96 36.11 0.00072 ctrl only
A0A286ZNY1 Tubulin alpha chain TUBA4A 23543 85 96 36.11 0.00072 ctrl only
A0A287B5H5 Tubulin alpha chain TUBA8 23543 79 90 36.11 0.00072 ctrl only
F2Z5B2 Tubulin beta chain TUBB 11323 242 251 42.97 0.0002 ctrl only
A5GFX6 Tubulin beta chain TUBB1 11323 242 251 42.97 0.0002 ctrl only
F1S6M7 Tubulin beta chain TUBB3 11323 242 251 42.97 0.0002 ctrl only
F2Z5K5 Tubulin beta chain TUBB4A 11323 242 251 42.97 0.0002 ctrl only
A0A287A217 Tubulin beta chain TUBB4B 11323 262 271 42.97 0.0002 ctrl only
A0A287B749 Tubulin beta chain TUBB6 11323 242 251 42.97 0.0002 ctrl only
A0A287B1K1 Gamma-tubulin complex component TUBGCP5 8438 2 10 18.79 0.024 LPS only
A0A287AXA3 Uncharacterized protein TULP4 12998 558 567 19.5 0.046 both
A0A287BFL6 Uncharacterized protein TXLNG 8162 409 417 27.85 0.0066 ctrl only
P82460 Thioredoxin TXN 16997 95 105 23.63 0.024 both
A0A286ZJ07 Uncharacterized protein TXNRD2 14054 223 233 22.76 0.019 ctrl only
K7GRY0 Ubiquitin like modifier activating enzyme 1 UBA1 17870 1011 1021 36.16 0.014 both
B8Y648 Ubiquitin-conjugating enzyme E2L 3 UBE2L3 38229 53 67 28.54 0.0021 ctrl only
A0A287B778 Uncharacterized protein UBE2O 41823 930 946 17.59 0.045 ctrl only
A0A287BSL7 Uncharacterized protein UBE2V1 11224 54 63 28.23 0.0087 ctrl only
A0A287AHL7 Uncharacterized protein UBTD1 22415 163 175 19.05 0.033 ctrl only
F1S0D8 Uncharacterized protein UBXN4 34274 2 16 15.42 0.048 ctrl only
A0A287BRT0 Ubiquitin carboxyl-terminal hydrolase UCHL3 27998 122 134 57.29 1.40E-05 ctrl only
A0A287B0N8 Uncharacterized protein UNC5D 2304 1 6 25.26 0.049 ctrl only
F1SSS4 Uncharacterized protein UNC80 39536 967 981 16.68 0.038 ctrl only
A0A287AVG2 Uncharacterized protein URGCP 480 393 398 25.11 0.004 both
A0A287B6R5 Uncharacterized protein USH2A 3270 3103 3110 24.83 0.012 both
I3L945 Uncharacterized protein USP14 21865 31 43 30.64 0.0013 ctrl only
I3L8M9 Uncharacterized protein USP25 12671 823 831 16.27 0.048 both
A0A287A103 Uncharacterized protein USP4 6266 172 179 31.04 0.048 ctrl only
F1RUW2 Ubiquitinyl hydrolase 1 USP49 37114 97 112 17.99 0.031 both
F1SF51 Uncharacterized protein UTP25 291 75 80 32.6 0.038 ctrl only
A0A287A1Y2 Uncharacterized protein VANGL1 3453 379 386 28.94 0.027 both
A0A287BPW4 Uncharacterized protein VARS 10113 174 182 22.03 0.018 both
I3LS87 Vasorin VASN 14755 487 496 39.32 0.0012 both
F1S567 Uncharacterized protein VCAM1 15680 300 310 51.69 4.40E-05 both
A0A287BSL4 Vinculin VCL 10907 656 666 43.34 0.00027 both
P03974 Transitional endoplasmic reticulum ATPase VCP 4869 148 155 33.71 0.0048 both
A0A2C9F3B2 Voltage-dependent anion-selective channel protein 1 VDAC1 19652 1 12 23.48 0.041 ctrl only
Q9MZ15 Voltage-dependent anion-selective channel protein 2 VDAC2 56979 186 208 15.59 0.034 ctrl only
A0A2C9F3D9 Vimentin VIM 3005 114 120 36 0.0012 ctrl only
F1S3Q8 Uncharacterized protein VNN3 5354 49 56 20.88 0.011 both
A0A286ZW46 Uncharacterized protein VPS36 37199 204 216 22.98 0.018 LPS only
I3L638 Vitronectin VTN 646 247 251 35.1 0.028 both
Q28833 von Willebrand factor (Fragment) VWF 6800 651 659 16.09 0.031 both
A0A286ZYC8 Uncharacterized protein WAP-3 22222 52 63 28.92 0.0087 both
A0A287A1J0 Protein Wnt WNT5A 26796 216 227 17.64 0.046 LPS only
A0A287A1D2 Uncharacterized protein XPO1 1999 385 391 22.8 0.044 ctrl only
F1SDR7 Uncharacterized protein YWHAB 49263 141 159 109.78 5.10E-11 ctrl only
A0A287A2R9 Uncharacterized protein YWHAE 15539 107 118 52.24 2.40E-05 both
A0A287AXR5 Uncharacterized protein YWHAZ 17362 128 139 46.02 0.00015 ctrl only
A0A286ZTI8 Uncharacterized protein ZBTB20 1539 342 347 39.95 0.0057 LPS only
F1RUB7 Uncharacterized protein ZBTB33 22182 521 529 27.35 0.031 LPS only
F1S5G5 Uncharacterized protein ZBTB49 31297 488 500 24.08 0.024 both
M3UZ00 Zinc finger CCCH-type containing 18 ZC3H18 167 895 900 38.64 0.01 both
F1S7I8 Uncharacterized protein ZCCHC3 66275 378 402 15.99 0.048 ctrl only
A4U9C9 Zinc finger protein 216 ZFAND5 60040 87 111 17.4 0.023 ctrl only
A0A287BAB1 Zinc finger RNA binding protein ZFR 18737 756 766 19.73 0.036 LPS only
F1RR15 Zinc fingers and homeoboxes 1 ZHX1 7560 181 188 19.96 0.021 LPS only
I3LP64 Uncharacterized protein ZKSCAN2 15 929 934 32.5 0.049 ctrl only
F1RFI5 Zinc finger protein 48 ZNF48 1149 519 524 26.1 0.019 ctrl only
F1S2F2 Uncharacterized protein ZNF503 30277 1 14 21.28 0.012 LPS only
F1SC29 Uncharacterized protein ZNF518A 133 444 448 24.54 0.047 ctrl only
A0A287BJQ8 Uncharacterized protein ZNF691 201 62 67 36.69 0.0093 ctrl only
A0A287A5E4 Uncharacterized protein ZNF783 19196 1 12 21.69 0.0092 ctrl only
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